Paediatric atopic dermatitis and treatment adherence: Exploring factors contributing to topical corticosteroid phobia as a contributor to poor treatment adherence by Smith, Saxon Donald
DISCIPLINE OF DERMATOLOGY 
SYDNEY MEDICAL SCHOOL 
UNIVERSITY OF SYDNEY 
Paediatric atopic dermatitis and treatment adherence: Exploring factors contributing to 
topical corticosteroid phobia as a contributor to poor treatment adherence 
Clinical Associate Professor 
Saxon Donald Smith 
MBChB, MHL, FACD 
A thesis submitted in fulfilment of the requirements for the degree of Doctor of Philosophy 
2017 
TABLE OF CONTENTS 
Candidate declaration of authentication……………………………………………………VII 
Abstract……………………………………………………………………………………VIII 
Presentation of thesis………………………………………………………………………XV 
List of publications and presentations……………………………………………………..XX 
Acknowledgements………………………………………………………………………XXVI 
Abbreviations list ………………………………………………………………………XXVIII 
Chapter 1 General Introduction ..............................………………………………………..1 
Chapter 2 Introduction: Factors contributing to poor treatment outcomes in childhood atopic 
dermatitis – a review………………………………………………………………………...10 
Statement of authorship contribution……………………………………………….11 
Abstract……………………………………………………………………………..12 
Introduction…………………………………………………………………………12
Methods……………………………………………………………………………..13 
Results………………………………………………………………………………13 
Discussion…………………………………………………………………………..15 
References…………………………………………………………………………..15 
i
Chapter 3 Consensus statement and systematic review of the adverse effects of topical 
corticosteroids…………………….………………………………………………………...18 
Statement of authorship contribution……………………………………………….19 
Abstract……………………………………………………………………………..20 
Introduction…………………………………………………………………………21 
Methods……………………………………………………………………………..21 
Results………………………………………………………………………………21 
Discussion…………………………………………………………………………..27 
References…………………………………………………………………………..28
Chapter 4  Assessment of dermatologists’ attitudes to efficacy and safety of topical 
corticosteroids………………….....…………………………………………………………31
Statement of authorship contribution………………………………………………..32 
Abstract……………………………………………………………………………...33 
Introduction………………………………………………………………………….33 
Methods……………………………………………………………………………..34 
Results……………………………………………………………………………….34 
Discussion…………………………………………………………………………...36 
References…………………………………………………………………………...37 
Chapter 5 Assessment of pharmacist’s knowledge and understanding of topical 
corticosteroid efficacy and safety corticosteroids………………………………………......39 
Statement of authorship contribution……………………………………………….40 
Abstract……………………………………………………………………………..41 
ii
Introduction…………………………………………………………………………..41 
Methods………………………………………………………………………………42 
Results………………………………………………………………………………..42 
Discussion……………………………………………………………………………43 
References……………………………………………………………………………46 
Chapter 6 Assessment of general practitioners’ attitudes to efficacy and safety of topical..47 
Statement of authorship contribution………………………………………………..48 
Abstract……………………………………………………………………………...49 
Introduction………………………………………………………………………….49 
Methods……………………………………………………………………………...50 
Results……………………………………………………………………………….50 
Discussion…………………………………………………………………………...52 
References…………………………………………………………………………...53 
Chapter 7 Evaluation of the influence of pharmacists and GPs on patient perceptions of 
long-term topical corticosteroid use...……………………………………………………….55 
Statement of authorship contribution………………………………………………..56 
Abstract……………………………………………………………………………...57 
Introduction………………………………………………………………………….57 
Methods……………………………………………………………………………..57 
Results……………………………………………………………………………….58 
Discussion…………………………………………………………………………...60 
References…………………………………………………………………………...62 
iii
Chapter 8 Evaluation of the influence of family and friends, and the Internet on patient 
perceptions of long-term topical corticosteroid use…………………………….…………..64 
Statement of authorship contribution……………………………………………….65 
Abstract……………………………………………………………………………..66 
Introduction…………………………………………………………………………66 
Methods……………………………………………………………………………..66 
Results……………………………………………………………………………….67 
Discussion…………………………………………………………………………...68 
References…………………………………………………………………………...70 
Chapter 9 A comparison between parental perception of disease severity and clinician 
assessed disease severity in childhood atopic dermatitis …....……………………………..71 
Statement of authorship contribution……………………………………………….72 
Abstract……………………………………………………………………………..73 
Introduction…………………………………………………………………………75 
Methods……………………………………………………………………………..76 
Results……………………………………………………………………………….78 
Discussion…………………………………………………………………………...81 
References…………………………………………………………………………...83 
Tables ……………………………………………………………………………….90 
Chapter 10 Discussion Part 1: Childhood atopic dermatitis: exploring the safety, efficacy 
and potential misinformation around topical corticosteroids from healthcare 
professionals…………………………………......................................................................93 
iv
Statement of authorship contribution………………………………………………94 
Body of chapter…………………………………………………………………….95 
References………………………………………………………………………….99 
Chapter 11 Discussion: Influence and impact of family/friends and the Internet as non-
healthcare professional sources of information about topical corticosteroids……………101 
Body of chapter…………………………………………………………………...102 
References………………………………………………………………………...110 
Chapter 12 Conclusions……………………………………………………....................116 
Concluding remarks……………………………………………………………...117 
Clinical Implications……………………………………………………………..125 
Limitiations………………………………………………………………………126 
Future directions …………………………………………………………………128 
APPENDIX I Key background article: Hong E, Smith SD and Fischer G. “Evaluation of 
dermal atrophy in pediatric patients using long-term topical corticosteroid.”  Pediatric 
Dermatology 28:393-396, 2011. ………………………………………………………..130 
APPENDIX II Key background article: Smith SD, Hong E, Fearns S, Blaszczynski A and 
Fischer G. Corticosteroid phobia and other confounders in management of childhood atopic 
eczema explored using parent focus groups.  Australasian Journal of Dermatology 51(3):168-
174, 2010. ……………………………………………………………………………….134 
v
APPENDIX III Assessment of dermatologists’ attitudes to efficacy and safety of topical 
corticosteroids survey document………………………………………………………….141 
APPENDIX IV Assessment of pharmacist’s knowledge and understanding of topical 
corticosteroid efficacy and safety survey document…………………………………......143 
APPENDIX V Assessment of general practitioner’s attitudes to efficacy and safety of topical 
corticosteroids survey document.………………………………………………………..146 
APPENDIX VI Evaluation of the influence of pharmacists, general practitioners, family and 
friends, and the Internet on patient perceptions of long-term topical corticosteroid use survey 
document. ……………………………………………………………………………….148 
APPENDIX VII Evaluation of the influence of pharmacists, general practitioners, family 
and friends, and the Internet on parent perceptions of long-term topical corticosteroid use 
survey document.…………………………………………………………………………152 
APPENDIX VIII A comparison between parental perception of disease severity and 
clinician assessed disease severity in childhood atopic dermatitis………………………156 
vi
vii
ABSTRACT 
Atopic dermatitis (AD), also known as eczema or atopic eczema, is the most common chronic 
inflammatory dermatosis (skin condition) affecting paediatric patients in the western world. 
There continues to be a rapid rise in incidence of this condition worldwide with a doubling of 
prevalence in children under age five years in the past 30 years. It also remains one of the 
most treatable with correct management.  Topical corticosteroids (TCS), which have a topical 
anti-inflammatory action, remain central to this management. However, parent and patient 
poor adherence to prescribed treatment plans often leads to less effective control of their AD.  
A review of the literature demonstrated that one of the commonly cited contributing factors to 
treatment non-adherence in paediatric AD is a fear or anxiety regarding the use of TCS, a 
condition termed ‘TCS phobia’ (Chapter 2). Although moderate to severe atopic dermatitis is 
disabling and highly disruptive for patients and their families, TCS phobia is a significant 
barrier to effective treatment.   
This thesis presents a body of work that aims to identify the sources of information or 
misinformation about the safety and efficacy of TCS, as well as assessing the impact of this 
information on parents’ and patients’ perception on the long term use of TCS to manage their 
AD. 
Previous research has identified that parents of children with AD highlight the role of family 
and friends, the Internet, pharmacists and general practitioners as key sources of information 
that contribute to fear and anxiety towards using TCS to manage AD.  This can create 
conflicting information leading to confusion and ultimately poor or non-adherence to 
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prescribed treatment plans.  This is especially the case when the conflicting information 
comes from different members of the multidisciplinary treatment team. A multidisciplinary 
treatment team incorporates health care professionals from different disciplines who provide 
a specific service and associated health information to the patients, and in the setting of AD 
in Australia includes general practitioners, dermatologists, and pharmacists.  
Therefore, it is important to investigate the knowledge and attitudes of these health 
professionals about the safety and efficacy of TCS that forms the advice provided to parents 
and patients in paediatric AD.  This is because treatment adherence is directly related to 
risk/benefit of treating a condition as well as the perception of disease severity.  If the 
perceived risks associated with treatment, such as TCS in paediatric AD, out way the 
perceived benefits or perceived disease severity, then there is significant risk of treatment 
non-adherence. 
 
A consensus statement and systematic review of the adverse effects arising from the use of 
TCS in children with atopic dermatitis was performed (Chapter 3). The aim of the consensus 
meeting was to identify the potential and perceived adverse effects and systematically review 
the literature for each. 
 
Dermatologists play a key role as clinical educators around the use, safety and efficacy of 
TCS. A cross-sectional survey of all Australian dermatologists was performed to assess their 
attitudes towards the use and safety of TCS in paediatric AD (Chapter 4).  Close to half 
(44%) of the 455 dermatologists in Australia completed the survey (n=198).  Nearly all 
responders prescribed potent or super-potent TCS in the management of paediatric AD. The 
most common side-effect cited by over two-thirds of the respondents was peri-orificial 
dermatitis with only a minority (6%) citing cutaneous atrophy. Most dermatologists stated 
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that pharmacists were the most common source of misinformation leading to TCS phobia. Of 
the respondents, 75% strongly agreed that TCS do not cause skin atrophy when used 
appropriately and under clinical supervision. Furthermore, 77% agreed or strongly agreed 
that the words ‘use sparingly’ should be removed from pharmacist labels on TCS 
prescriptions. This study indicates that dermatologists comfortably manage paediatric AD 
with potent or super-potent TCS and believe that TCS do not cause skin atrophy in paediatric 
AD.  This is in keeping with the current up to date literature on the safety and efficacy of 
TCS in this setting and represents the baseline against which other healthcare professionals 
should refer to when providing advice about the treatment of paediatric AD.  
 
Parents and dermatologists commonly cite conflicting information provided by pharmacists 
on the safety and efficacy of TCS in paediatric AD as contributing to TCS phobia and serving 
as a major impediment to treatment adherence. Consequently, a study was conducted to 
assess pharmacists’ beliefs and information on the safety of TCS in paediatric AD treatment 
(Chapter 5). A cross-sectional survey to assess attitudes and knowledge on the use of TCS in 
paediatric AD was completed by Australian pharmacists (n=292) who attended a continuing 
professional development conference. The mean response rate for each question was 86% of 
the 292 surveyed. Of the responders, 64% recognised that treatment non-adherence was a 
major reason for treatment failure in paediatric AD. Only a quarter (27%) of the pharmacists 
would instruct parents/patients to apply TCS until the eczema is clear. Over half (54%) of the 
responders indicated they would instruct patients to use TCS sparingly.  Nearly half (46%) of 
the responders believed that cutaneous atrophy was the commonest side-effect from use and 
over half (56%) indicated that side-effects would occur, even if used appropriately. This 
study demonstrated the existence of significant knowledge gaps about the use and safety of 
TCS in paediatric AD in Australian pharmacists. Furthermore, their advice to patients 
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potentially contributes to poor treatment adherence because of this misinformation which can 
contribute to the fear and anxiety around using TCS.  
 
Parents cite general practitioners and pharmacists as a source of information that contributes 
to TCS phobia which can in turn affect treatment adherence. The previous study 
demonstrated the knowledge gap amongst Australian pharmacists.  Therefore, a study was 
conducted to assess general practitioners’ beliefs and information on the safety of TCS in 
paediatric AD treatment (Chapter 6). A cross-sectional survey was performed on Australian 
general practitioners (n=257) participating in continuing professional development programs. 
Over a third (40.7%) instruct parents to apply TCS for two weeks or less.  Nearly half 
(47.7%) instruct parents to apply TCS sparingly or with the smallest amount possible.  
Furthermore, nearly a third (30.2%) reported skin atrophy as the most common TCS side 
effect. Therefore, this study demonstrates that advice from their general practitioner may 
carry unintentional risk messages contributing to a fear and anxiety about using TCS and 
ultimately can lead to treatment non-adherence.  
 
The studies in chapters 4 to 6 demonstrate the potential for conflicting advice from healthcare 
professionals in a patient’s multi-disciplinary treatment team.  However, an investigation was 
needed to assess the actual impact of the advice from healthcare professionals on patients and 
parents’ perception of the safety and efficacy of TCS in AD. Furthermore, it is important to 
assess the advice provided by pharmacists and general practitioners as related to and reported 
by patients and parents of patients using TCS on a long-term basis for AD (Chapter 7). A 
multi-centre cross-sectional survey was performed on a total of 123 adult patients and 78 
parents (n=201). Of the total respondents, three quarters (76.6%) reported consistently 
(“Often” or “Always”) receiving one or more message(s) regarding TCS “risk” from a 
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general practitioner (GP) and/ or pharmacist (n=192). Respondents reported being told to “try 
natural or complementary and alternative therapies before resorting to the use of TCS” 
significantly more often by pharmacists than by GPs (p=0.039).  This study demonstrates that 
high rates of consistently delivered messages about TCS “risk” from GPs and pharmacists do 
affect patient/parent understanding about TCS safety.  This “risk” messaging can contribute 
to fear and anxiety about using TCS and may lead to treatment non-adherence. 
 
Chapters 4 to 7 provide evidence that conflicting information from different healthcare 
professionals in the multi-disciplinary treatment team leads to the delivery of negative risk 
messaging to parents and patients with AD.  This contributes to TCS phobia and can lead to 
poor treatment outcomes due to non-adherence.  However, non-health professional such as 
parents, family and friends, and the Internet are others sources of knowledge about AD and 
its treatment.  This was also investigated. 
 
The perception of TCS safety in the management of AD is influenced by family/friends of the 
patient or parent of children with AD.  This means these are another potential source of 
misinformation on TCS which can negatively impact perceptions of TCS safety. A multi-
centre cross-sectional survey of patients (aged >18years old) and parents of patients (aged 
<18years old) with a history of a chronic inflammatory dermatosis was performed to assess 
information they receive from family/friends and the Internet about TCS use (Chapter 8).  A 
total of 123 patients and 78 parents completed the survey (n=201). Parents/Patients reported 
that they were more likely to be informed by the Internet “[having] my [child’s] skin 
condition means that [I/he/she] will need to use topical corticosteroids” (p <0.001) and that 
“inflamed skin conditions will improve with the topical corticosteroids” (p = 0.007). On the 
other hand, family/friends were more likely to recommend parents/patients “try non-
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prescription creams/ointments before resorting to the use of prescription topical 
corticosteroids” (p = 0.014).  This study highlights that high rates of messages about TCS 
‘risk’ from family/friends and the Internet may affect patient/parent understanding about TCS 
safety.  Furthermore, this may contribute to treatment non-adherence. 
 
Chapters 3 to 8 have demonstrated external influence that can deliver negative biases that 
contribute to fear and anxiety about TCS use and ultimately lead to non-adherence in the 
treatment of paediatric AD.  However, a parent’s perception of disease severity, representing 
an ‘internal’ influence bias, can contribute to whether or not they treat their child’s AD.  If a 
parent assesses their child’s AD to be less severe than it actually is, they are much more 
likely to undertreat and more likely to be non-adherent with the prescribed management plan.  
A study was performed comparing parent reported disease severity compared to physician 
assessed disease severity (Chapter 9). A prospective cohort study recruited fifty paediatric 
patients and their caregivers from an outpatient dermatology clinic. Two clinicians completed 
ratings on the Eczema Area and Severity Index (EASI) tool and caregivers completed ratings 
on the Self-Administered EASI (SA-EASI) and Dermatology Quality of Life Index (DLQI) 
tools. EASI scores between clinicians were compared and there was good inter-clinician 
reliability (p = 0.351 ). There was a strong, positive statistically significant correlation 
between EASI and SA-EASI (r = 0.865, p= <0.01). The EASI score mean was statistically 
significantly higher than the SA-EASI mean (p = <0.001) for a given patient.  
 
This study looked to establish a discrepancy between clinician and caregiver perception of 
atopic dermatitis severity. It showed that caregivers significantly underestimate the severity 
of their child’s atopic dermatitis. This provides the clinician with a greater understanding into 
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poor treatment compliance commonly observed in clinical practice and highlights a need to 
provide parents with a greater understanding of their child’s disease.  
By establishing the severity of the eczema to the caregiver, the clinician is empowered to 
provide education about the expectations surrounding treatment, allowing greater insight into 
noncompliance. This can facilitate an approach to the fears and misconceptions that 
caregivers may have.  
 
Overall, the studies in this thesis contribute to an awareness of the sources of negative risk or 
misinformation about the safety and efficacy of TCS in the setting of paediatric AD.  
Furthermore, it demonstrates the direct impact of this information on patients and parents.  
These findings provide the basis for education programs to help educate the healthcare 
professional members of the multi-disciplinary treatment team.  It is through consistent 
positive messaging from these healthcare professionals that patients and parents will be better 
equipped and supported to combat the negative risk messaging from non-healthcare 
professional sources such as family, friends and the Internet.  Ultimately, this has the capacity 
to positively impact treatment adherence and outcomes for both the patient with AD and their 
entire family unit. 
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PRESENTATION OF THESIS 
 
Atopic dermatitis (AD), also known as eczema, is the most common paediatric dermatology 
condition.  The incidence of AD is increasing across the world.  AD is a chronic condition 
that most of the time will remit or become less severe as the child ages with most children 
growing out of it.  However, it is also a debilitating condition with significant negative 
biopsychosocial impacts for both the child and their entire family unit.  For the majority of 
children who suffer with AD, it is a condition that can be readily managed with a 
combination of general skin measures (such as regular emollient and humectants, soap-free 
wash, and short luke-warm showers or bath oils), environmental modifications to minimise 
triggers, and topical anti-inflammatory creams or ointments (such as TCS).  Unfortunately, 
compliance is a significant problem when managing AD. This is attributed to a number of 
factors including a fear of using TCS known in the literature as TCS phobia.   
 
This thesis focuses on identifying the origins and sources of misinformation in the safety and 
efficacy of TCS which can contribute to ‘TCS phobia’ as well as the impact of this 
misinformation on the patient and the parents. 
 
This thesis contains 12 chapters. 
 
Chapter 1 gives a broad overview of paediatric AD. 
 
Chapter 2 reports more detailed information from a systematic review about the factors 
contributing to poor treatment compliance as well as potential strategies to manage these 
confounders in the setting of paediatric AD.  This has been published in the Australasian 
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Journal of Dermatology. Sokolova S and Smith SD. Managing treatment adherence 
confounders in atopic dermatitis: A review.  Australasian Journal of Dermatology 56:252-
257, 2015.  
 
Chapter 3 outlines a systematic review on the potential and perceived adverse effects from 
TCS in paediatric AD. This chapter reports the outcome of an Australasian consensus 
statement with subsequent systematic literature review.  It provides the basis of evidence with 
which dermatologists practice and against which other healthcare professionals and 
influencers were compared against.  This has been published in the Australasian Journal of 
Dermatology. Mooney E, Rademaker M, Dailey R, Daniel BS, Drummond C, Fischer G, 
Foster R, Grills C, Halbert A, Hill S, King E, Leins E, Morgan V, Phillips RJ, Relic J, 
Rodrigues M, Scardamaglia L, Smith SD, Su J, Wargon O and Orchard D. Adverse effects of 
topical corticosteroids in paediatric eczema: Australasian consensus statement.  Australasian 
Journal of Dermatology 56:241-251, 2015. 
 
Chapter 4 directs focus on the role that TCS phobia can have in poor treatment adherence as 
identified in the systemic review. In this setting, it is important to explore the advice that 
healthcare professionals provide parents of children with AD with respect to the safety and 
efficacy of TCS. This chapter reports the results of a cross-sectional study investigating the 
attitudes of Australian dermatologists towards the efficacy and safety of TCS in paediatric 
AD.  This has been published in the Australasian Journal of Dermatology. Smith SD, Lee A, 
Blaszczynski A and Fischer G. Assessing dermatologists’ attitudes to efficacy and safety of 
topical corticosteroids. Australasian Journal of Dermatology 57:278-283, 2016. 
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Chapter 5 examines the first of the two other key members of the multidisciplinary healthcare 
treatment team who help manage paediatric AD.  This chapter reports the results of a cross-
sectional study investigating the knowledge and understanding of Australian pharmacists 
about the safety and efficacy of TCS in paediatric AD. This has been published in the 
Australasian Journal of Dermatology. Smith SD, Lee A, Blaszczynski A and Fischer G. 
Assessing pharmacist’s knowledge and understanding of topical corticosteroid efficacy and 
safety. Australasian Journal of Dermatology 57:199-204, 2016. 
Chapter 6 examines the third and final key member of the multidisciplinary healthcare 
treatment team who help manage paediatric AD.  This chapter reports the results of a cross-
sectional study investigating the knowledge and attitude of Australian general practitioners 
towards the safety and efficacy of TCS in paediatric AD.  This has been accepted for 
publication in Australian Family Physician. Smith SD, Harris V, Lee A, Blaszczynski A and 
Fischer G. Assessing general practitioner’s attitudes to efficacy and safety of topical 
corticosteroids. Australian Family Physician 46(5): 335-340, 2017. 
Chapter 7 builds on the results of chapters 3, 5 and 6 which documented potential differences 
in education and attitudes towards the safety and efficacy of TCS amongst the healthcare 
professionals in the multidisciplinary treatment team in paediatric AD.  These differences 
potentially lead to confusion and contribute to misinformation which can lead to TCS phobia.  
Chapter 7 reports the results of a cross-sectional study investigating the influence that the 
advice from pharmacists and general practitioners has on the perceptions of adult patients and 
parents of children with AD on the safety and efficacy of long-term use of TCS.  This has 
been published in Journal of Dermatological Treatment. Farrugia L, Lee A, Fischer G, 
Blaszczynski A, Carter S and Smith SD. Evaluation of the influence of pharmacists and GPs 
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on patient perceptions of long-term topical corticosteroid use. Journal of Dermatological 
Treatment 28(2):112-118, 2017. 
Chapter 8 explores the role that non-healthcare professional sources of information on the 
safety and efficacy of TCS can have in paediatric AD.  This chapter reports the results of 
cross-sectional study which evaluates the influence family and friends, and the Internet have 
on perceptions of long-term TCS in adult patients and parents of children with AD.  This 
work has been published in the Journal of Dermatological Treatment. Smith SD, Farrugia L, 
Harris V, Lee A, Blaszczynski A, and Fischer G. Evaluation of the influence of family and 
friends, and the Internet on patient perceptions of long-term topical corticosteroid use.  
Journal of Dermatological Treatment Published online 28th March 2017 
DOI:10.1080/09546634.2017.1306017 
Chapter 9 examines the potential influence parents, as the actual administrators of treatment 
in paediatric AD, may have on treatment outcome.  This chapter reports the results of a cross-
sectional study which examined differences in the perception of disease severity in paediatric 
AD.  Parental underassessment of disease severity can be a contributing factor to treatment 
non-adherence because of decreased perception of the need to treat active paediatric AD. This 
is an unpublished manuscript.  
Chapter 10 presents a summary and discussion, in the form of a systemic review, of the role 
of healthcare professionals as a source of misinformation on the safety and efficacy of TCS 
and the potential impact on treatment adherence. This has been published in the Australian 
Journal of Pharmacy. Smith SD and Fischer G. Childhood atopic dermatitis: Exploring the 
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safety, efficacy and potential misinformation around topical corticosteroids. Australian 
Journal of Pharmacy October Issue 83-88, 2016. 
Chapter 11 presents a discussion of the influence of family, friends and the Internet as a 
source of misinformation about the safety and efficacy of TCS in paediatric AD, and poor 
disease understanding.  These non-healthcare professional influences can contribute to poor 
treatment adherence. This is an unpublished manuscript. 
Chapter 12 presents the conclusions of the research undertaken, and discusses clinical 
implications, limitations and further research directions. 
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CHAPTER 1 
 
 
General Introduction 
 
ATOPIC DERMATITIS 
 
Atopic dermatitis (AD), or eczema, is the most common dermatological condition in children 
worldwide. Mild to moderate AD is also one of the most treatable dermatological conditions 
when correct management is instituted.  The use of topical corticosteroids (TCS) remain a 
key criterion standard in the care of all AD. Although AD, especially in moderate to severe 
cases, can be disabling and highly disruptive for patients and their entire family unit, fear and 
anxiety with respect to the use of TCS can be a significant barrier to effective treatment [1-7]. 
The literature often refers to this fear and anxiety relating to TCS use as ‘corticosteroid 
phobia’. 
 
Previous published research has demonstrated a link between ‘corticosteroid phobia’ with a 
preference for ‘natural therapies’ [7]. Furthermore, patients and their parents often have a 
poor understanding of the pathophysiology of AD which has a predominantly genetic basis.  
This often leads patients and parents to pursue perceived ‘cures’ for their disease and often 
focus on a search for offending specific allergens in the environment or food that can be 
eliminated [7]. The abandonment of evidence-based medical therapy can have potentially 
detrimental outcomes for the paediatric patient [8-11]. Furthermore, in extreme examples of 
this abandonment it can lead to legal neglect and even death of the patient [12].  
 
Parents frequently cite ‘skin thinning’, or cutaneous atrophy, as the side effect they fear the 
most [7]. Concern about this specific perceived or potential side effect of TCS is entrenched 
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in parents in Australia, and is also seen around the world [4,5,13]. Cutaneous atrophy is a 
documented side effect of TCS.  However, it is not seen in the setting of paediatric AD when 
TCS are used appropriately with supervision [14]. In the clinical circumstances that it can 
occur, it is usually when potent products are used inappropriately, such as under plastic 
occlusion or on macerated skin of the flexures for extended periods of time [15]. The fear of 
causing cutaneous atrophy by using TCS has become pronounced in members of the 
healthcare professional multi-disciplinary team and in general communities so that many 
patients and parents receive grossly exaggerated risk warnings.  In particular, 88% of parents 
with children who suffer from paediatric AD report friends and family (50%), with 
pharmacists (44%) and GPs (25%) as sources of information characterising TCS as 
dangerous [7]. This can result in a confusion in patients and parents about the safety and 
efficacy of TCS to manage their AD and leads to poor treatment adherence [8,9]. Education 
of patients and parents whose children have AD helps to deconstruct this complex issue and 
dramatically increases treatment adherence.  
 
HEALTH BURDEN OF ATOPIC DERMATITIS 
 
The prevalence of symptoms of AD in children under 5 years of age in Australia is 
approximately 20%, which has more than doubled over the past three decades [16,17].  This 
increase in prevalence has been seen in other western countries such as the USA [18]. The 
reason for this continued increase in disease prevalence is not currently well understood.  
However, environmental and socioeconomic factors appear to play an important role in 
disease prevalence [19]. AD can be managed well in most patients and usually remits with 
age with most children growing out of their AD.  However, AD places a significant burden 
on patients and their family unit. In fact, it has previously been shown that a child with AD 
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has a higher biopsychosocial impact on the entire family unit than having a child with 
diabetes because of the problems with itching, sleep loss, problems at school and mood and 
behavioural changes [2,3,5,20].  
 
The financial and social burden of eczema in children is significant. A previous Australian 
study calculated conservative estimates of annual personal costs for managing atopic 
dermatitis [20].  For each child with mild eczema, the cumulative costs of direct medical, 
hospital and treatment as well as the indirect costs such as time off work for caregivers have 
been estimated to be AUD 1100 per year. For a child with severe eczema, these costs increase 
to over AUD 6000. This study also found that this financial cost incurred in the management 
of AD was greater than that for the management of asthma. There are also other practical 
difficulties that occur when caring for a child with AD which impact and restrict a family’s 
lifestyle including skin care, feeding, shopping, washing and cleaning, psychological 
pressure, and physical exhaustion [21]. 
 
TREATING ATOPIC DERMATITIS 
 
Generally, AD is a condition that can be well managed.  This involves a combination of 
environmental modification, infection control, identification and management of triggers and, 
in some children, investigation of allergies. A key component of the pathophysiology of AD 
is an associated mutation in a gene coding for a protein called filaggrin [21]. AD sufferers 
who have this mutation results in a poorer keratinocyte adhesion and decreased natural 
moisturising factors [23]. Therefore, treatment of AD necessitates the restoration of 
epidermal barrier function with emollients. Emollients are the basis of management and 
should be used even when the skin is clear [24]. When there is active AD characterised by 
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inflammation of the skin, TCS are the mainstay of medical therapy because of their anti-
inflammatory effect. 
  
TREATMENT NON-ADHERENCE 
Treatment non-adherence occurs when patients/caregivers change or do not follow the 
management plan prescribed to them.  It may arise from intentional conscious decision 
making by the patient or by unintentional effects [25].   
 
There are a variety of reasons why patients become intentionally non-adherent to treatment 
including health beliefs [12,25] or a desire to pursue complementary and alternative medicine 
therapies [7].  Intentional treatment non-adherence also occurs when patients or their 
caregivers hold fears about treatment due to a perceived risk of adverse effects.  This may 
lead patients/caregivers to change the treatment plan independently of the doctor’s original 
guidance [26].  This may include alteration of their dosage, increase or decrease, or even 
cessation of therapy completely without the direct involvement of their treating physician.  
 
Alternatively, patients/caregivers can become unintentionally non-adherent to treatment. The 
most common reasons are forgetfulness or lack of knowledge about the disease and its 
treatments [26].  Poor knowledge about the amount and frequency of application, whether by 
poor instructions or conflicting information from members of the healthcare professional 
team have been identified as another potential cause of unintentional non-adherence [27]. 
 
Irrespective of whether treatment non-adherence is intentional or unintentional, poorer 
treatment outcomes can occur from the divergence from physician directed management plan 
[26]. 
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AIMS OF THE THESIS 
 
To date, there has been a discussion in the literature about the role of TCS phobia, 
characterised by a fear and/or anxiety about the use of TCS in treatment non-adherence.  
Previous research in which I participated has demonstrated the safety profile of TCS in the 
setting of paediatric atopic dermatitis (Appendix I).  Furthermore, other previous published 
research in which I have participated has indicated that information received from 
family/friends, the Internet, pharmacists and general practitioners can all contribute as 
sources of misinformation leading to TCS phobia (Appendix II).  Furthermore, other previous 
research has demonstrated that there is a paucity in the literature around the detailed 
examination of these healthcare professional and non-healthcare sources of information and 
their impact on patient/parent’s perception about the safety and efficacy of TCS.  This thesis 
presents several studies addressing this important gap in the medical literature. 
 
The aims of these studies were to: 
1) Systematically review the literature on factors which contribute to poor treatment 
adherence in AD and determine the importance of TCS phobia as a key contributing 
factor to poor treatment adherence (Chapter 2). 
2) Systemically review the safety and efficacy of TCS in paediatric AD (Chapter 3) 
3) Investigate the knowledge and attitudes of Australian dermatologists to the use of 
TCS in paediatric AD (Chapter 4). 
4) Investigate the knowledge and attitudes of Australian pharmacists to the use of TCS 
in paediatric AD (Chapter 5). 
5) Investigate the knowledge and attitudes of Australian general practitioners to the use 
of TCS in paediatric AD (Chapter 6). 
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6) Investigate the impact of advice from pharmacists and general practitioners about the 
use of TCS as reported by patients and parents (Chapter 7). 
7) Investigate the impact of information from family/friends and the Internet about the 
use of TCS as reported by patients and parents (Chapter 8). 
8) Investigate the potential differences between in parental reported assessment of 
disease severity and clinician assessed disease severity in paediatric AD as a potential 
contributor to treatment non-adherence (Chapter 9). 
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CHAPTER 2 
 
 
 
 
 
Factors contributing to poor treatment outcomes in childhood atopic dermatitis: A 
review. 
 
 
 
This chapter contains the systematic review, “Factors contributing to poor treatment 
outcomes in childhood atopic dermatitis: A review,” published in the Australasian Journal of 
Dermatology 2015;56:252-257. 
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Factors contributing to poor treatment outcomes in
childhood atopic dermatitis
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ABSTRACT
Atopic dermatitis (AD) is a chronic relapsing inflam-
matory disease of the skin and is the most common
paediatric dermatological condition. While no cure is
available, it can be treated effectively if adherence to
a therapeutic plan is maintained. Poor adherence to
treatment is common in AD and can lead to treatment
failure, which has significant impacts on the patient,
family and society. A comprehensive literature search
was conducted to identify factors that contribute to
poor treatment adherence in childhood AD and to
identify possible strategies to remedy these. Identified
factors leading to poor treatment adherence include:
complexity of treatment regimen, lack of knowledge,
impaired quality of life, dissatisfaction with treatment
strategies, infrequent follow up, corticosteroid phobia
and the use of complementary and alternative medi-
cine. Effective strategies to increase treatment adher-
ence include: caregiver education and utilisation
of education adjuncts, optimisation of the patient/
caregiver–clinician relationship, early and frequent
follow up and improvement of patient and caregiver
quality of life.
Key words: adherence, atopic dermatitis, compli-
ance, eczema, management, treatment.
INTRODUCTION
Atopic dermatitis (AD) is a common inflammatory disease of
the skin with a chronic relapsing course.1,2 Treatment regi-
mens are often complex, consisting of the daily application
of emollients and long-term topical corticosteroid (TCS) or
the use of calcineurin inhibitors. Further strategies include
environmental modification, avoidance of triggers, photo-
therapy and the management of complications such as sec-
ondary infections. Oral anti-inflammatory medications and
immunomodulators may be required in severe cases. The
available treatment strategies are effective.3,4 However, poor
treatment adherence is common, and only 32% of patients
have been found to be adherent to topical therapy in AD
when measured with electronic monitoring,5 leading to
poor treatment outcomes. This highlights the fact that non-
adherence to treatment is an important cause of treatment
failure.5
Implications of poor treatment adherence in AD
Poor treatment outcomes have significant consequences for
patients and their families.6 Children with AD suffer from
sleep disturbance, are more irritable, require greater
attention7–9 and are at increased risk of mental health prob-
lems by the age of ten.10 This has substantial psychosocial
implications for their caregivers and families.11 The ability
of parents to work, complete household duties and engage
in social activities is impaired6,12–14 and parents also experi-
ence significant psychological strain from self-blame, guilt
and sadness.7 The personal economic burden of AD is also
significant; with one Australian study quantifying the direct
mean costs to families of AU$330, AU$818 and AU$1255
annually for mild, moderate and severe AD, respectively,
with further indirect costs including the loss of income from
time taken off work, travel and the cessation of employ-
ment.14 In addition, the economic burden to society is con-
siderable, with significant costs resulting from primary
care and emergency department presentations, hospital
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admissions, speciality consultations, prescription medica-
tions, procedures and laboratory costs,15 with estimates of
direct financial costs in the USA of between US$364 million
to US$3.8 billion annually.15–17 Treatment may be escalated
inappropriately if poor treatment outcomes are interpreted
as ineffectiveness of the treatment rather than poor adher-
ence to treatment,18 whichmay result in significant systemic
side-effects for the individual,1 additional psychosocial
burden on families and further financial costs to society.
Limitations of assessing treatment adherence
It is difficult to gauge treatment adherence in the clinical
setting. Self-reports by patients and caregivers may overes-
timate treatment adherence, though diary and question-
naire measures may bemore accurate than interview-based
self-reports.19 Non–self-report measures include pill counts,
canister weights, pharmacy claims and electronic monitor-
ing. However, all these measures reflect presumed adher-
ence rather than providing an absolute measure of
medication applied or ingested.20 Despite these difficulties,
findings from studies of treatment adherence suggest that
non-adherence is extremely common in patients with
chronic disease21 and this has significant implications for
treatment outcomes.
Objectives
The purpose of this review article is to identify the major
causes of poor treatment adherence in childhood AD and to
suggest mitigating strategies to improve adherence.
METHODS
A comprehensive literature search was conducted using
PubMed/MEDLINE, Embase, the Cochrane Database of
Systematic Reviews and the Cochrane Central Register of
Controlled Trials in October and November 2013. The fol-
lowing search terms were used: ‘atopic dermatitis’ or ‘atopic
eczema’ or ‘eczema’ and ‘adherence’ or ‘compliance’. Pub-
lished studies up to November 2013 were included. The
search was limited to English language studies. The highest
level of evidence and grade of recommendation was noted
for each suggested mitigating strategy, using a modified
version of the Oxford Centre for Evidence-based Medicine
levels of evidence table (Table 1).22
RESULTS
Factors contributing to poor treatment outcomes
Complexity of treatment regimens
Treatment regimens are perceived to be complex and bur-
densome as a result of the prescription of multiple medica-
tions, frequent dosing schedules and the cumbersome
application of topical preparations.23 The requirement for
long-term therapy is also often problematic. Adherence to
even a twice-daily application of topical therapy drops by
60% a few days after the commencement of treatment.5
Parents and caregivers admit that taking shortcuts, such as
the reduced frequency of topical therapy application, is nec-
essary to simplify treatment regimens.23
Lack of knowledge
Lack of understanding of the disease pathogenesis and pre-
scribed treatments is common in AD.24,25 Nearly half the
parents and caregivers, when questioned, cannot correctly
identify the potency of commonly prescribed TCS or the
nature of the antimicrobial components correctly.25 Such
lack of understanding may result in the incorrect applica-
tion of topical therapy and confusion about the escalation
of treatment, leading to poor treatment adherence and
outcomes.
Impaired quality of life
To be successful, complex treatment regimens in the
context of chronic disease require ongoing commitment
from patients and caregivers. Emollients are applied even
when there is no evidence of active disease on the skin,
giving little respite from caregiver duties. Health-related
quality of life (HRQoL) is significantly impaired in children
with AD and their caregivers,6 which has direct negative
implications for treatment adherence.26,27
Table 1 Levels of evidence and associated grade of recommendation. Modified from the Oxford Centre for Evidence-based Medicine Levels
of Evidence22
Grade of
recommendation
Level of
evidence Description
1a Systematic review of RCT
A 1b Individual RCT with narrow confidence interval
1c All or none
2a Systematic review of cohort studies
B 2b Individual cohort study (including low quality RCT, e.g., < 80% follow up)
3a Systematic review of case-control studies
3b Individual case-control study
C 4 Case series and poor quality cohort and case-control studies
D 5 Expert opinion without explicit critical appraisal, or based on physiology, bench research or first principles
RCT, randomised controlled trial.
Treatment adherence in atopic dermatitis 253
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Patient dissatisfaction
Patient satisfaction is a determinant of treatment adher-
ence.28,29 A cross-sectional survey in Japan reported that a
satisfactory patient/caregiver–clinician relationship was the
most important factor driving treatment adherence in their
population.30 However, a survey of the UK National Eczema
Society showed that only 19% of initial consultations with a
dermatologist met patients’ expectations and only 40% of
patients were satisfied with the treatment given.12 Acknowl-
edging patients’ preference is an important component of
patient satisfaction. Recommendations for topical therapies
should take patient/caregiver vehicle preference into
account,31 including the type of preparation32 and the fre-
quency of application.23 Treatment plans designed without
the patient/caregiver preferences in mind are likely to lead
to treatment failure.24
Frequency of follow up
Adherence to topical therapy in AD increases significantly
around the time of follow-up appointments.5 This finding,
termed ‘white coat compliance’,33 has also been reported in
psoriasis34 and hand dermatitis.35 The timing of follow-up
appointments also seems to be important, with earlier
follow up resulting in higher rates of treatment adherence.36
Corticosteroid phobia
Corticosteroid (CS) phobia is a common phenomenon in
parents caring for children with AD,37,38 with over 80%
fearing potential local and systemic side effects associated
with regular CS application.39 Fears include irreversible
skin atrophy, immune suppression and growth failure with
long-term steroid application,37,40 frequently resulting in
treatment failure due to non-adherence.39
Use of complementary and alternative medicine
Despite the lack of evidence for complementary and alter-
native medicine (CAM) in the management of AD,41 CAM
continues to be a popular adjunct to treatment. Common
strategies include homeopathy, the use of botanical extracts
and Chinese herbal medicine.41 More than half of AD
patients may include a form of CAM in their management.42
CAM is more likely to be used, usually upon recommenda-
tion by friends or family, by patients with a long duration of
disease and if they perceived that orthodox treatment strat-
egies have failed.42 Side-effects, medication interactions and
the worsening of AD symptoms with the use of some CAM
have been reported,43–46 confounding treatment outcomes.47
Further, the inappropriate sole use of CAM to manage AD
can have catastrophic consequences.46
Improving treatment adherence
Optimisation of the patient/caregiver-clinician relationship
A satisfactory relationship between the physician and
patient/caregiver is one that involves good verbal and non-
verbal communication, effective listening and collabora-
tive decision-making.48 Physicians who appear to show a
genuine interest in their patients, who are able to foster
understanding and enquire about psychosocial issues are
likely to achieve greater patient satisfaction.49,50 As clini-
cians we can embrace our role of health educator to provide
disease and treatment specific information to meet the
parents’ needs and simplify the complexity of treatment to
aid their understanding. The use of topical combination
formulations has been shown to increase treatment adher-
ence and improve clinical outcomes in acne management.51
Grade of recommendation: B (level 2b evidence)
Patient education Patient education is a key strategy to
improving treatment adherence, as the lack of understand-
ing of the prescribed treatment and fear of medication side-
effects are significant adherence confounders in the
management of AD. Educational approaches range from the
medical practitioner giving simple information and advice
to offering comprehensive multidisciplinary strategies. Sys-
tematic reviews examining the utility of patient education in
AD have been difficult to interpret due to the diversity of
educational approaches used, small sample sizes and vari-
ability in treatment end-points.41,52,53 However, the quality of
education is important as longer, more structured sessions
improve patient satisfaction54 and disease outcomes.55
Accordingly, the addition of nurse-led education sessions to
standard dermatological consultations has been shown to
result in improved patient satisfaction, quality of life and
disease outcomes,56,57 although large-scale prospective
studies are lacking.
Given the proposed benefit of comprehensive education
in AD management, guidelines for therapeutic patient edu-
cation (TPE) have recently been developed,58 which will
allow for the standardised delivery of a multidisciplinary
educational strategy in AD. TPE aims to empower patients
with the relevant skills and knowledge required to manage
their chronic disease while maintaining their quality of
life.58 It is a multimodal, patient-centred approach, combin-
ing structured teaching with skill transference and psycho-
social support and requires input from a number of health
professionals, including doctors, nurses and clinical psy-
chologists. It comprises a thorough initial consultation with
a doctor and nurse team and the identification of educa-
tional objectives to allow targeted delivery of information
using a variety of educational resources. Collective teaching
sessions can also be incorporated into the model using
either lecture or workshop formats. Standardisation of the
educational model will allow for a more rigorous investiga-
tion into its usefulness in improving treatment adherence
in AD.
Grade of recommendation: A (level 1b evidence)
Written eczema action plans Written action plans have
been proposed as useful educational adjuncts to verbal
instruction in AD.59 Two studies, including a small
randomised controlled trial60 and a quality improvement
254 A Sokolova et al.
© 2015 The Australasian College of Dermatologists
14
study,61 have shown beneficial outcomes following the addi-
tion of eczema action plans to simple verbal instruction
during patient consultations. Benefits included increased
patient understanding as well as decreased anxiety about
self-management in AD, which may increase patient satis-
faction, improve their quality of life and result in better
treatment adherence.
Grade of recommendation: B (level 2b evidence)
Other education adjuncts Additional education adjuncts
have been suggested to promote treatment adherence but
have not been rigorously studied. The accuracy of topical
agent application by adults with AD was improved when
fluorescent cream was used as a teaching aid62 and the
regularity of topical agent application may be increased
with positive reinforcement strategies in children, such as
sticker charts63 and with memory aids such as regular text
messages in adolescents.64
Grade of recommendation: C (level 4 evidence)
Targeted education regarding TCS Educating caregivers
about the important role of TCS in AD management is criti-
cal at the time of treatment prescription to overcome the
potential impact of CS phobia. Side-effects from TCS are
extremely rare and are usually secondary to an inappropri-
ate prescription of highly potent formulations or incorrect
application of the TCS.65–67 Correctly applied TCS are well
tolerated, even with prolonged use,68 with most side-effects
being reversible if they are diagnosed early.69 Counselling
patients and parents about the role of TCS in AD treatment,
as well the method of application, leads to decreased paren-
tal anxiety and a higher acceptance of CS treatment.70
Grade of recommendation: B (level 2b evidence)
Early and frequent follow up Regular follow up may
reduce the perceived burden of treatment, maintain
patients’ motivation and convey the physician’s interest in
patient adherence.48 More frequent follow ups may facilitate
treatment adherence.31 Further, as treatment adherence
declines rapidly following the initial consultation, earlier
follow ups may lead to increased adherence,36 although a
small randomised controlled trial was unable to confirm
this.71
Grade of recommendation: B (level 2b evidence)
Improving quality of life A number of studies have under-
lined the importance of maintaining quality of life of both
patients and caregivers in AD management as impaired
HRQoL has negative implications for the use of topical
therapy.28 The number and severity of AD flares are directly
correlated with reduced HRQoL,11 suggesting that strategies
that aim to improve disease outcomes through better treat-
ment adherence should lead to an improvement in the
patients’ quality of life. Better disease control may then
serve as positive reinforcement for ongoing treatment
adherence and may potentially reduce caregiver’s willing-
ness to try adjunct strategies such CAM due to perceived
futility of orthodox treatments.
Grade of recommendation: D (level 5 evidence)
Future research Poor treatment adherence is common in
childhood AD, with significant implications for the individu-
als concerned, their family and society. While a number of
prospective trials have been conducted to investigate strat-
egies that are effective in improving treatment adherence,
more research is needed. Educational interventions can
now be studied more rigorously with the publication of
standardised guidelines for TPE in AD. While the regularity
of follow up is important, further research into the exact
frequency and mode of follow up is warranted. The car-
egiver burden may be improved and the perceived com-
plexity of treatment strategies can be rendered less
daunting with the development of new vehicles that reflect
patient/caregiver preferences. It is also essential to define
the sources and impact of misinformation on the use and
safety of TCS to better support the patient/caregiver and
improve treatment adherence.
CONCLUSION
Identifying the major factors that lead to poor treatment
adherence is of particular importance in childhood AD,
where a common cause of treatment failure is poor adher-
ence rather than disease severity or the ineffectiveness of
treatment. A prescribed treatment plan can lead to signifi-
cant improvements in disease and psychosocial outcomes.
However, poor adherence is very prevalent for a variety of
reasons. Building a strong patient/caregiver–clinician rela-
tionship, simplifying treatment regimens, implementing
comprehensive education sessions and increasing the fre-
quency of follow up are important mitigating strategies
against poor treatment adherence in childhood AD. Future
research will better define the most effective ways of imple-
menting these strategies in the clinical setting, improving
both disease outcomes and the quality of life of patients and
caregivers.
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ABSTRACT
Atopic eczema is a chronic inflammatory disease
affecting about 30% of Australian and New Zealand
children. Severe eczemacosts overAUD 6000/year per
child in direct medical, hospital and treatment costs as
well as time off work for caregivers and untold distress
for the family unit. In addition, it has a negative impact
on a child’s sleep, education, development and self-
esteem. The treatment of atopic eczema is complex
andmultifaceted but a core component of therapy is to
manage the inflammation with topical corticosteroids
(TCS). Despite this, TCS are often underutilised by
many parents due to corticosteroid phobia and
unfounded concerns about their adverse effects. This
has led to extended and unnecessary exacerbations of
eczema for children. Contrary to popular perceptions,
(TCS) use in paediatric eczema does not cause atro-
phy, hypopigmentation, hypertrichosis, osteoporosis,
purpura or telangiectasia when used appropriately as
per guidelines. In rare cases, prolonged and excessive
use of potent TCS has contributed to striae, short-term
hypothalamic-pituitary-adrenal axis alteration and
ophthalmological disease. TCS use can also exacer-
bate periorificial rosacea. TCS are very effective treat-
ments for eczema. When they are used to treat active
eczema and stopped once the active inflammation
has resolved, adverse effects are minimal. TCS should
be the cornerstone treatment of atopic eczema in
children.
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INTRODUCTION
Atopic dermatitis or eczema is a chronic inflammatory
disease of the skin with a relapsing course. It affects 20% of
children aged 3–11 years,1 with a higher incidence in cities
in developed countries. The prevalence of eczema in young
children in Australia has increased from 10 to 30% over the
last 15 years.2,3
The financial and social burden of eczema in children is
significant. For each child with mild eczema, the direct
medical, hospital and treatment costs and the indirect costs
such as time off work for caregivers have been estimated to
be AUD 1100 per year. For a child with severe eczema, these
costs increase to over AUD 6000.4 The psychological toll on
the children and their families is at least as great as that
seen in children with diabetes.5 Therefore, for financial,
developmental and emotional reasons, it is of the consider-
able importance to have an effective and safe treatment.
Fortunately, such a treatment exists. It was developed in
the 1950s as compound F, the first topical corticosteroid
(TCS) preparation.6 The potential value and importance of
TCS cannot be overstated, but steroid phobia due to misin-
formation among the general community, pharmacists and
prescribing physicians, has led to its underutilisation. We
have therefore reviewed the relevant medical literature and
have developed a position statement on the safe use of TCS
in children with atopic eczema, with a particular focus on
adverse effects.
METHODS
An Australian and New Zealand panel of physicians with an
interest in managing paediatric eczema was constituted to
review the use of TCS in children with atopic eczema. The
aim of the consensus meeting was to identify and address
misconceptions on corticosteroid treatment of eczema,
using published evidence combined with over 430 person-
years of clinical practice in paediatric dermatology. The
panel included practicing paediatric dermatologists from
Australia and New Zealand, paediatricians, dermatology
nurses and advanced dermatology trainees. Each reported
TCS side-effect was reviewed in the context of a paediatric
eczema population and key practice points agreed upon.
These are listed at the end of this review.
RESULTS
There was universal agreement that the underutilisation of
TCS due to the widespread fear of side-effects leads to
worse outcomes for children with eczema in both the short
and long term.
Corticosteroid efficacy and potency
Glucocorticosteroids have anti-inflammatory, immunosup-
pressive, anti-proliferative and vasoconstrictive effects.7 In
the target cell, glucocorticoids bind to receptors in the cyto-
plasm before traversing the nuclear envelope and binding,
either directly or indirectly, to DNA. Gene regulation and
transcription of various mRNA follows, resulting in both the
beneficial and potentially deleterious effects of steroids.7
TCS reduce protein synthesis and cellular mitosis as well as
inhibiting the proliferation, migration and chemotaxis of
fibroblasts. The secretion of certain interleukins is inhibited
and the vasoconstrictive effects of adrenaline promoted.
TCS also reduce the inflammatory action of histamine and
bradykinin.
The potency of TCS depends on the inherent character-
istics of the particular steroid molecule and the amount of
the molecule that reaches the target cell. Only 1% of hydro-
cortisone cream is absorbed in the forearm skin of a normal
individual.8 In a single application study using radiolabelled
hydrocortisone, absorption varied from 0.25 to 3%.8 Factors
that influence absorption of TCSs through the skin include:
Penetration
How the TCS is formulated will influence its penetration
through the skin. In a comparison of a cream, ointment, gel
and foam formulation of betamethasone, the foam produced
the highest vasoconstrictor activity (a measure of potency)
and the cream the least.9 In a similar comparison of cream,
gel and ointment preparations of fluocinolone acetonide,
the cream formulation was more potent than the ointment
preparation, with the gel having an intermediate activity.10
Occlusion has been reported to cause increased absorption
in 96-h studies, but not in 24-h.
Concentration
A number of experimental (animal and human) studies
from the 1970s and 1980s show little or no correlation
between the vasoconstrictor test results and the concentra-
tion of topical steroid applied.
Saturation
Within three applications a steroid reservoir develops in the
dermis (once it has been absorbed through the epidermis),
which influences the rate of subsequent absorption. Dou-
bling the number of hydrocortisone molecules on the skin
from a 1–2% hydrocortisone cream increases absorption in
a linear fashion with the first application, but absorption
falls once dermal saturation occurs, thereby negating the
concentration effect.11
Elimination
The elimination of steroids from the dermis affects subse-
quent absorption. This occurs either by transport into the
circulation or via its metabolism.
The most important factor, however, in determining the
potency of a TCS is how well the active agent binds to
corticosteroid receptors (i.e., the inherent potency of the
steroid molecule) (Table 1). TCS potency is measured
by the cutaneous vasoconstrictor assay.9,12–14 This mea-
sures the degree of pallor of the skin caused by both
2 E Mooney et al.
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an augmentation of the vasoconstrictive response to
adrenaline/noradrenaline and via occupancy of classical
glucocorticoid receptors.7,15
Steroid concentration
There is very little clinical difference in the potency of 0.5%,
1% and 2% hydrocortisone. Diluting a strong steroid by
mixing it in a moisturiser base will not make it significantly
less potent. If you wish to reduce potency, use a less potent
steroid molecule.
Frequency of application
Putting a steroid on thrice daily adds very little to a once-
daily application, particularly after several days of use.
Apply steroids once or twice daily as directed.
Use liberally
The recommendation ‘use sparingly’ is nonsensical and
has no value. Moreover, it unfortunately promotes inad-
equate use of the drug. In focus groups of parents, signifi-
cant concern was generated by the instruction to use
sparingly. Parents felt this created the impression that cor-
tisone should be used only when eczema was severe and
that this contributed to the underutilisation of TCS.16 It is
better to recommend that the steroid is applied liberally
and then carefully rubbed or massaged into inflamed skin.
A very thick application is, however, wasteful. Use the fin-
gertip unit as a guide to the quantities that should be used
(Appendix 1).17,18
Atrophy
The most frequent fear and misunderstanding about TCS
use is clinically relevant skin thinning. In a survey of 276
pharmacists (Dr S. Smith, pers. comm., 2014), 46% stated
that atrophy of the skin is the most common side-effect of
TCS use. Two-thirds (67%) reported telling patients not to
use TCS for a period longer than 2 weeks at a time.
This fear is not well founded. Much of the early literature
on the side-effects resulting from TCS use comes from
1960–1980s.19–22 In these articles, cutaneous atrophy is high-
lighted as a potential side-effect of TCS use. However, these
studies were generally of low quality, with small numbers of
patients, and methods that are not consistent with the
manner or nature of steroid use today (i.e., prolonged con-
tinuous application under occlusion in flexural areas).20,21
At the biological level, atrophy refers to a decrease in
dermal connective tissue and is characterised by the loss of
elasticity and thinning. Histologically, there is a reduction in
size of the corneocyte in the epidermis as well as thinning
of the dermis.23 The initial reduction in size of the
keratinocytes reflects a reduction in metabolic activity. With
prolonged exposure to high-potency steroids the number of
cell layers is reduced, with the disappearance of the stratum
granulosum and the thinning of the stratum corneum.22,24,25
In a study of three cases, there was significant resorption of
mucopolysaccharide ground substance after 6 weeks of
very potent steroid application (clobetasol propionate under
occlusion in Duhring chambers).22 This rapidly reversed on
discontinuation.22,25,26
However, these observations have little clinical rel-
evance. A recent Australian cross-sectional study27 stressed
that routine, long-term use of TCS in children with eczema
does not cause skin atrophy. In total, 70 children were
initially treated with a potent TCS (betamethasone dipro-
pionate ointment 0.05% or methylprednisolone aceponate)
before changing to a less potent TCS (betamethasone
valerate). The mean amount of potent topical steroid per
month used was 79 g, medium potency TCS was 128 g and
weak potency TCS was 34 g. A validated dermoscopic tech-
nique was used to determine skin atrophy at 210 TCS sites
and 70 control sites.28,29 None of the treatment or control
sites demonstrated atrophy (all scored 0). Seven sites did
show grade 1 telangiectasia, all in the cubital fossa;
however, the same degree of telangiectasia was observed in
the control group (3.2% vs 3.1%), suggesting that having
some telangiectasia in the cubital fossa is a normal variation
in the paediatric population.
A randomised controlled trial in adults with active
eczema treated with 2 weeks of daily potent TCS (flu-
ticasone 0.0005% ointment) followed by 16 weeks of twice
weekly application showed no evidence of atrophy in the
serial skin biopsies compared to placebo.30 In a study of 174
children with atopic eczema treated with a 3-day bursts of a
potent TCS (0.1% betamethasone valerate) showed no dif-
ference in skin thinning.31 Using ultrasonography the base-
line thickness was measured at 0.91 mm thick. At the end of
the 18-week study there was only 0.01 mm difference com-
pared with baseline.
In the combined experience of the panel members no
cases of steroid atrophy has been observed if TCS were used
for the treatment of atopic eczema and if it were discontin-
ued once the acute inflammation had settled. The cases of
Table 1 Potency ranking of selected topical corticosteroid
preparations
Class I: mild Usual concentration (%)
hydrocortisone 0.5–1.0
hydrocortisone acetate 0.5–1.0
Class II: moderate
clobetasone butyrate 0.05
hydrocortisone butyrate 0.1
betamethasone valerate 0.02
betamethasone valerate 0.05
triamcinolone acetonide 0.02
methylprednisolone aceponate 0.1
triamcinolone acetonide 0.05
Class III: potent
betamethasone dipropionate 0.05
betamethasone valerate 0.05–0.1
mometasone furoate 0.1
Class IV: very potent
betamethasone dipropionate in
optimised vehicle
0.05
clobetasol propionate 0.05
Adverse effects of topical steroids 3
© 2015 The Australasian College of Dermatologists
22
steroid atrophy seen in children by the panel members were
in the setting of ‘off label use’ to areas of hyperpigmentation
or hypopigmentation for prolonged periods of time
(months), particularly in higher absorption sites such as the
axillae, flexures and groin. Occlusion, particularly with
plastic wraps, has also been observed to increase the risk in
these sites. It is, however, very important to recognise that
parents and non-dermatologists often incorrectly ascribe
the changes of active atopic eczema to be evidence of ‘skin
thinning’.
Summary
What is commonly referred to as skin thinning by parents
and non-dermatologists is usually a misrepresentation of
active eczema; (ii) irreversible skin thinning does not occur
when TCS, used for eczema in children, is stopped on reso-
lution of the dermatosis.
Striae/rubra distensae
Striae are visible, linear scars forming in areas of dermal
damage produced by the stretching of the skin. Initially
there may be inflammation and oedema of the dermis, fol-
lowed by the deposition of dermal collagen along the lines
of mechanical stress. Histologically, striae are characterised
by the thinning of the overlying epidermis, with fine dermal
collagen bundles arranged in straight lines parallel to the
surface.32 Striae represent scar tissue and therefore, once
they have developed, are permanent. They occur most com-
monly in association with rapid vertical growth (i.e., the
back of young teenagers, excessive weight gain or loss and
in association with pregnancy (striae gravidarum).
The evidence that TCS lead to striae is mostly low level,
and includes five case reports, two small case series, one
randomised controlled trial and three review articles. In
total, striae were observed in 15 of 312 patients. In a head to
head comparison of pimecrolimus and TCS (0.1% triamci-
nolone acetonide to the trunk or limbs and 1% hydrocorti-
sone to the face, neck or intertriginous areas) for 1 year in
658 adults, only three patients developed striae.33 However,
in a specific study of TCS (moderate and potent) used in
children over a mean of 10.8 months, in 210 test sites and 70
controls no striae were observed.27
In over 430 person-years of paediatric dermatology prac-
tice, the panel recalls only one case of striae in a child using
TCS for eczema. In contrast most of the panel members had
seen striae, albeit very rarely, when used for non-
eczematous conditions, particularly in overdose and under
occlusion for extended periods of time.
Although concern is occasionally expressed over the pos-
sibility of delayed striae formation due to childhood use of
TCS, there is no evidence to support this, even when TCS
have been used inappropriately. Striae do occur commonly
in children and teenagers during rapid growth phases with
an estimated incidence of 25–35%,34 but TCS do not
produce striae in children using standard TCS treatment
for eczema.
Summary
TCS do not induce striae when used to treat atopic eczema
in children unless used inappropriately or in overdose and
only then at certain sites (i.e. the axillae and groin).
HPA axis suppression
HPA axis suppression can occur following use of any exog-
enous steroid. Physiological adrenal suppression has been
defined as a ‘cortisol level below the normal range but with
the capacity for prompt recovery’ while pathological
adrenal suppression is described as ‘a state of adrenal insuf-
ficiency, adrenal crisis or persistent laboratory evidence of
adrenal suppression without prompt recovery’.35 Following
exposure to exogenous corticosteroid, the body adjusts the
HPA axis through the physiological suppression of endog-
enous cortisol. Following weeks to months of persistent
exogenous corticosteroid exposure, the adrenal glands may
become atrophic and are temporarily unable to produce
adequate glucocorticoids to meet the body’s requirements.
In this situation, the adrenal suppression becomes patho-
logical and an adrenal crisis may occur.
Following TCS use, temporary physiological adrenal sup-
pression may be apparent within 2–4 weeks but is quickly
reversible and the patient recovers fully.35–38 We are
unaware of any reports of pathological adrenal suppression
during the use of TCS that is discontinued on resolution of
the active eczema.
In a review of 16 TCS trials that recorded HPA suppres-
sion, only one reported pathological adrenal suppression:
five adult psoriasis patients who used more than 100 g
clobetasol propionate a week for between 10 weeks to 18
months developed features of Cushing’s syndrome. On
withdrawal they suffered symptoms of adrenocortical insuf-
ficiency; and in addition they developed pustular psoriasis.35
There are 25 paediatric case reports in the literature of
HPA axis suppression. These children had mostly used
super-potent topical steroids (clobetasol propionate) for
1–17 months for diaper eczema.39–47 There have been two
reports of death due to sepsis in association with marked
overuse of TCS in very young infants.48,49
It is clear that physiological HPA axis suppression can
occur for the duration of treatment with potent TCS. When
used for routine eczema management in children, patho-
logical HPA suppression has not been reported.
Summary
Physiological HPA axis suppression can occur with wide-
spread and prolonged, or occlusive use, of potent/super-
potent TCS. Clinically significant or pathological adrenal
suppression is very rare in the treatment of paediatric
eczema with topical agents.
Infected or excoriated skin
Most children with eczema are colonised with Staphylococ-
cus aureus50,51 and many will develop secondary bacterial or
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viral infections, such as Herpes simplex or Molluscum. Con-
versely, children’s eczema will often flare following primary
skin infection.52 There is, however, little evidence that treat-
ment with TCS worsens any outcomes associated with
infection. Indeed, adequate treatment of the eczematous
skin with TCS generally restores the barrier function of the
skin and greatly aids control of any associated infection,
without the need for antibiotic or antiviral treatment.53,54 In
children with significant secondarily infected eczema, TCS
use should be combined with oral antibiotics or antivirals
as clinically indicated. Topical antibiotics should generally
be avoided to minimise the development of antibiotic
resistance.
Children with atopic eczema often have areas of excori-
ated or weeping skin, or both. Corticosteroids have the
potential to slow the healing of ulcerated skin, through
reduced epidermal DNA synthesis and morphological
changes in fibroblasts.19 When applied daily to incised pig-
skin, triamcinolone acetonide was found to reduce the rate
of wound healing in the pigs by 62% by day 7.19 However,
the control of inflammation of atopic eczema by using TCS
far outweighs the slight reduction in the rate of wound
healing. There is little evidence to contraindicate the use of
TCS on excoriated atopic eczema.
The members of the panel recommend moderate to
potent strength TCS for children with atopic eczema with
superimposed bacterial or viral infection, provided they are
also receiving appropriate antiseptic, antibacterial or anti-
viral treatment if clinically indicated.
Summary
TCS should be the first-line treatment for excoriated or
infected eczematous skin. Concurrent infection (e.g. S.
aureus, H. simplex, Molluscum) should be treated if clini-
cally significant. There is no evidence that putting TCS on
excoriated or infected eczema is deleterious.
Allergic contact dermatitis to TCS
TCS allergy is a delayed hypersensitivity reaction whose
reported prevalence is increasing.55,56 The low molecular
weight of corticosteroid molecules should prevent it from
becoming immunogenic but the degradation of the C17 side
chain allows it to bind to amino acids to generate a hapten-
protein complex, which can act as an allergen.57
There is significant geographical variability in the
reported prevalence of TCS allergy in both adults and chil-
dren. This is due, in part, to regional differences in patch-
test methodology and the prescribing habits of different
countries.58–60 A meta-analysis by Dooms-Goossens and col-
leagues showed that approximately 1% of children patch-
tested demonstrate allergy to TCS, although the relevance
was not always clear.61 In children who do not respond to, or
are made worse by topical steroid use, the incidence of
steroid allergy was found to be 25%, although the overall
incidence was not reported;62 85% of those with positive
patch test had multiple allergies.63
Summary
Allergy to TCS is uncommon in children with atopic eczema
but should be considered in those children who demon-
strate a poor response to appropriate-strength TCS.
Osteopaenia/osteoporosis
Osteopenia or osteoporosis with resulting bone fractures is
a well-known side-effect following the chronic use of oral
corticosteroids in adults and children alike.64–66 The quality
of evidence that TCS has any effect on bone mineral density
(BMD) manifesting as osteopenia or osteoporosis, is rela-
tively low. In one case-control study of 43 children with
eczema using TCS, only children also on oral cyclosporin
were found to have lower BMD and bone mineral apparent
density) in the lumbar spine.67 However, when the six
patients with cyclosporin were excluded there was no sig-
nificant difference found between those treated with TCS
and the controls. There was no correlation between
corticosteroid variables (eczema severity scoring system,
dose of TCS, years of TCS usage, affected body surface area)
and bone density at any site. The body location of eczema,
vitamin D intake and the use of occlusion with TCS were not
examined as potential confounders. Cyclosporin itself is
thought to activate osteoclasts and suppress osteoblasts and
bone formation,68 and is known to be associated with an
increase in osteocalcin levels, pointing to a secondary
process of bone loss.69
The limited research available to date suggests the risk of
bone thinning in children with moderate to severe atopic
eczema does not appear to differ from the expected preva-
lence of low BMD in the general population.70
Summary
Reduced BMD is unlikely to occur in children with eczema
treated with TCS. The panel has not identified any children
with atopic eczema using only TCS who have developed
osteopenia or osteoporosis.
Ocular effects
Potential adverse effects of systemic corticosteroids on the
eyes include changes to intraocular pressure (glaucoma),
cataract formation and infection. There is medium quality
evidence that the prolonged application of corticosteroid
eyedrops for ophthalmological conditions can result in
ocular complications such as cataracts, glaucoma and
ocular infections.71 There is, however, only level 4 and 5
evidence on the ocular side-effects of corticosteroid used
topically near the eye.
Intraocular side-effects are rare when TCS is used appro-
priately in the periocular region (i.e., one week of moderate
or potent TCS use, followed by mild potency TCS or
calcineurin inhibitors for maintenance). A recent study
assessed 88 patients with atopic eczema who utilised topical
steroids to the eyelids and periocular region, with no
increased risk of glaucoma observed.72 However, there are a
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few case reports of adverse effects, which are primarily
based around medication errors.73–75 In most of these cases
there has been prolonged use of potent or very potent TCS
for months to years. In many instances the TCS was origi-
nally prescribed for use in non-facial areas or for another
patient altogether.
In the setting of atopic eczema, cataracts can develop
through one of two distinct pathways. The more common is
related to the disease itself; persistent itching and rubbing
of the eyelids may induce traumatic cataracts. Systemic
steroids (> 15 mg prednisone/day for over 12 months) can
also induce posterior subscapular cataracts,.76 Lower doses
of systemic corticosteroids in combination with TCS use in
the periocular region, subconjunctival and nasal steroid
sprays has also been associated with posterior subcapsular
cataracts, with seven cases reported in a 5-year period to
2001.77
In a study of 37 atopic eczema patients who used moder-
ate potency TCS periorbitally for an average of 6 months/
year over 5 years, seven were found to have cataracts.72 Two
of these patients were also using oral steroids, four of the
seven were found to have age-related cataracts and one
patient was found to have cataracts secondary to rubbing, in
the setting of atopic eczema. None was directly related to
TCS use.
It is currently unclear as to whether there is a thres-
hold of TCS use which can induce cataract or glaucoma.
It is possible that susceptible individuals, such as those
with a personal or family history of cataracts, glaucoma,
diabetes, myopia or previous eye problems have a lower
threshold.
Summary
In predisposed individuals, the prolonged use of potent TCS
in the periorbital area has been rarely associated with cata-
ract and glaucoma. However, there is little evidence that
less potent TCS used on the eyelids and periorbital area,
even if used for a long duration, cause ocular sequelae. TCS
use elsewhere on the face or body has not been shown to
cause ocular sequelae. If potent TCS are to be used for
prolonged periods in high-risk patients it may be advisable
to obtain a baseline ophthalmology review and consider
using a topical calcineurin inhibitor instead.
Hypertrichosis
Hypertrichosis may be generalised or localised, congenital
or acquired. It must be differentiated from hirsutism. There
is no high-quality evidence to support an association
between TCS use and hypertrichosis. While various texts
report an association between the two, each references a
statement in a previous article or textbook, with no actual
cases clearly documented. However, nine members of the
consensus group report having seen localised hyper-
trichosis in children with a discoid pattern of atopic eczema
(with or without prurigo nodularis), in the skin immediately
surrounding the discoid patches or nodules. The localised
hypertrichosis resolved on discontinuation of the potent
TCS (and the eczema). It is unknown whether this reported
localised hypertrichosis is an epiphenomenon due to
lichenification, traumatic rubbing or itching, the underlying
discoid pattern of atopic eczema or an adverse effect of
TCS use.
Summary
TCS do not cause permanent hypertrichosis. Transient
hypertrichosis has been seen in discoid eczema and prurigo
nodularis treated with potent TCS.
Periorificial dermatitis/rosacea
The pathogenesis of perioral dermatitis or rosacea is not
completely understood. Fluorinated TCS, tacrolimus,
inhaled steroids, Demodex mites, tartar control tooth-
pastes, cosmetics, hormonal influences, occlusive
moisturisers, cosmetics and amalgam fillings have all been
implicated at one time or another.78–82 TCS are commonly
prescribed in children for mild perinasal, periocular or
perioral erythema, which initially are often effective.
However, continued use or discontinuation, or both, can
induce perioral dermatitis. In a study of 79 children with
periorificial rashes, two-thirds (66%) were reported to be
using TCS at the time of the initial evaluation.79 However,
it was not clear whether the periorificial rash had occurred
prior to use of the TCS or following treatment. All cleared
with the cessation of the topical steroid and use of topical
metronidazole.
A number of studies have reported a rosacea-like erup-
tion occurring in patients using tacrolimus.80–82 One study of
16 children with periorificial dermatitis compared those
using topical tacrolimus with those using TCS.80 The clinical
presentation was similar, with a significant colonisation of
Demodex mites occurring in both groups. All patients
cleared on stopping the topical agents and treatment with
topical metronidazole. There have been reports of inhaled
steroids inducing perioral rosacea.83
The consensus group believes that perioral dermatitis or
rosacea can be induced in predisposed children, even by
simple emollients or mild over-the-counter TCS (e.g. 1%
hydrocortisone). The presence of a perioral, perinasal or
periocular rash should raise suspicion of possible perioral
dermatitis or rosacea. TCS should not be used to treat
rosacea, as they typically lead to a cycle of dependence with
flare on treatment withdrawal.
Perioral dermatitis or rosacea is generally easy to manage
by avoiding all topical preparation (TCS, thick emollients,
sunscreens, cosmetics, etc.). If treatment is required, con-
sider 6 weeks of systemic antibiotics (e.g., erythromycin or
tetracycline if the patient is over 12 years of age). If systemic
treatment is inappropriate, consider topical metronidazole
or azelaic acid. Patients should be warned to expect a flare
following the cessation of treatment, and counselled about
the importance of avoiding topical preparations, including
TCS on the central portion of the face.
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Summary
TCS may aggravate a tendency for perioral dermatitis/
rosacea in predisposed individuals. Physicians who pre-
scribe TCS for facial eczema should to be aware of this
complication.
Red face
The presentation of patients with a red face, often with the
headlight sign (large areas of facial erythema with sparing
of the nose and upper lip), has been described in adults
using potent TCS, mostly for seborrhoeic dermatitis.84
Nitric oxide is suggested to be a mediator of the rebound
vasodilation reported in these cases. These patients are
often described as being steroid dependent or addicts.
Treating this involves cessation of all topical steroids and
other skin-care products but it may take many months of
discomfort to achieve this. Systemic therapy with anti-
inflammatory antibiotics is often necessary (e.g., tetracy-
clines). The red face has not been reported as occurring in
children, but should be kept in mind in teenagers whose
inflammatory dermatosis deteriorates despite increasing
steroid potency use.
Summary
The red face has not been described in children with
eczema but should be kept in mind in teenagers who con-
tinue to deteriorate despite increasing steroid potency.
Tachyphylaxis
Tachyphylaxis refers to a progressive reduction in efficacy
of an agent with its continued use and is often reported by
patients and their families following TCS usage. The evi-
dence for tachyphylaxis is, however, weak and is con-
founded by issues of non-compliance, and other reasons for
failure to respond to treatment (e.g., acute flare due to
secondary infection or exposure to irritants). In a mouse
model TCS cause the inhibition of DNA synthesis and
mitosis in the epidermis. With ongoing treatment DNA syn-
thesis and mitosis recover and the tissue becomes insensi-
tive to further stimulation.85
A study of adolescents and adults86 used either fluticasone
0.05% cream or ointment, or the equivalent base. Following
clearance, patients entered a 16-week follow-up study. All
patients applied an emollient once daily; half the patients
then applied a TCS twice weekly, while the control group
applied the base twice weekly. Those patients using twice
weekly TCS had a median time to relapse of more than 16
weeks as opposed to 6 weeks for the base only. Most patients
who applied a potent TCS twice weekly had not relapsed at
4 months.
In a 12-week study, none of the 32 patients being treated
for psoriasis with TCS exhibited detectable signs of
tachyphylaxis.87 In another review there was no evidence
that the clinical efficacy of glucocorticoids had diminished
significantly in long-term continuous use in inflammatory
skin diseases.88 However, in 10 volunteers with normal skin,
a histamine-induced wheal was suppressed following 14
days of daily fluocinolone acetonide 0.01% applied under
occlusion to the flexor aspect of the forearm. Maximal
wheal suppression occurred on day 8, but by day 14 the
study reported almost total tolerance to the TCS.89
Non-compliance with treatment or the inadequate use of
TCS is often a more common explanation for loss of
response to TCS. Lack of adherence results from many
factors: the chronic nature of eczema, the need for the
ongoing application of creams, the prohibitive costs of
topical agents and complexities in coordinating school,
work and family plans. A study of adherence to topical
treatment of eczema revealed only a 32% adherence in 8
weeks of treatment.90 Non-compliance is particularly
affected by steroid phobia. In one study 73% of dermatology
outpatients reported being worried about using TCS and
33% confessed to non-compliance.91
Summary
There is no evidence to show that tachyphylaxis occurs in
children with eczema treated with TCS. While there are
some animal studies showing tachyphylaxis with TCS use,
clinical studies have generally failed to confirm this.
Purpura
Purpura is not uncommon in individuals with significant
sun damage, particular if they have also received prolonged
courses of systemic or topical steroids. Purpura develops
secondary to the loss of the supporting architecture of the
local vasculature and is precipitated by shearing stress. It is
usually asymptomatic.92,93 Although it is commonly listed as
an adverse effect, the evidence for TCS-induced purpura
without significant phototrophy, is poor.
A small study of six patients reported atrophy, telangi-
ectasia and purpura related to TCS use.94 One patient had
used flurandrenolide 0.05% under occlusion for 5 years
and experienced easy bruising. A second patient had used
the same agent four times daily for 10 months. Two other
patients used very potent TCS up to four times a day for 18
months and 5 years, respectively. All had continued to use
the potent TCS long after the initial dermatosis had
settled, i.e., they were being applied to non-diseased
skin.
Purpura is a theoretical risk with TCS use but the litera-
ture does not support its presence in children nor in any
individual using TCS to treat active eczema and ceasing on
the resolution of disease activity. In addition, none of the
consensus group had experience of TCS-related purpura in
children. Summary Purpura does not occur in children with
eczema being treated with TCS when they are stopped on
the resolution of the active dermatosis.
Hypopigmentation
TCS produce vasoconstriction, which can be confused with
hypopigmentation. It is mediated via occupancy of classical
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glucocorticoid receptors.15 The time profile of vasoconstric-
tion is dependent on the agent used, with carbon-11-
chlorosteroid being the quickest.95 The vehicle used also
seems to contribute to the blanching profile, with beta-
methasone dipropionate ointment having a different profile
to the same chemical in a cream base.95
Although there are very few reports in the literature of
TCS causing hypopigmentation, this side-effect continues
to be widely reported. The literature includes two case
reports96 of hypopigmentation following the use of
intralesional steroids, and one case of hypopigmentation
localised to sites of use of flurandrenolide impregnated
tape.97 Fortunately, the hypopigmentation resolved within 7
days on cessation of use.
Hypopigmentation in the context of treating eczema in
children is very common. This is largely due to the under-
lying disease (e.g., pityriasis alba).98–99 In the experience of
the review group, only two children have been observed to
develop localised hypopigmentation; both occurred in
Fitzpatrick skin types IV–V and both had been using potent
or very potent TCS. Fortunately, the hypopigmentation
occurred only at the treated site, and in each case the pig-
mentary change was transient and resolved completely over
a period of a few weeks to months following cessation of the
TCS.
Summary
The hypopigmentation seen in patients with eczema is
usually secondary to the eczema (e.g., pityriasis alba). It
resolves with appropriate treatment of the eczema, particu-
larly after exposure to UV light. TCS do cause short-term
vasoconstriction, which may be mistaken as hypopig-
mentation. Very potent TCS have been used inappropriately
as a skin lightening agent.
Telangiectasia
There is some evidence from animal studies that triamci-
nolone acetonide and fluocinolone acetonide can induce
telangiectasia in rats.100 It is notable that the studies used
excessive quantities of TCS. While telangiectasia have been
reported with prolonged, excessive and occlusive use of
TCS,100–105 there is little evidence that telangiectasia occur
when used to treat active childhood eczema when treat-
ment is stopped on resolution of the dermatosis.
In a recent study, 92 Australian children treated using
mild to potent TCS or emollients as per their eczema sever-
ity were followed over a mean of 10.6 months.27 Mild grade
1 telangiectasia was seen in 3% of the cases, all of which
involved the antecubital fossa. However, this was similar to
the control group (3%).
In another study investigators undertook a right-left com-
parison in the same individual using between hydrocorti-
sone 1% cream and pimecrolimus 1% cream. This was an
8-week single centre study of the uninvolved forehead skin
of 20 patients with atopic eczema.33 Following a twice-daily
application for 2 months, no dermal thinning or telangiec-
tasia was demonstrated, as measured by ultrasound or
dermoscopic photography.
Alclometasone dipropionate 0.05% was compared with
hydrocortisone 1% in a randomised double blind manner in
32 children with eczema, looking for evidence of atrophy or
telangiectasia following its twice-daily application for 3
weeks. There was no evidence of telangiectasia or sign of
cutaneous atrophy in any child.102
It is the panels’ opinion that telangiectasia can develop
after the prolonged use of very potent TCS, but is very
unlikely in children when TCS are used appropriately for
active eczema. Care should be taken with prolonged and
excessive use of very potent topical steroids, particularly
when used in combination with inhaled, intranasal and
systemic steroids.
Summary
Routine use of TCS in children with eczema should not
cause telangiectasia.
CONCLUSION
TCS remain the mainstay of the management of active
atopic eczema in combination with the regular use of emol-
lients, the management of triggers and the treatment of
concurrent infection. The safety profile of TCS remains
robust when it is used appropriately. Appropriate use is
defined as 1–2 generous applications per day to all the
inflamed skin until the active eczema is controlled as per
guidelines (Appendix 1). The advice given by dermatolo-
gists to parents of children with eczema regarding the use of
TCS is unfortunately frequently undermined by other health
professionals. There is a pressing need for the re-education
of these health professionals on the excellent safety record
of these medications.
Key Points
There is little difference in the clinical effect between 0.5, 1
and 2% hydrocortisone.
Diluting a strong steroid with moisturiser does not reduce
its clinical effect. Potency reduction is achieved by using a
less potent steroid molecule.
Most topical steroids can be applied once daily, preferably
in the evening or at night.
The recommendation ‘use sparingly’ is nonsensical and
has no value. Use the fingertip unit as a guide.
What is commonly referred to as skin thinning by parents
and non-dermatologists is usually a misinterpretation of
active eczema.
When TCS used for eczema in children are stopped on
resolution of the dermatosis, irreversible skin thinning does
not occur.
TCS do not induce striae when used to treat atopic
eczema in children, unless used inappropriately, or in over-
dose and only then at certain sites (i.e., axillae and groin).
Physiological HPA suppression can occur with very wide-
spread and prolonged, or occlusive use of potent/super-
potent TCS. This recovers quickly.
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Clinically significant/pathological adrenal suppression is
very rare in the treatment of paediatric eczema with TCS.
There is no evidence that applying TCS on excoriated or
infected eczema is deleterious.
TCS should be the first-line treatment for atopic eczema,
regardless of whether the skin is excoriated or infected.
Clinically significant concurrent infection (e.g., S. aureus,
H. simplex, Molluscum) should be treated.
Allergy to TCS is rare in children with atopic eczema, but
should be considered in those children who demonstrate a
poor response to appropriate strength TCS.
Reduced bone mineral density is very unlikely to occur in
children with eczema treated with TCS.
Prolonged use of potent TCS in the periorbital area has
rarely been associated with cataract and glaucoma.
TCS use away from the eyes has not been shown to cause
ocular sequelae.
Transient hypertrichosis has been seen in discoid eczema
and prurigo nodularis treated with potent TCS.
TCS may aggravate a tendency for periorificial/perioral
dermatitis, in predisposed individuals.
The red face has not been described in children with
eczema, but should be kept in mind in teenagers who con-
tinue to deteriorate despite increasing steroid potency.
There is no evidence to show that tachyphylaxis occurs in
children with eczema treated with TCS.
TCS do not induce purpura in children with atopic
eczema.
The hypopigmentation seen in patients treated with TCS,
as their eczema clears, is caused by the eczema (as in
pityriasis alba), not the treatment.
TCS do cause short-term vasoconstriction, which can be
mistaken as hypopigmentation.
Routine use of TCS in children with eczema should not
cause telangiectasia.
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APPENDIX I
Appendix 1. Guidelines for the practical use of TCS
When to apply
Apply 1–2 applications per day as per the product informa-
tion, to all the inflamed skin until eczema is cleared. There
is no requirement for intervals without therapy.
How much to apply
There is no requirement to use sparingly. Please refer to the
following table of application volume recommendation.
Table A1 Fingertip unit17,18
Patient’s age
Face
and
neck
Arm
and
hand
Leg
and
foot
Anterior
chest and
abdomen
Back
and
buttocks
3–12 months 1 1 11⁄2 1 11⁄2
1–3 years 11⁄2 11⁄2 2 2 3
3–6 years 11⁄2 2 3 3 31⁄2
6–10 years 2 21⁄2 41⁄2 31⁄2 5
>10 years 2 1⁄2 4 8 7 7
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ABSTRACT
Background: Atopic dermatitis is a common paedi-
atric dermatological condition. Topical corticosteroids
(TCS) are central to treatment, but non-adherence
leads to poor outcomes and treatment failure. Parents
commonly cite TCS phobia as an obstacle to treatment
adherence. Dermatologists play a key role as clinician
educators around the use, safety and efficacy of
TCS.
Objectives: To assess dermatologists’ attitudes
towards and experiences of the use and safety of TCS
in managing paediatric atopic dermatitis (pAD).
Methods: All 455 practicing Australasian College of
Dermatologists fellows in Australia were surveyed
either when attending the May 2014 annual scientific
meeting or via two subsequent emails. The survey
assessed their attitudes towards the use and safety of
TCS in treating pAD.
Results: Of 198 completed surveys, nearly all
responders prescribed potent or super-potent TCS to
treat pAD. The most common TCS side-effect cited by
over two-thirds of respondents was peri-orificial der-
matitis. Most stated that pharmacists were the most
common source of misinformation leading to TCS
phobia. Of the respondents, 75% strongly agreed that
TCS do not cause skin atrophy when used appropri-
ately and under clinical supervision. Furthermore,
77% agreed or strongly agreed that the words ‘use
sparingly’ should be removed from pharmacist labels
on TCS prescriptions.
Conclusions: Dermatologists manage pAD with
potent or super-potent TCS. Pharmacists are cited as
the main contributor of misinformation leading to
TCS phobia, supporting the removal of the words ‘use
sparingly’ from prescription TCS. Most dermatologists
believe TCS do not cause skin atrophy when used
appropriately in pAD.
Key words: atopic dermatitis, attitudes,
corticosteroid phobia, dermatologists, efficacy,
paeditarics, safety, topical corticosteroids.
INTRODUCTION
Atopic dermatitis (AD) is the most common paediatric der-
matological condition in the world.1 With correct manage-
ment it is also one of the most treatable. Topical
corticosteroids (TCS) are accepted as the gold standard of
treatment of active disease. However, inadequate adher-
ence to medical therapy frequently results in unsatisfactory
treatment outcomes.1–5 Poor adherence often stems from
corticosteroid phobia. That is, although paediatric atopic
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dermatitis (pAD) can be disabling and disruptive of patients
and their families, anxiety over the use of TCS leads to poor
adherence to topical treatment regimens.2,5–8
Corticosteroid phobia is a major cause of non-compliance
and treatment failure in pAD.9–12 This fear of using TCS is
also seen by paediatricians attempting to manage asthma
with inhaled corticosteroids.8–11 Whilst the use of the term
phobia may be a relative misnomer, the resultant fear and
its impact on treatment adherence is very real. Parents are
often warned of the dangers of TCS, not only by their
friends, relatives and the media, but also by traditionally
trusted sources, including their family doctor and pharma-
cists.8 Often when advice and information is offered by
family and friends, it is unsolicited by the parents of chil-
dren with pAD and contributes to the creation of a negative
cultural environment as parents contend with the demands
of managing their child’s illness.
Treatment of AD with TCS results in very few side-effects
when correctly used and a recent consensus statement from
a group of Australian paediatric dermatologists has stated
this categorically.13 However, it is a common belief among
Australian parents that medical treatment for pAD with TCS
is dangerous and that ‘natural’ therapy is safe and therefore
preferable.8 The most common danger associated with the
use of TCS that parents cite is that it will ‘thin the skin’
irreversibly.8 Parents also voice concerns about immune
suppression and growth failure.
Fear of TCS has also been linked to a preference for
natural therapies promoted by complementary and alterna-
tive medicine (CAM) practitioners.8 Parents, who often have
a poor understanding of the predominantly genetic basis of
pAD, frequently pursue the ‘cures’ that CAM purports to
provide.8 This can result in parental abandonment of
evidence-based medical therapy, resulting in potentially
serious, detrimental outcomes for their children. In the
extreme case this has resulted in the death of a child from
sepsis secondary to untreated atopic dermatitis.14
Parents of children with pAD seek advice and support
from their treating dermatologist. In particular, this trusted
relationship is critical to treatment adherence in the face of
the sea of misinformation that parents frequently have to
negotiate. It is important for dermatologists to recognise
their key role as health educators in relation to the use,
safety and efficacy of TCS in pAD.
OBJECTIVES
To assess current attitudes and experience of practicing
dermatologists about the use and safety of TCS in managing
pAD.
MATERIALS AND METHODS
A survey of all 455 Australian-based practicing fellows of the
Australasian College of Dermatologists (ACD) was per-
formed. Initially surveys were distributed at the ACD May
2014 annual scientific meeting (ASM). Two subsequent
follow-up emails were sent to all Fellows, inviting those
who had not already completed the initial survey at the ASM
to complete an electronic version of the survey. The survey
assessed as to their attitude towards the use and safety of
TCS in treatment pAD (Table 1).
RESULTS
Data were collected and analysed from 198 (44%) com-
pleted surveys from a total of 455 dermatologists. A small
number of responses (1%) were excluded since they pro-
vided either nil or multiple answers. Of the sample, 118
(60%) participants completed the paper-based survey while
80 (41%) did so through a web-based format. The 1% of
errors occurred in the paper-based versions of the survey.
Participants’ characteristics (Table 2)
There was a relatively even representation from respond-
ents with a different duration of experience as practising
dermatologists. There was more representation by those
who had been practising for more than 20 years (36%) and
by those who had been practicing for fewer than 5 years
(21%; Table 2). However, this variation in the spread of
experience closely reflects the composition, by years of
practice, of current Fellows of the college (pers. com., ACD,
25 February 2015).
TCS prescribing behaviour (Table 3)
More than half (52%) of the dermatologists reported pre-
scribing between six and 10 topical corticosteroids prescrip-
tions on an average working day for any condition; 7%
reported prescribing more than 16 scripts a day, and 24%
reported prescribing five or fewer a day. Nearly all respond-
ents (98%) reported using a potent or super-potent TCS in
AD when required. A minority (2%) reported that the
strongest class of TCS they would use was moderate. No
dermatologist reported that the strongest TCS they would
use was a weak TCS.
TCS side-effects and source of phobia (Table 4)
Most dermatologists (69%) reported that the most common
side-effect they encountered with TCS use was peri-orificial
dermatitis, with 16% reporting bruising. Only 6% reported
that the most common side-effect seen was cutaneous
atrophy.
Two-thirds (64%) indicated that pharmacists were the
most common source of TCS phobia, followed by 23% who
believed it resuted from the influence of family and friends.
Instructions given when prescribing
TCS (Table 5)
Two-thirds of the dermatologists surveyed (67%) reported
informing their patients that TCS may thin their skin. In this
there was no difference related to the number of years they
had practiced. Instructions to use TCS sparingly were given
by 21% of dermatologists. This instruction was increasingly
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likely as the number of years practiced increased
(P < 0.001). Of the group of dermatologists who had been
practising the shortest period (fewer than 5 years), 3/41
(7%) instructed patients to use TCS sparingly, compared to
Table 1 Assessing dermatologists’ attitude to and use of topical corticosteroids
I have been a consultant dermatologist for
a. 0–5 years
b. 6–10 years
c. 11–15 years
d. 16–20 years
e. >20 years
1. On an average day in my rooms I write scripts for topical corticosteroids
a. 1–5 times
b. 6–10 times
c. 11–15 times
d. 15–20 times
e. >20 times
2. The strongest topical corticosteroid I prescribe is
a. Weak
b. Moderate
c. Potent
d. Superpotent
e. I avoid topical corticosteroids in preference for other topical medications
3. The commonest side-effect I see from topical steroid use is
a. Cutaneous atrophy
b. Striae
c. Telangiectasia
d. Bruising
e. Peri-orificial dermatitis
4. Patients are often concerned about topical corticosteroid use. What do you think is the most common source of this fear?
a. Pharmacist warnings
b. GP warnings
c. Naturopaths or other complementary and alternative medicine provider
d. The internet
e. Influence from friends and family
5. When prescribing topical corticosteroids I do the following
Warn that the medication may thin their skin Yes □ No □
Instruct them to use the medication sparingly Yes □ No □
Give patients a time limit on how long they can use their treatment Yes □ No □
Tell patients to use their treatment until their skin has normalised regardless of how long this takes Yes □ No □
6. On a scale of 1 (strongly disagree) to 5 (strongly agree) indicate to what extent you agree with the following statement:
If used as directed at an appropriate dose and time for skin site and severity of disease, topical corticosteroids are very unlikely to cause
cutaneous atrophy
1 2 3 4 5
Strongly disagree Strongly agree
7. On a scale of 1 (strongly disagree) to 5 (strongly agree) indicate to what extent you agree with the following statement:
The term sparingly should NOT be written on the label of prescribed tubes of topical corticosteroid
1 2 3 4 5
Strongly disagree Strongly agree
Table 2 Surveyed dermatologists’ duration of practice
Respondents,
n (%)
Total 198
Duration of practice (years)
0–5 41 (21)
6–10 28 (14)
11–15 31 (16)
16–20 27 (14)
> 20 71 (36)
Missing 0
Table 3 Average number of topical corticosteroids (TCS) prescrip-
tions written daily by dermatologists
Respondents
n (%)
Number of TCS scripts daily
0–5 47 (24)
6–10 103 (52)
11–15 35 (18)
16–20 7 (4)
20 + 6 (3)
Missing 0
Strongest TCS used
Weak 0 (0)
Moderate 3 (2)
Potent 35 (18)
Super-potent 159 (80)
Avoid 1 (1)
Missing 0
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23/70 (33%) of dermatologists who had been practising for
more than 20 years.
Most dermatologists (61%) gave patients a time limit for
how long TCS could be used. However, 56% also instructed
patients to use their treatment until their skin had normal-
ised, regardless of how long it took with TCS use.
Dermatologists’ beliefs on TCS atrophy and
labelling of TCS (Table 6)
Most (93%) of the dermatologists either agreed (17%) or
strongly agreed (76%) that TCS, if used as directed at an
appropriate dose and duration in accordance with disease
severity, are unlikely to cause cutaneous atrophy. Further-
more, 77% of the dermatologists either agreed (27%) or
strongly agreed (51%) that the term ‘sparingly’ should not
be written on the label of prescribed tubes of TCS. A further
12% were ambivalent on this issue while a minority (11%)
disagreed with this statement.
DISCUSSION
Australian parents commonly believe that TCS used in the
treatment of pAD are dangerous and that natural therapy is
safe and therefore preferable.8 In fact, Charman and col-
leagues9 found that 73% of people were anxious about using
TCS on their own or their child’s skin. Typically, parents
were most anxious that TCS would cause skin thinning
(35%), and 10%were concerned about systemic absorption,
resulting in the retardation of growth and development.
These fears surrounding TCS are common. TCS phobia is
expressed by up to 73% of dermatology patients and
parents.9,15–17 This phenomenon is also encountered by pae-
diatricians attempting to manage asthma with inhaled
corticosteroids.8,10–12 However, the fear associated with
using TCS is not a true phobia. It is the result of misinfor-
mation on the dangers of TCS propagated not only by
friends, relatives and the media but also by traditionally
trusted sources, including their family doctor and, in par-
ticular, pharmacists.8
Our study shows that dermatologists at all levels of clini-
cal experience prescribe potent or super-potent TCS where
clinically appropriate in pAD. This is in contrast to the fear
expressed by parents and even general practitioners of
using even the weakest TCS (1% hydrocortisone) in the
treatment of pAD. While this was not directly assessed in the
survey, it is not unreasonable to assume that the willingness
of dermatologists to prescribe TCS relates to their level of
specific knowledge about the safety and efficacy of TCS and
their general experience of using TCS to manage a spec-
trum of skin conditions.
It was interesting to find that most dermatologists sur-
veyed (64%) believe that pharmacists are the main con-
tributor to misinformation. A further 23% suggest that the
Table 4 Most commonly seen side-effects of topical corticosteroids
(TCS) and most common source of TCS phobia, according to
dermatologists
Respondents
n (%)
Most common side-effect of TCS
Cutaneous atrophy 11 (6)
Striae 3 (2)
Telangiectasia 15 (8)
Bruising 31 (16)
Peri-orificial dermatitis 135 (69)
Missing 3
Source of TCS phobia
Pharmacist 120 (64)
General practitioner 8 (4)
Naturopaths or complementary and
alternative medicine provider
8 (4)
The internet 8 (4)
Influence of family and friends 43 (23)
Missing 11
Table 5 Instructions given by dermatologists when prescribing
topical corticosteroids (TCS)
Respondents
n (%)
Warn that TCS may thin skin
Yes 132 (67)
No 64 (33)
Missing 2
Use TCS sparingly
Yes 41 (21)
No 155 (79)
Missing 2
Time limit on TCS use
Yes 119 (61)
No 76 (39)
Missing 3
Use TCS until skin has normalised
regardless of how long this takes
Yes 108 (56)
No 86 (44)
Missing 4
Table 6 Dermatologists’ beliefs on topical corticosteroids (TCS)
causing atrophy and labelling of TCS
TCS, if used at an appropriate dose and duration,
are unlikely to cause cutaneous atrophy
Respondents
n (%)
Strongly disagree 6 (3)
Disagree 1 (1)
Ambivalent 8 (4)
Agree 33 (17)
Strongly agree 150 (76)
Missing 0
The term ‘sparingly’ should not be written on
the label of prescribed tubes of TCS
Strongly disagree 11 (6)
Disagree 11 (6)
Ambivalent 23 (12)
Agree 53 (27)
Strongly agree 100 (51)
Missing 0
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influence of family and friends is the main contributor. This
is in contrast to a previously reported study of parents in
which friends (88%) and family (50%) were reported to be
a greater influence than pharmacists (44%).8 Nevertheless,
both dermatologists and parents cite these groups as being
very influential in their attitude to TCS, and thus any TCS
safety and education programme needs to target both these
groups.
The most common side-effect seen by dermatologists in
the use of TCS in pAD is peri-orifical dermatitis (69%) and
only a minority cite cutaneous atrophy (6%) as a side-effect.
However, it has previously been shown that when used
under appropriate supervision with careful instructions
from the dermatologist, cutaneous atrophy does not occur
in TCS-treated pAD.18 Despite these facts there is a discon-
nect between the 67% of dermatologists who still specifi-
cally warn parents about TCS as a side-effect while the
majority (79%) do not suggest that TCS should be applied
sparingly. However, this disconnect may be explained by
respondents perhaps answering ‘yes’ to warning about
atrophy, when in fact they were simply mentioning it and
explaining that if TCS is used correctly atrophy should not
occur, and thus addressing patients’ fears about it. For this
reason, the true number of dermatologists reinforcing the
warning that TCS may cause cutaneous atrophy is likely to
be lower.
Nonetheless, in the current climate of widespread TCS
phobia, such warnings may reinforce the existing misinfor-
mation that prevents patients’ adherence to treatment. This
has implications for the education of dermatologists on
their own influence on patients’ behaviour.
Dermatologists who had been practising for longer
periods were more likely to advise patients to use TCS
sparingly. This could either reflect out-of-date information
or the fact that dermatologists who had practised for longer
periods had seen more cutaneous atrophy as an adverse
event across all the conditions they treat. Furthermore, it
could represent the impact of earlier reports exploring side-
effects of TCS.19,20 In light of the finding from this study that
93% of dermatologists believe that TCS was unlikely to
cause cutaneous atrophy and were comfortable with the
safety and efficacy of TCS, it more likely represents practice
methods that do not reflect current evidence.
Another finding from this survey was that there
relabelling TCS prescriptions should be considered. Specifi-
cally, the common recommendation on TCS tubes to use it
sparingly should be removed, as this has the potential of
affecting compliance rates and therefore interfere with the
medical advice given to patients who require TCS for their
treatment. This warning, in fact, directly contravenes most
medical advice from dermatologists and has the potential to
confuse and influence patients to use inadequate amounts
of TCS, leading to the poor management of pAD. A large
number of dermatologists (77%) in this survey believed that
the term ‘sparingly’ should be removed from TCS labels.
The warning also contravenes the pharmacists’ code of
ethics, which specifically states that pharmacists should
label medications only in accordance with what is written
on the prescription by the doctor.21
The lack of need for phrase ‘use sparingly’ of TCS label-
ling is further supported by the fact that a significant portion
of dermatologists treating pAD advise patients that there is
no strict time limit on the duration of TCS use, and that it
should be used until the condition is normalised regardless
of how long it takes.
CONCLUSION
Dermatologists in Australia commonly utilise potent or
super-potent TCS for the treatment of pAD. Most report that
skin atrophy is rare and that side-effects are uncommon
when TCS are used appropriately. Despite the known facts
on the safety of TCS a substantial number of dermatologists
still advise their patients that cutaneous atrophy is a risk of
this treatment, which, in the current climate, may contrib-
ute to TCS phobia. Dermatologists believe that the effective
management of pAD is affected by TCS phobia, for which
pharmacists are cited as the main contributor. Most derma-
tologists support removing the phrase ‘use sparingly’ from
TCS labelling.
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ORIGINAL RESEARCH
Pharmacists’ knowledge about use of topical
corticosteroids in atopic dermatitis: Pre and post
continuing professional development education
Saxon D Smith,1,2,3 Andrew Lee,2,3 Alex Blaszczynski4 and Gayle Fischer2,3
1Dermatology and Skin Cancer Centre, Gosford, 2Department of Dermatology, Royal North Shore Hospital,
3Northern Clinical School, and 4School of Psychology, Sydney University, Sydney, New South Wales, Australia
ABSTRACT
Background/Objectives: Topical corticosteroids
(TCS) are the standard of care in paediatric atopic
dermatitis (pAD). Parents commonly cite TCS phobia
as a major impediment to treatment adherence. Mis-
information on TCS side-effects can impact on per-
ceptions of TCS safety. We aimed to assess
pharmacists’ beliefs and information on the safety of
TCS in pAD treatment and determine whether their
beliefs could be modified.
Methods: Australian pharmacists attending a con-
tinuing professional development conference were
assessed before and after an evidence-based lecture
on the use of TCS in pAD. Responses were recorded in
real time on electronic keypads.
Results: The mean response rate was 86% of the
292 surveyed. Of responders, 64% recognised that
treatment non-adherence was a major reason for
treatment failure in pAD. The post-education session
assessment demonstrated a major attitude shift com-
pared to the pre-education assessment. After educa-
tion, pharmacists would instruct parents/patients to
apply TCS until the eczema is clear (27 vs 92% pre
and post-education, P < 0.0001). The proportion that
would instruct patients to use TCS sparingly dropped
from 54 to 8% (P < 0.0001). The belief that cutaneous
atrophy was the commonest side-effect dropped from
46 to 7% (P < 0.0001). The belief that side-effects from
TCS would occur, even if used appropriately, dropped
from 56 to 11% post-education (P < 0.0001).
Conclusions: The significant knowledge gaps
about the use and safety of TCS in pAD in Australian
pharmacists and their advice to patients poten-
tially contributes to poor treatment concordance.
These attitudes appear modifiable through
targeted, evidence-based education delivered by a
dermatologist.
Key words: adherence, corticosteroid phobia,
knowledge, pharmacist, topical corticosteroid.
INTRODUCTION
Paediatric atopic dermatitis (pAD) is the commonest
paediatric dermatological condition worldwide and, when
managed using topical corticosteroids (TCS), also one of the
most treatable. However, inadequate compliance with
medical therapy frequently results in unsatisfactory treat-
ment outcomes.1–5 Poor concordance often stems from
so-called corticosteroid phobia. That is, although severe
pAD is disabling and disruptive to patients and their fami-
lies, anxiety over the use of TCS leads to poor adherence to
topical treatment regimens and subsequent poor responses
to treatment.1,4–7
Corticosteroid phobia is a major cause of non-
concordance and treatment failure in pAD.8–11 This
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phenomenon is also seen by paediatricians attempting
to manage asthma with inhaled corticosteroids.7–10 The
amount of misinformation current on TCS means that this
concern is widespread.
Treatment of pAD with TCS is accepted as the standard of
care in dermatology. Furthermore, it has very few side-
effects if correctly used.12 However, it is a common belief
among Australian parents that medical treatment for pAD
with TCS is dangerous and that ‘natural’ therapy is safe and
therefore preferable.7 The most common belief that parents
offer regarding perceived risks associated with the use of
TCS is that it will thin the skin irreversibly. Many parents
also voice concerns about immune suppression and growth
failure.7
Fear of TCS appears to be linked to a preference for the
so-called natural therapies promoted by complementary
and alternative medicine (CAM) practitioners.7 Parents,
who often have a poor understanding of and guilt-driven
emotional resistance to the predominantly genetic basis of
pAD, frequently pursue the cures that CAM purports to
provide and also focus on allergy as a cause of atopic der-
matitis (AD).7 This can result in parents’ abandoning
evidence-based medical therapy with potentially serious,
detrimental outcomes for children.12
The objective of this study was to assess pharmacists’
beliefs and sources of information on the safety of TCS in
treatment of pAD and to determine whether their beliefs
can be modified by re-education.
MATERIALS AND METHODS
Pharmacists attending a plenary continuing professional
development conference were assessed on their sources of
education and knowledge of the use of TCS in the treatment
of pAD. All attendees at the conference were able to attend
an evidence-based education session conducted by a paedi-
atric dermatologist presenting data on TCS safety and TCS
phobias, previously published in peer-reviewed jour-
nals.7,12,13 Pre and post-education session assessments were
performed with responses recorded on an electronic keypad
in real time. The questions were developed with the assis-
tance of a psychologist (author AB) and were piloted with
pharmacists prior to the session.
The Northern Sydney Local Health District Human
Research and Ethics Committee indicated that no formal
ethics approval was required due to the voluntary attend-
ance by participants at a conference session where their
attendance formed part of personal professional develop-
ment. Participants gave implied consent by their voluntary
participation in the questions.
A cross-sectional survey was performed at a continuing
professional development conference for pharmacists in
Australia held on the Gold Coast, Queensland, in February
2014. The participants were pharmacists practicing in Aus-
tralia in a range of clinical settings. Participants were
attending an education session delivered by dermatologists
on the management of skin diseases.The participants were
asked a series of multi-choice questions before to a session
specifically dealing with the use and safety of TCS in the
treatment of pAD. They had 15 seconds to respond to each
question. The responses were collected via an individual
de-identified electronic keypad and for each question were
shown to participants in the form of aggregated anonymous
results after the time to respond had expired. The initial 14
questions covered information of the participants’ charac-
teristics, their primary sources of education of TCS during
their pharmacy degree and continuing education, and their
attitudes and knowledge on the use and safety of TCS in
treatment of pAD.
After the education session the final six questions focus-
ing on pharmacist behaviour in dispensing TCS were
repeated to assess any change in their attitudes or future
behaviour as a direct result of the education intervention.
Descriptive statistics were used to characterise question
responses. McNemara’s test was used to compare propor-
tions of correct responses pre and post-education. All analy-
ses were conducted using SPSS 20.0 (SPSS, IBM, Armonk,
NY).
RESULTS
The total number of pharmacists surveyed was 292. The
average number of response per question was 250 of 292
(86%) with the spread of actual response rate of 94 to 276
per question. The median response rate was 261/292 (89%).
Respondents’ characteristics
There was a relatively even spread of pharmacists across all
age groups, with a slight, expected decline in representation
as the age increased. The proportions seen in those sur-
veyed were similar (<30-year-olds, 32 vs 29%; 30–40-year-
olds, 23 vs 31%; 40–50-year-olds, 16 vs 17%; 50–60-year-olds
22 vs 13%; >60-year-olds, 8 vs 15%) to national averages.14
Of those surveyed, 43% had been practising for less than 10
years and 39% for more than 20 years (Table 1).
Half of those present (49%) indicated that their primary
source of continuing information about TCS was from phar-
macy journals, 8% from dermatology journals and 21%
from the internet. The majority (64%) received their under-
graduate education about TCS from a pharmacist and 10%
received it from a dermatologist (Table 2).
Pre-education responses (Table 3)
TCS advice
Just under half (46%) of the respondents stated that they
spent time informing the patient about TCS use even when
prescribed by a dermatologist.
A large portion of pharmacists surveyed did not recom-
mend the use of the TCS in line with the prescription advice.
Of responders, 6% reported that they would suggest an
alternative frequency of application and a further 5% would
advise twice a day regardless of formulation. Furthermore,
67% of pharmacists advised that the maximum duration
that TCS could be used was 2 weeks or less. When directing
the amount of TCS to be applied, 54% reported informing
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© 2015 The Australasian College of Dermatologists
42
the patient that TCS should be used sparingly, while 41%
reported advising patients to use TCS either generously or
based on fingertip unit guidelines. Pharmacists under 40
years of age and those who had been practising for less than
10 years were more likely to recommend TCS use for a short
duration. Only 14 out of 95 who had been practising for less
than 10 years (15%) recommended that TCS be used until
the eczema was clear.
Knowledge
Almost half (46%) of pharmacists believed that skin atrophy
was the most common side effect of TCS. Pharmacists who
had been practising for less than 10 years were more likely
to incorrectly understand this side effect of TCS than those
who had been practising more than 10 years.
Of those surveyed, 64% believed that poor TCS compli-
ance was a major reason why patients with AD fail to get
better. The survey did not explore the source of this infor-
mation and it was therefore not clear if this was because of
patients are not following pharmacist advice or medical
advice. However, it was clear that most are aware of this
problem.
Counselling behaviour
Almost 60% of pharmacists asked patients about the loca-
tion and reasons of their TCS use, and held discussions in
front of other patients. Pharmacists who had been practis-
ing for fewer than 10 years or pharmacists aged under 40
and were more likely to ask questions in a non-private
setting about patients’ TCS use.
Internet education
Pharmacists whose primary source of TCS information was
stated as being from internet sources (21%) were the most
likely to give incorrect answers before the education
session. In general, this subgroup was twice as likely to give
the incorrect answer to every question (except those about
counselling) compared to those who had received their
primary education about TCS from pharmacy and clinical
dermatology journals.
Post-education responses (Table 3)
After the education session, the likelihood of well-informed
responses significantly improved in all seven questions
regarding correct TCS advice, knowledge and counselling
behaviour. More pharmacists now stated they would dis-
pense TCS only as indicated on the prescription (52 vs 88%,
P < 0.0001). Of those surveyed, 92% stated they would
advise TCS be used until the eczema is clear, compared to
27% prior to education (P < 0.0001). Most pharmacists
stated they would now instruct the patient to apply TCS
generously or according to fingertip guidelines (41 vs 72%,
P < 0.0001). Nearly all pharmacists acknowledged that side-
effects do not occur with TCS when they are used appropri-
ately (43 vs 89%, P < 0.0001) and 88% stated they would
now counsel patients about TCS out of earshot of others or
in a private setting, compared to 41% pre-education
(P < 0.0001).
DISCUSSION
Poor compliance with treatment is common in pAD and can
lead to treatment failure. Treatment failure has significant
Table 1 Respondents’ characteristics
Respondents,
n (%)
Total 292
Age (years)
<30 77 (32)
30–40 54 (23)
40–50 38 (16)
50–60 52 (22)
>60 19 (8)
Missing 52
Years of practice
<5 95 (36)
5–9 18 (7)
10–14 26 (10)
15–19 21 (8)
>20 103 (39)
Missing 29
Average number of patients who are prescribed
TCS daily
<1 6 (6)
1–5 41 (44)
6–10 22 (23)
11–15 8 (9)
>15 17 (18)
Missing 198
Table 2 Education of pharmacists
Respondents,
n (%)
Primary source of information about prescription of
TCS:
Pharmacy journals 131 (49)
Clinical dermatology journals 20 (8)
Internet-based sources 57 (21)
Pharmaceutical representatives 35 (13)
Pharmacy meetings 24 (9)
Missing 25
Primary source of education on TCS at university
received from:
A lecturer who was a pharmacist 165 (64)
A lecturer who was a dermatologist 25 (10)
A lecturer who was a non-dermatologist 18 (7)
A pharmacologist 41 (16)
Other source 11 (4)
Missing 32
When dispensing TCS, time spent informing patient/
parent about their use:
Rarely 10 (4)
Only when purchased over the counter 31 (12)
Even when prescribed by a general practitioner 78 (30)
Even when prescribed by a non-dermatologist
specialist
22 (8)
Even when prescribed by a dermatologist 120 (46)
Missing 31
TCS, topical corticosteroids
Pharmacist knowledge of topical steroids 3
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impacts on the patient, family and society.3 A previous study
has shown that patients commenced on topical therapies for
dermatological conditions frequently fail to comply with
their treatment instructions.15 One of the significant contrib-
uting factors affecting treatment adherence in pAD is
corticosteroid phobia. In fact, corticosteroid phobia is
expressed by between 40 and 73% of dermatology patients
and parents.8,16–18
Parents often say that they have been warned of the
dangers of TCS not only by friends, relatives and the media
but also by traditionally trusted sources, including their
general practitioner and pharmacist.7 This helps to create a
negative cultural environment for parents of children with
pAD, which they contend with as well as managing the
treatment demands of their child’s illness.
A recent Australian focus group study showed that
parents commonly believe that medical treatment for pAD
with TCS is dangerous and they prefer ‘natural’ therapy,
which they believe is safer.7 Charman and colleagues found
that 72.5% of people worried about using TCS on their own
or their child’s skin. Although skin thinning remains the
most prevalent fear (35%), 10% of patients were concerned
about systemic absorption resulting in the retardation of
growth and development. Hydrocortisone 1% was the most
commonly used TCS and one-third of the patients using this
classified it as being either strong or very strong, or were
unsure of its potency. This highlights the need for evidence-
based health literacy education to improve patient educa-
tion regarding the safety, potency and appropriate use of
TCS.8 It is important that the education provided to parents
Table 3 Pre and post-education responses of pharmacists
Pre-education,
n (%)
Post-education,
n (%)
Respondents for
both questions,
P-value
When dispensing TCS I recommend it should be applied:
Once a day regardless of formulation 2 (0.8) 4 (2) n = 235
P < 0.0001Twice a day regardless of formulation 12 (5) 4 (2)
Once/twice a day depending on formulation 99 (37) 11 (4)
†Only as indicated on the prescription supplied 137 (52) 220 (88)
I suggest alternative frequency of application 16 (6) 10 (4)
Missing 26 43
When dispensing TCS I recommend the be used for:
Maximum of 3 days 6 (2) 12 (5) n = 247
P < 0.0001Maximum of 1 week 100 (37) 4 (2)
Maximum of 2 weeks 74 (28) 3 (1)
Maximum of 1 month 16 (6) 1 (0)
†Until the eczema is clear 73 (27) 241 (92)
Missing 23 31
When dispensing TCS I instruct the patient/parent to apply:
Only the smallest amount possible 9 (3) 9 (34) n = 246
P < 0.0001Sparingly 145 (54) 21 (8)
As the patient/parent feels appropriate 6 (2) 41 (16)
†Generously 19 (7) 120 (47)
†Based on fingertip unit guidelines 92 (34) 66 (26)
Missing 21 35
The most common side effect from regular use of TCS is:
Stinging/itching 17 (6) 2 (1) n = 251
P < 0.0001Hypo or hyper-pigmentation of the skin (discolouration) 9 (3) 0 (0)
Thinning of the skin (Skin atrophy) 126 (46) 19 (7)
Growth retardation 4 (1) 7 (3)
†None of the above when used appropriately 120 (44) 233 (89)
Missing 16 31
Compliance/adherence with the use of TCS in the treatment of skin conditions:
An insignificant problem as patients with eczema use their medication 17 (7) 9 (4) n = 207
P = 0.002Impossible to prevent 25 (10) 10 (4)
†A major reason patients with eczema fail to get better 155 (64) 189 (79)
A more significant problem with oral agents 25 (10) 6 (3)
A poor excuse for ineffective drug treatment 19 (8) 25 (11)
Missing 51 53
When I counsel patients about using TCS, I:
†Take them to a separate room 1 (0) 24 (10) n = 240
P < 0.0001†Take them aside so that other patients are out of earshot 109 (41) 197 (78)
Talk to them in front of other patients 45 (17) 18 (7)
Ask them why they are using their treatment 48 (18) 1 (0)
Ask them where they will applying their treatment 64 (24) 12 (5)
Missing 25 40
†Correct response, TCS, topical corticosteroids.
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of children suffering with pAD acknowledges the impact of
the pAD and pays particular attention to addressing carers’
treatment beliefs.19
Community pharmacists play a role in educating pati-
ents about the management of dermatology conditions.20,21
The pharmacists’ code of ethics requires that they offer
information on the use of medications but that this
information should never conflict with the prescriber’s
recommendation.22
However, research from our group shows that misinfor-
mation offered by pharmacists in Australia has a major
impact on the perceptions of TCS safety and also reveals
that pharmacists are the most influential group contributing
to TCS phobia in the general public.7 Anecdotally, many
dermatologists have had the experience of patients failing
to respond to treatment due to the modifications imposed by
the pharmacist from whom they obtained their prescription
medication. Reports by patients to dermatologists cite
verbal advice and changes to the labelling on the medica-
tion, particularly the addition of the word sparingly, which
sends a message that the medication is inherently danger-
ous. There is also evidence from a previous French study
that showed that more than 50% of patients reported that
they had been warned about the use of TCS by pharma-
cists.23 This research confirmed that this is also happening
commonly in the community in Australia, with 88% of phar-
macists stating that they would change instructions indicted
on a prescription. Although this dropped to 52% after the
education session, this indicates that this behaviour is dif-
ficult to modify. That 46% of pharmacists reported that skin
atrophy was a common side-effect of the use of TCS also
highlighted the need for further education to pharmacists
about TCS safety. A previous study has called for the
removal of the words use sparingly from the label on pre-
scribed TCS.24 In Australia this is printed automatically by
pharmacy software. It is possible that this influences not
only patients but pharmacists as well.
The data in this study also demonstrate that pharmacists’
sources of information may not be optimal or evidence-
based, and it would appear that this has been amplified in
the last decade, as evidenced by the responses of younger
pharmacists, who are more conservative than older ones.
The data do, however, demonstrate that evidence-based
information may have a prompt impact on beliefs which
were, in the majority, obviously not always firmly held and
were amenable to re-education. The attitude that it is
acceptable to change the content of the label on the medi-
cation from the prescription written by the doctor requires
further exploration, as the reasons for this are likely to be
complex.
A secondary finding that became evident in the data from
this study was that pharmacists not only contradict medical
advice on TCS but engage patients publicly within earshot
of other patients. Again anecdotally, many dermatologists
have heard this from their patients who may find it embar-
rassing and intrusive. Further, this behaviour breaches Aus-
tralian privacy legislation. It would appear that pharmacists
need to become more aware of their impact on patients and
indeed, their vulnerability to patients’ complaints over
privacy. The results from our demographic data are also a
reasonably good representation of the general pharmacist
population, making our results even more applicable.
The responses from the pharmacists in this study also
ironically demonstrate that, despite the fact that they them-
selves realise that poor concordance is a major factor in
poor treatment response, they are unwittingly part of the
problem. The source of their knowledge of poor concord-
ance was not explored by this study as this finding was not
anticipated.
A limitation of our study was that the phrasing of some
questions may have resulted in ambiguity and potentially
reduced validity in some of the responses elicited, and also
contributed to some of the missing responses. A question
that could have been improved included ‘when I dispense
TCS I spend time informing the patient/parent about using
them.’ We also acknowledge that our question on counsel-
ling on TCS use, the questions could have been split into
two separate components such that the first three responses
were separate from the last two options, in order to improve
the validity of the question. The limitations imposed by the
keypads which allowed only one correct answer were not
anticipated.
A further limitation of the study was that we were unable
to assess whether short-term changes in attitudes evi-
denced during the session would translate into long-term
behavioural change. However, most pharmacists receive
information from other pharmacists rather than clinicians,
and this implies that their own health beliefs are subject to
misinformation generated within their own group, without
the involvement of actual stakeholders. Education of phar-
macists by dermatologists on the use of TCS would appear
to be critical to changing the information given to
patients.
Poor concordance with TCS treatment is costly to the
community and to patients, disruptive to the family unit,
frustrating to treating doctors and not based on evidence.
The generation of more evidence of their safety should be a
priority for researchers and every attempt should be made
to disseminate this information to the pharmacy community
both at undergraduate and postgraduate level. Dermatolo-
gists, who have the most confidence in and experience with
the use of TCS, have a critical role in potentially changing
the way pharmacists influence patients in the Australian
community through pharmacy journals, conferences and at
undergraduate level in pharmacy schools at Australian uni-
versities. Removal of the use sparingly instruction on medi-
cation labels should also be a priority.
CONCLUSION
It is evident that there are wide education gaps in Australian
pharmacists’ knowledge of the use and safety of TCS in
pAD. This ultimately contributes to the misinformation
parents and patients receive about the use and safety of
TCS, which in turn directly affects the compliance that is the
key to good treatment outcomes. Targeted education, espe-
cially in pharmacy journals and at undergraduate level,
preferably delivered by a dermatologist, is needed to
Pharmacist knowledge of topical steroids 5
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improve pharmacist’s knowledge and eliminate misconcep-
tions. Our data indicate that their attitudes may be modified
by evidence-based, clinically centred re-education.
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General practitioners’ knowledge 
about use of topical corticosteroids in 
paediatric atopic dermatitis in Australia
Saxon D Smith, Victoria Harris, Andrew Lee, Alex Blaszczynski, Gayle Fischer
aediatric atopic dermatitis (pAD) is the most common 
paediatric dermatological condition, affecting >20% of 
children aged five years or younger.1 All cases of pAD 
require environmental modification, identification and avoidance 
of the triggers that cause flares, but in virtually all except 
mild cases, topical corticosteroids are an essential part of 
management. Poorly controlled pAD has a significantly negative 
impact on the quality of life of affected children, as well as 
their entire family.2,3 Frequently, unsatisfactory outcomes occur 
because of poor adherence with medical therapy4–8 and this 
can stem from multiple sources.9 In particular, ‘corticosteroid 
phobia’ has been identified as a major cause of non-adherence 
and treatment failure.10–13 Despite the burden of pAD to patients 
and families, anxiety regarding the use of topical corticosteroids 
poses a dilemma for parents, where unnecessary fear of using 
a safe and effective treatment paralyses their ability to help their 
child.4,7,8,14,15 This phenomenon is also seen by paediatricians 
when managing asthma with inhaled corticosteroids.10–12,15
Topical corticosteroids are the standard of care in the 
treatment of pAD. When used appropriately they have very 
few side effects.16 However, there is a common belief among 
Australian parents that topical corticosteroids can be dangerous, 
and they prefer ‘safe’, ‘natural’ therapy.15 Parents believe 
irreversible skin thinning (atrophy) to be the most common 
perceived risk. This is also a common belief among Australian 
pharmacists.17 However, dermatologists as a group do not see 
skin atrophy as a common complication,18 and there is a lack of 
evidence from current clinical research for such complications 
when topical corticosteroids are used appropriately.19 The 
subject of general practitioners’ (GPs’) attitudes to the safety of 
topical corticosteroids has not been specifically examined. 
Parents’ attitudes can result in abandonment of 
evidence-based medical therapy, with potentially detrimental 
outcomes.20 Furthermore, inadequately applied topical 
corticosteroids results in poor outcomes, such as rapid rebound 
Background and objective
Topical corticosteroids are the standard of care in paediatric 
atopic dermatitis (pAD). However, messages that overstress 
possible side effects can have a negative impact on perceptions 
of safety and contribute to treatment non-adherence. The aim of 
this study was to assess general practitioners’ (GPs’) perception 
of the safety of topical corticosteroids in pAD treatment.
Methods
Australian GPs participating in continuing professional 
development programs were assessed before an education 
session on pAD. Responses were recorded via an electronic 
survey. 
Results
A total of 257 GPs were surveyed. More than one-third (40.7%) 
of the GPs instructed parents to apply topical corticosteroids 
for two weeks or less. Nearly half (47.7%) instructed parents 
to apply topical corticosteroids sparingly or with the smallest 
amount possible. Furthermore, nearly one-third (30.2%) 
reported skin atrophy as the most common side effect of topical 
corticosteroids. 
Discussion
Advice to patients given by Australian GPs may carry 
unintentional risk messages contributing to treatment 
non-adherence. Evidence-based information on the safety of 
topical corticosteroids is needed to empower GPs to improve 
treatment outcomes in pAD.
P
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flare of pAD from prematurely ceased 
treatment. This creates the impression 
of treatment failure. The objective of 
this study was to assess Australian GPs’ 
beliefs and sources of information on 
topical corticosteroid safety. 
Methods
A survey was administered to Australian 
GPs participating in continuing 
professional development (CPD) 
programs. Participants were invited to 
complete a survey, which assessed 
sources of education and knowledge of 
topical corticosteroids in the treatment 
of pAD. Three separate CPD events 
were used: a web-based education 
module and two separate face-to-
face CPD conferences. Each program 
was approved by The Royal Australian 
College of General Practitioners 
(RACGP) or Australian College of Rural 
and Remote Medicine (ACRRM) for CPD 
accreditation. 
An evidence-based education session 
was conducted by a dermatologist on 
the management of pAD. Surveys were 
completed prior to participating in CPD 
education events. Responses were 
recorded using a web-based module with 
inbuilt data collection and an online survey 
tool (SurveyMonkey) for face-to-face 
conference attendees. Questions were 
developed with the assistance of a 
psychologist (author AB) and piloted with 
GPs prior to the events.
The Northern Sydney Local Health 
District Human Research and Ethics 
Committee indicated that no formal ethics 
approval was required because of voluntary 
attendance by participants at a conference 
session where their attendance formed 
part of personal professional development. 
Participants gave implied consent by their 
voluntary participation in the questions.
Chi-squared test was used to analyse 
question responses using SPSS 20.0 
(SPSS Inc, Chicago, IL).
Results
A total of 257 GPs were surveyed. Of 
these, 109 (42.4%) completed the survey 
prior to the web-based module and 148 
(57.6%) participated in two separate 
face-to-face CPD events. Of those who 
participated in the face-to-face events, 
108 (42.0%) were located in Brisbane and 
40 (15.6%) in Perth.
Demographic data
There was an even spread of GPs across 
all age groups, with the exception of 
those aged <30 years of age (Table 1). 
This broadly compares with national 
averages for the age of practising GPs in 
Australia (<35 years: 13.4%; 35–44 years: 
24.9%; 45–54 years: 24.9%; 55–64 years: 
23.1%; 65–74 years: 11.2%; ≥75 years: 
2.5%).21 Of those surveyed, 16.2% had 
been practising for <10 years and 58.1% 
>20 years.
Source of education
Table 2 shows the sources of education 
about topical corticosteroids. More than 
Table 1. Demographic data
Topics
Respondents, 
n (%)
Total 257
Age (years)
<30
30–39
40–49
50–59
>60
Missing
11 (4.3) 
57 (22.1)
60 (23.3)
78 (30.2)
51 (19.8)
0
Years of practice
<5
5–9
10–14
15–19
≥20
Missing
16 (6.2)
38 (14.7) 
32 (12.4)
40 (15.5)
131 (50.8)
0
Average number of 
patients who are 
prescribed topical 
corticosteroids daily
<1
1–5
6–10
11–15
>15
Missing
69 (26.7)
171 (66.3)
9 (3.5)
3 (1.2)
5 (1.9)
0
Table 2. Education of general practitioners about topical corticosteroids
Respondents, n (%)
Primary source of information about prescription:
• General practice journals
• Dermatology journals
• Internet-based sources
• Pharmaceutical representatives
• Clinical meetings
Missing
106 (41.1)
14 (5.4)
39 (15.1)
20 (7.8)
78 (30.2)
0
Primary source of education at university received from:
• lecturer who was a pharmacist
• lecturer who was a dermatologist
• lecturer who was a non-dermatologist specialist
• lecturer who was a general practitioner
• other source
Missing
19 (7.4)
162 (62.8)
22 (8.5)
20 (7.8)
34 (13.2)
0
Primary source of education during general practice training:
• lecturer who was a pharmacist
• lecturer who was a dermatologist
• lecturer who was a non-dermatologist specialist
• lecturer who was a general practitioner
• other source
Missing
4 (1.6)
99 (38.4)
18 (7.0)
81 (31.4)
55 (21.3)
0
50
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one-third of participants (38.5%) 
indicated that their primary source of 
continuing information about topical 
corticosteroids was from general practice 
journals, 34.5% from clinical meetings/
conferences, 12.8% from the internet 
and 4.0% from dermatology journals. The 
majority (57.4%) received undergraduate 
education about topical corticosteroids 
from a dermatologist. However, during 
postgraduate general practice training, 
nearly as many received their education on 
topical corticosteroids from a GP (31.4%) 
as from a dermatologist (38.2%). 
Topical corticosteroid advice
Responses to questions about prescribing 
and advice given to parents are shown 
in Table 3. The majority of responders 
indicated that they vary the strength 
of topical corticosteroids on the basis 
of disease severity (69.0%) and site 
(63.2%). Twice as many GPs indicated 
that the maximum strength of topical 
corticosteroids they would prescribe was 
potent (36.8%), compared with those 
who would prescribe moderate potency 
(15.1%) or weak potency (16.9%). 
Furthermore, only 3.9% indicated they 
avoid topical corticosteroids.
Less than half (46.9%) of the GPs 
indicated they would recommend applying 
a topical corticosteroid until active 
disease clears and, 40.7% responded that 
they instructed parents to apply topical 
corticosteroids for only two weeks or 
less. There was a trend across the group 
based on age and years of experience. 
GPs younger than 39 years of age were 
more likely to instruct application for 
two weeks or less, whereas GPs aged 
50 years or older were more likely to 
instruct application until pAD was cleared. 
Similarly, GPs with more than 20 years’ 
experience were more likely to instruct 
application of topical corticosteroids until 
pAD cleared.
When directing the amount of topical 
corticosteroids to be applied, nearly equal 
numbers of GPs reported instructing 
parents to apply ‘sparingly’ (37.6%) or 
the smallest amount possible (10.1%) 
as compared with those who instructed 
an amount based on fingertip guidelines 
(39.1%) or ‘generously’ (7.4%). Only a 
minority (5.4%) instructed parents to apply 
as they felt appropriate. There was no 
discernible trend across age or years of 
practice.
Knowledge
More than half (58.1%) of GPs believe 
that when topical corticosteroids are used 
appropriately, side effects are unlikely 
to occur, yet nearly one-third (30.2%) 
indicated that skin atrophy was the most 
common side effect from regular use 
(Table 3). Across all ages and years of 
practice, if a GP indicated they instruct 
parents to apply topical corticosteroids 
sparingly or thinly, they were statistically 
more likely to select skin atrophy as the 
most common side effect (P = 0.002).
Treatment adherence
Of those surveyed, the majority either 
strongly disagreed (17.1%) or disagreed 
(48.8%) that topical corticosteroid 
adherence was an insignificant problem 
because parents/patients use their 
medications. Furthermore, the majority 
either strongly disagreed (14.3%) or 
disagreed (50%) that poor treatment 
adherence was impossible to prevent. 
However, the majority either strongly 
agreed (8.9%) or agreed (57.4%) that 
Table 3. General practitioners’ knowledge responses
n (%)
When I prescribe topical corticosteroids the maximum strength I use is:*
• I avoid topical corticosteroids
• Weak
• Moderate
• Potent
• Based on severity
• Based on site
10 (3.9)
42 (16.9)
39 (15.1)
95 (36.8)
178 (69.0)
163 (63.2)
When I prescribe I recommend they be used for:
• Maximum of 3 days
• Maximum of 1 week
• Maximum of 2 weeks
• Maximum of 1 month 
• Until the eczema is clear†
• Missing
5 (1.9)
28 (10.9)
72 (27.9)
31 (12.0)
121 (46.9)
0
When I prescribe topical corticosteroids I instruct the patient/parent to apply:
• Only the smallest amount possible
• Sparingly
• As the patient/parent feels appropriate
• Generously†
• Based on fingertip unit guidelines†
• Missing
26 (10.1)
97 (37.6)
14 (5.4)
19 (7.4)
101 (39.1)
0
The most common side effect from regular use of topical corticosteroids is:
• Stinging/itching
• Hypo or hyper-pigmentation of the skin (discolouration)
• Thinning of the skin (Skin atrophy)
• Growth retardation
• None of the above when used appropriately†
• Missing
13 (5.0)
14 (5.4)
78 (30.2)
1 (0.4)
150 (58.1)
1
*Multiple responses possible
†Correct response
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poor treatment adherence was the major 
reason patients with pAD fail to get better. 
Interestingly, there were essentially equal 
numbers of respondents who indicated 
they disagreed (33.7%), were neutral 
(34.1%), or agreed (23.3%) that treatment 
adherence issues were a more significant 
problem with oral agents than topical 
agents (Table 4).
Discussion
Paediatric atopic dermatitis is a common 
condition. If managed appropriately, 
mild-to-moderate cases respond readily 
to treatment. This involves using topical 
corticosteroids of adequate potency 
matched to the severity of pAD, in 
amounts that cover all involved areas 
daily until the skin is a normal colour and 
texture, and without a specified time limit. 
Despite this, children with pAD and their 
families continue to experience disruption 
to health and sleep because of parental 
reluctance to undertake safe and effective 
therapy. Children who could be effectively 
treated in general practice find their way 
to a dermatologist, with resultant cost 
to themselves and the community. This 
survey did not explore the information 
source(s) that may contribute to poor 
treatment adherence, but it was clear 
that the majority of GPs are aware of this 
problem.
The role of dermatologists in this 
multidisciplinary team is to increase 
confidence in treatment and educate 
parents on the best use of topical 
corticosteroids. This can involve de-briefing 
anxious and disbelieving parents regarding 
previous treatment advice.
One of the most significant contributing 
factors affecting treatment adherence 
in pAD is corticosteroid phobia, which is 
expressed by 40–73% of dermatology 
patients and parents.10,22–24 Previous 
research shows some parents state one 
source of treatment information leading to 
this fear comes from their GP.15 This study 
sought to explore this further.
A 2006 Australian study found that 
moderate-to-severe pAD caused maternal 
stress equivalent to that associated 
with the care of children with severe 
developmental and physical problems 
such as Rett syndrome.25 More recently, 
an Australian focus group study showed 
parental concerns about the safety of 
topical corticosteroids come from many 
sources, not only pharmacists, family, 
complementary and alternative medicine 
(CAM) practitioners and online information, 
but also their GPs.15 Interestingly, this 
study showed a possible link between 
a fear of using topical corticosteroids 
and a preference for CAM. Parents, who 
often have a poor understanding of, and 
guilt-driven emotional resistance to, the 
genetic basis of pAD, frequently pursue 
‘cures’ that CAM purports to provide. 
Furthermore, this research revealed that 
parents sometimes experienced difficulty 
in convincing their GPs to refer their child 
to a dermatologist. 
GPs are aware that poor adherence is 
a cause of treatment failure. However, 
when GPs instruct parents on short time 
limits and minimal volume application of 
topical corticosteroids in this chronic skin 
disease, or warn about skin atrophy, they 
may unintentionally convey a risk message 
about side effects that confirms parents’ 
misunderstanding of the nature and 
treatment of chronic skin disease.26 
Our group has shown that the word 
‘sparingly’, routinely printed on topical 
corticosteroid labels by pharmacists even 
when not written on prescriptions, has a 
negative impact on patients’ perceptions of 
topical corticosteroid safety.26 In this study, 
the concept of sparing application was also 
embraced by a substantial number of GPs. 
Negative risk messages have a greater 
impact and are more powerfully recalled 
than positive ones, and a warning that is 
casually mentioned by a GP may have a 
profound effect on a parent, particularly 
when this is reinforced by misinformation 
found on the internet.26
In the crowded undergraduate 
curriculum of medical schools, 
dermatology education tends to be 
kept to a minimum. In general practice, 
at least 10% of daily consultations 
relate to the skin. GPs receive further 
training at the postgraduate level, but 
less than half of this is delivered by 
dermatologists, who have hands-on 
experience and confidence in using 
topical corticosteroids. It is interesting 
that younger GPs in our cohort are more 
cautious than older ones. This may 
Table 4. General practitioners’ 
non-compliance responses
n (%)
An insignificant problem as 
patients with eczema use 
their medication:
• Strongly disagree
• Disagree
• Neutral
• Agree
• Strongly agree
• Missing
44 (17.1)
126 (48.8)
41 (15.9)
40 (15.5)
6 (2.3)
0
Impossible to prevent: 
• Strongly disagree
• Disagree
• Neutral
• Agree
• Strongly agree
• Missing
37 (14.3)
129 (50.0)
56 (21.7)
32 (12.4)
3 (1.2)
0
A major reason patients 
with atopic dermatitis fail to 
get better: 
• Strongly disagree
• Disagree
• Neutral
• Agree
• Strongly agree
• Missing
8 (3.1)
35 (13.6)
43 (16.7)
148 (57.4)
23 (8.9)
0
A more significant problem 
with oral agents: 
• Strongly disagree
• Disagree
• Neutral
• Agree
• Strongly agree
• Missing
13 (5.0)
87 (33.7)
88 (34.1)
60 (23.3)
9 (3.5)
0
A poor excuse for 
ineffective drug treatment: 
• Strongly disagree
• Disagree
• Neutral
• Agree
• Strongly agree
• Missing
13 (5.0)
68 (26.4)
78 (30.2)
81 (31.4)
17 (6.6)
0
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reflect changes in medical teaching and 
lack of personal experience.
Research from our group shows that 
misinformation offered by pharmacists 
in Australia has a major impact on 
perceptions of topical corticosteroid safety 
and also reveals that pharmacists are 
the most influential group contributing 
to topical corticosteroid phobia.15 This 
study presents further investigations 
indicating that GPs can have a similar, if 
somewhat less negative, attitude to the 
use of topical corticosteroids. Ultimately, 
this suggests that it is important that 
both groups require an evidence-based 
update on this subject to ensure the best 
outcomes for patients. With a view to 
clarify the safety and efficacy of topical 
corticosteroids, a consensus statement 
by Fellows of the Australasian College of 
Dermatologists regarding the side effects 
of topical corticosteroids has recently been 
published.16
Evidence shows appropriate use of 
topical corticosteroids in treatment of 
pAD does not result in skin atrophy.19 In 
terms of treatment duration, it is important 
that GPs recognise that inflammatory 
skin diseases, which are usually chronic, 
require ongoing topical corticosteroid 
treatment that cannot be time-limited. 
Currently, pharmacists and GPs appear 
to be unwittingly contributing to topical 
corticosteroid phobia, which in turn results 
in treatment failure. In terms of health 
economics, increased confidence at the 
GP level in the appropriate use of topical 
corticosteroids would relieve the burden 
on dermatology services and empower 
GPs to successfully manage pAD. 
There are potential limitations to this 
study, given this is a sample of GPs who 
were participating in CPD activities. This 
may mean that the participant GPs were 
attempting to upskill in an area in which 
they felt deficient, which might mean 
the results overstate the issue at hand. 
Conversely, the results may understate the 
issue at hand with GPs who do not actively 
participate in regular CPD activities in the 
area of dermatology. Another limitation 
is the practical nature of survey-based 
research, which limits a broader diversity 
of potential answers. A further potential 
limitation is that while this study explored 
the management of pAD, it is possible that 
a child’s age (in addition to the site and 
severity of the atopic dermatitis) may also 
affect the maximum strength of a topical 
corticosteroid that a GP will prescribe.
Implications for general practice
There may be education gaps in Australian 
GPs’ knowledge of the use and safety 
profile of topical corticosteroids in pAD. 
This may contribute to exaggerated risk 
messaging that reinforces misinformation 
parents/patients currently receive about 
use and safety of topical corticosteroids 
from numerous sources. In turn, this can 
directly affect treatment adherence, which 
is the key to good outcomes. Targeted 
education, especially in general practice 
journals and CPD conferences, is needed 
to enable successful management of pAD 
in general practice.
For further reading about the clinical 
management of pAD, please refer to an 
article by Page, Weston and Loh, published 
in Australian Family Physician.27
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CHAPTER 7 
Evaluation of the influence of pharmacists and GPs on patient perceptions of long-term 
topical corticosteroid use 
This chapter contains the original research, “Evaluation of the influence of pharmacists and 
GPs on patient perceptions of long-term topical corticosteroid use,” published in the Journal 
of Dermatological Treatment 2017;28:112-118. 
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ABSTRACT
Purpose: To assess pharmacist and general practitioner (GP) advice and behaviors, as related to and
reported by patients and parents of patients using topical corticosteroids (TCS) on a long-term basis.
Materials and methods: Multicenter cross-sectional survey of patients (aged 18þ) and parents of pediat-
ric patients (aged<18) with a history of long-term (1 month) TCS use, assessing: TCS treatment adher-
ence and reasons for non-adherence; beliefs regarding TCS use and safety; messages regarding TCS
received from community pharmacists, GPs, family/friends and the Internet; and experiences of GP and
pharmacist counseling regarding TCS use.
Results: A total of 123 patients and 78 parents completed the survey (n¼ 201). 76.6% of respondents repor-
ted consistently (“Often” or “Always”) receiving one or more message(s) regarding TCS “risk” from a GP and/
or pharmacist (n¼ 192). Respondents reported being told to “try natural or complementary and alternative
therapies before resorting to the use of TCS” significantly more often by pharmacists than by GPs (p¼ 0.039).
Conclusions: High rates of consistently delivered messages about TCS “risk” from GPs and pharmacists
affect patient/parent understanding about TCS safety and may lead to treatment non-adherence. This indi-
cates a need for reeducation of these groups on the safety of TCS use.
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Introduction
Topical corticosteroids (TCS) have been a mainstay in the treat-
ment of inflammatory dermatoses for decades, and there is ample
evidence to support their long-term efficacy and safety. Clinical
dermatologists generally agree that with appropriate use, the ben-
efits of topical corticosteroid therapy continue to outweigh their
putative risks and side effects (1–3).
Despite this expert consensus, TCS treatment adherence tends
to be suboptimal in dermatological patients (4–6). The consequen-
ces of non-adherence in inflammatory skin conditions vary based
upon the severity of the patient’s disease, the condition’s respon-
siveness to TCS and the extent of non-adherence. Ramifications
range from unnecessary symptomatology to disability, with death
at the extreme end of the spectrum (7).
“Corticosteroid phobia” is a significant contributing factor to
TCS treatment non-adherence (8–11). This “phobia” can be attrib-
uted to irrational fear or a lay misunderstanding of the word
“steroid” either due to confusion around the difference between
systemic and topical usage, or between anabolic steroid abuse
and appropriate corticosteroid medication. However, derivation
and propagation of this “phobia” appear to be due to messages
disseminated in the media, on the Internet, amongst friends and
family, and, most troublingly, from conventionally trusted health
professionals such as general practitioners (GPs) and pharmacists
(8,9,12).
Significant knowledge gaps exist amongst pharmacists with
regard to TCS use in atopic eczema (13), and both pharmacists
and GPs continue to verbally warn patients about the presumed
“risks” of appropriate long-term TCS use (9,12). Calls to remove
the words “sparingly,” “thinly” and other warnings that may fuel
corticosteroid phobia from TCS packaging (14) have been only
sporadically heeded in community pharmacies. These observations
suggest that the use of warnings against long-term TCS usage is
deeply ingrained into pharmacy and GP professional cultures.
Thus, further investigation and intervention are required.
Community pharmacists and GPs are well placed to identify
and intervene in patient non-adherence since they see a given
patient more often than dermatologists do and may observe the
patient’s prescription refill patterns (15–18). Pharmacist and GP
interventions have been associated with improvements in treat-
ment adherence (19,20), but there is concern that messaging
inconsistent with dermatologist advice correlates with poorer
adherence (13,21). Hence, it is imperative that dermatologists, GPs
and pharmacists send consistent messages to dermatological
patients regarding the safety of long-term TCS use.
Materials and methods
Survey development
A cross-sectional survey was designed to assess pharmacist and
GP advice and behaviors, as related to and reported by patients
and parents of patients using TCS on a long-term basis.
The following information was collected:
 Demographics
 Rates of TCS treatment adherence
 Reasons for non-adherence
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 Beliefs regarding TCS concerns, necessity and self-efficacy
 Beliefs regarding consistency and reliability of information
sources
 Frequency of messages received from community pharma-
cists, GPs, family/friends and the Internet regarding TCS-
related risks and benefits
 Experiences of TCS-use counseling with GPs and
pharmacists
TCS treatment adherence was evaluated using the five-item
medication adherence report scale (MARS), a validated tool which
asks about unintentional (one item) and intentional (four items)
non-adherent behaviors (22,23). Respondents reported the fre-
quencies of these non-adherent behaviors on a five-point Likert-
type scale, from “Never” to “Always”.
The survey was piloted with patients and parents prior to the
commencement of data collection. The respondents’ pilot survey
responses and verbal feedback were utilized to optimize survey
design. Piloting and feedback incorporation were iterated until no
further changes were required.
Within questions, statements were ordered randomly so that
related statements were not clustered together and positive and
negative statements were interspersed. Questions were without
jargon or abbreviations. Adult and pediatric versions of the survey
differed in phrasing but not in content, except for one question
pertaining only to the pediatric population (“I worry that TCS may
reduce my child’s growth”).
A pharmacist (author SC) and a psychologist (author AB) were
involved with survey development.
The study protocol was approved by the Health Research
Ethics Committee of the Northern Sydney Local Health District at
Royal North Shore Hospital, and by the North Shore Private
Hospital Ethics Committee, as a low/negligible risk study.
Study participants and administration
The study participants included dermatological patients (aged
18þ) and parents of pediatric dermatological patients (aged<18)
with a history of long-term (1 month) TCS use. Participants were
recruited in the waiting rooms of three dermatology outpatient
clinical sites within Greater Sydney: public clinics at Royal North
Shore Hospital, private pediatric and vulvovaginal clinics at North
Shore Private Hospital and a private clinic in Gosford. Both adult
patients and parents of pediatric patients were recruited at each
site. All qualifying participants with English language literacy were
invited to participate in the study.
All study participants were informed about the objectives of
the study prior to enrollment, and were given an information
sheet about the safety of TCS upon completion and submission of
their survey. Survey responses were anonymous, and participant
consent was granted implicitly. Respondents were allowed to skip
questions or mark them as “not applicable” if the topic was not
relevant to their personal experiences to date. The participants
did not receive compensation for their time.
Statistical analysis
Survey responses were analyzed using descriptive statistics. Each
MARS item was analyzed separately (rather than using a combined
numerical score, which risks over-simplification of the results). All
ordinal analyses of five-item Likert-type scales were executed on
three composite categories (negative, neutral/equivocal and
positive):
 Adherence and Messages: Never/Rarely, Sometimes, Often/
Always
 Experiences: Strongly Disagree/Disagree, Neutral, Agree/
Strongly Agree
Wilcoxon signed-rank tests were used for paired comparisons
between pharmacists and GPs. Friedman tests were used for com-
parisons between messages received from pharmacists, GPs, fam-
ily/friends, and the Internet; messages with significant results were
followed up with post-hoc pairwise comparisons between each
unique pair of message sources to identify differences underlying
the result. All statistical analyses were performed with SPSS ver-
sion 23.0 (SPSS Inc., Chicago, IL).
Two surveys were excluded from the final results due to
incompleteness.
Results
A total of 201 completed surveys were collected between January
2015 and February 2016, with 61.2% from adult patients (n¼ 123)
and 38.8% from parents of pediatric patients (n¼ 78). Each study
site contributed surveys to this total, with 40.8% (n¼ 82) from
North Shore Private Hospital, 39.3% (n¼ 79) from Royal North
Shore Hospital and 19.9% (n¼ 40) surveys from the private clinic
in Gosford.
Respondent and patient characteristics
Characteristics of the survey respondents (adult patient or parent
of the pediatric patient) and the patients are given in Table 1.
Of the patients, 52.8% were aware of the concept of a
“fingertip unit” (104 out of 197 respondents) (24). Of those aware,
reported sources of information on the concept were (respond-
ents could select multiple sources if applicable): dermatologist
(54.8%, n¼ 57), GP (25.0%, n¼ 26), pharmacist (16.3%, n¼ 17) and
other (e.g. another type of specialist, the Internet, or written mate-
rials) (30.8%, n¼ 32).
Adherence
Responses to the five-item MARS are presented in Table 2. Non-
adherence rates, defined as reporting to engage in non-adherent
Table 1. Respondent and patient characteristics.
Survey type
Adult patients 61.2% n¼ 123
Pediatric patients 38.8% n¼ 78
Mean age
Respondents 47.9 years (range 20–82 years) n¼ 200
Adult patients 53.1 years (range 20–82 years) n¼ 123
Pediatric patients 7.5 years
(range 5 months–17 years)
n¼ 78
Gender
Respondents 21.1% male, 78.9% female n¼ 199
Adult patients 26.2% male, 73.8% female n¼ 122
Pediatric patients 38.7% male, 61.3% female n¼ 75
Highest level of education attained n¼ 197
Some High school 11.2% n¼ 22
Completed Year 12 8.6% n¼ 17
Diploma/Certificate 25.9% n¼ 51
Bachelor degree 35.5% n¼ 70
Master’s degree or Doctorate 18.8% n¼ 37
Median duration of TCS use 2.0 years (IQR 0.5–7.0 years) n¼ 201
TCS prescriber(s)a n¼ 201
Dermatologist 70.1% n¼ 141
GP 59.2% n¼ 119
Other 23.4% n¼ 47
aPatients may have been prescribed TCS by more than one type of healthcare
provider.
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behaviors “Sometimes”, “Often”, or “Always”, ranged from 30.9 to
56.3%. These high rates of non-adherence are consistent with pre-
vious studies (5,6,8–10).
Respondents who reported imperfect adherence (i.e. did not
answer “Never” to all five MARS items, n¼ 177) indicated their rea-
sons for non-adherence by selecting any/all applicable reasons, as
summarized in Figure 1.
Beliefs
Respondents’ reported beliefs are summarized in Table 3. Overall,
respondents described high rates of self-efficacy, and a majority of
respondents acknowledged the necessity for TCS therapy. Rates of
reported concern about TCS varied, depending on the specific
concern. The concern statement with the highest “Agree”/
“Strongly Agree” rate was “I worry about the long-term effects of
TCS [on my child]” (58.1%, n¼ 115). Only 27.8% of respondents
“Disagree” or “Strongly Disagree” with the statement “I worry that
TCS thin my [child’s] skin” (n¼ 55).
Only 44.8% of respondents “Agree” or “Strongly Agree” that
“Pharmacists instruct me to apply the TCS exactly as directed by
my doctor” (n¼ 87).
Messages
The reported frequencies of message receipt regarding TCS bene-
fits and “risks” from GPs and pharmacists are presented in Table 4,
along with the results of the Wilcoxon signed-rank tests compar-
ing paired reported rates for GPs vs. pharmacists. The paired
nature of the analyses required valid responses from both the GP
and pharmacist subparts of a question. This resulted in relatively
lower analyzable populations (n¼ 139–160).
Respondents reported receiving all four messages about the
benefits of TCS significantly more often from GPs than from phar-
macists (p< 0.001). They also reported being encouraged to “try
natural or complementary and alternative therapies before resort-
ing to the use of TCS” significantly more often by pharmacists
than by GPs (p¼ 0.039).
The other five messages about the “risks” of TCS were not
reported as being received significantly more often from either
GPs or pharmacists. Overall, 76.6% of 192 respondents received at
least one of the six messages about TCS “risk” from a GP and/or
pharmacist “Often” or “Always”.
Friedman tests (and post-hoc pairwise comparisons) between
the reported frequencies of message receipt from GPs,
Table 2. Five-item medication adherence report scale (MARS) responses.
Question stem: “Many people find a way of using their medicines that suits them. This may differ from the instructions on the label or from what their doctor had
said. For each statement please tick one circle that best applies to you [and your child]:”
Statement “Never” or “Rarely”, n (%) “Sometimes”, n (%) “Often” or “Always”, n (%) Missing, n
“I alter the amount of TCS that I use [on my child].” 90 (45.9%) 65 (33.2%) 41 (20.9%) 5
“I forget to use the TCS [on my child].” 124 (65.6%) 54 (28.6%) 11 (5.8%) 12
“I stop using the TCS [on my child] for a while.” 84 (43.8%) 66 (34.4%) 42 (21.9%) 9
“I use less of the TCS [on my child] than instructed.” 130 (69.1%) 46 (24.5%) 12 (6.4%) 13
“I decide to skip an application of the TCS [on my child].” 121 (63.4%) 57 (29.8%) 13 (6.8%) 10
Figure 1. Reported reasons for non-adherence to TCS therapy. Respondents could choose multiple responses.
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pharmacists, family/friends and the Internet showed the following:
family/friends and the Internet reportedly provided some of the
messages about TCS benefits significantly less often than GPs and
pharmacists, yet they provided some of the messages about TCS
‘“risk” significantly more often. The exception to this was the “risk”
message “Apply topical corticosteroids ‘sparingly’ or ‘thinly’”,
which was reported as being received more often from GPs and
pharmacists than from family/friends and the Internet (n¼ 133,
p< 0.001).
Experiences
The reported experiences of respondents with GPs and pharma-
cists in relation to TCS use are detailed in Table 5. As with the
message analyses, the paired nature of the Wilcoxon signed-rank
tests required valid responses from both the GP and pharmacist
subparts of a question. This resulted in relatively lower analyzable
populations (n¼ 124–152). For all eight experiences examined,
GPs were reported to perform incorrect behaviors significantly less
often than pharmacists.
Discussion
Our study confirms the high rates of non-adherence with topical
corticosteroid therapy reported by others (Table 2) (5,6,8–10). It
also substantiates the high rates of concern about TCS use
amongst patients and parents in the community (3,9–14), with a
majority of respondents reporting that they worry about the long-
term effects of TCS (Table 3). The high rates of risk-related mes-
sages received from pharmacists and GPs provide additional
evidence that these healthcare team members are inaccurately
warning patients against purported “risks” of long-term TCS use
(4,8,9,12).
Our study is unique in that it quantifies the frequency of
patient-reported receipt of six of these risk-related messages
(Table 4). These rates were very high with 29.9 and 35.3% of
respondents reported “Often” or “Always” being told by their GPs
and pharmacists, respectively, that TCS cannot be used long-term.
Despite increased levels of education in and experience with
inflammatory skin conditions, GPs performed similarly to pharma-
cists with regard to their frequency of TCS “warnings” (with the
exception of encouraging “natural” and “complementary and alter-
native therapies” over TCS use, which is more commonly attrib-
uted to pharmacists). Adding to the concern, a majority of
patients did not agree that pharmacist instructions on TCS appli-
cation are exactly the same as instructions from their doctor.
Respondents reported that GPs delivered messages about the
benefits of TCS use more frequently than pharmacists. While this
is a positive indicator for how GPs support their patients with
chronic inflammatory skin conditions when compared to pharma-
cists, there is still scope for improvement. Also, GPs are delivering
messages about the benefits of TCS more often than pharmacists,
most probably due to the different, more personal nature of their
interactions with the patient. While community pharmacists and
GPs are both constrained by limitations on time, pharmacists are
also constrained by the lack of private consultation areas and a
lack of access to the patient’s clinical history (17,21).
Patient and parent experiences were reported as being more
positive with GPs than with pharmacists (Table 5). Again, this
could be explained by the comparatively thorough nature of GPs’
Table 3. Patient beliefs.
Question stem: “For each of the following statements, please place a tick in the circle under the level of agreement that best reflects your current opinion of using
TCS [on your child]:”
Category (not
indicated on survey) Statement
“Strongly Disagree”
or “Disagree”, n (%) “Neutral”, n (%)
“Agree” or “Strongly
Agree”, n (%) Missing, n
Necessity “My life would be more difficult without topical corticoste-
roids for my [child’s] skin condition”
20 (10.3%) 39 (20.1%) 135 (69.6%) 7
“The health of my [child’s] inflamed skin, at present, depends
on using TCS”
30 (15.2%) 24 (12.2%) 143 (72.6%) 4
“In the future, the health of my [child’s] inflamed skin will
depend on using TCS”
30 (15.4%) 50 (25.6%) 115 (59.0%) 6
“Without TCS, my [child’s] inflamed skin would be worse” 15 (7.7%) 19 (9.7%) 161 (82.6%) 6
“TCS keep my [child’s] inflamed skin condition under control” 15 (7.6%) 32 (16.2%) 150 (76.1%) 4
Concern “I worry that TCS cause changes in my [child’s] skin color” 97 (49.5%) 60 (30.6%) 39 (19.9%) 5
“I worry that TCS make my [child’s] immune system less
effective”
78 (40.2%) 76 (39.2%) 40 (20.6%) 7
“I worry that TCS cause unwanted hair growth [on my
child]”
123 (63.4%) 51 (26.3%) 20 (10.3%) 7
“I worry about [my child] becoming too dependent on TCS” 72 (36.7%) 53 (27.0%) 71 (36.2%) 5
“I worry that TCS thin my [child’s] skin” 55 (27.8%) 56 (28.3%) 87 (43.9%) 3
“I worry about the immediate effects of TCS [on my child]” 77 (39.3%) 60 (30.6%) 59 (30.1%) 5
“I worry about the long-term effects of TCS [on my child]” 48 (24.2%) 35 (17.7%) 115 (58.1%) 3
“Using TCS [on my child] is disruptive to my life” 127 (65.1%) 36 (18.5%) 32 (16.4%) 6
“I worry that TCS may reduce my child’s growth” (Pediatric
question only)
38 (51.4%) 24 (32.4%) 12 (16.2%) 4
Self-efficacy “I am capable of following the doctor’s instructions to apply
TCS”
6 (3.0%) 15 (7.6%) 176 (89.3%) 4
“I am confident that I can follow the directions of the doctor
in using TCS”
4 (2.0%) 14 (7.1%) 179 (90.9%) 4
“Following the doctor’s instructions to use TCS is easy” 10 (5.1%) 18 (9.1%) 170 (85.9%) 3
Information sources “Pharmacists instruct me to apply the TCS exactly as directed
by my doctor”
48 (24.7%) 59 (30.4%) 87 (44.8%) 7
“I feel more confident following the advice of a pharmacist
than a GP”
126 (64.3%) 53 (27.0%) 17 (8.7%) 5
“I feel more confident following the advice of a pharmacist
than a dermatologist”
162 (82.7%) 28 (14.3%) 6 (3.1%) 5
“If a pharmacist gave me different advice to a doctor, I
would follow the pharmacist’s advice in preference to the
doctor”
159 (81.1%) 27 (13.8%) 10 (5.1%) 5
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patient–provider relationships. However, both GPs and pharma-
cists need to improve their practices around TCS counseling since
patients reported negative experiences with both groups. For
example, only 24.8% of patients/parents “Agree” or “Strongly
Agree” that pharmacists make them feel reassured about TCS,
with the proportion increasing to only 57.9% for GPs.
Pharmacists may be unaware of their impact on patients using
long-term TCS. In this study, only 64.3% of respondents said that
they “Disagree” or “Strongly Disagree” with the statement “I feel
more confident following the advice of a pharmacist than a GP”,
while 27.0% were “Neutral”, and 8.7% said they “Agree” or
“Strongly Agree” (i.e. they may preferentially follow the pharma-
cist's advice, with 5.1% agreeing that they would follow pharma-
cist advice in the event of a conflict with the doctor’s advice). This
suggests that pharmacist advice about TCS use is highly influen-
tial. In an unpublished pilot focus group study with seven com-
munity pharmacists by our research group (25), pharmacists did
not recognize their role in the management of chronic inflamma-
tory skin conditions, and explained that their influence primarily
lies in the management of acute conditions with Schedule 3
(behind the counter) TCS. In addition, they did not perceive any
patient concerns about TCS use, except in parents of pediatric
patients. A lack of awareness of the extent of patient TCS phobia
coupled with an under-appreciation of pharmacists’ influence as
trusted experts in chronic disease management constitutes a trou-
bling combination. It is unlikely that community pharmacists are
aware of the impact of their brief counseling or the impact of
“throwaway” statements about TCS on patients.
Future research should include further exploration of commu-
nity pharmacist and GP views on their TCS-related practices, and
on their educational sources. To this aim, our research group will
be holding focus groups with community pharmacists, based on
the methodology already piloted (25). The focus group results will
subsequently inform the development of a widely distributed sur-
vey of community pharmacists on their TCS beliefs and counseling
practices with the ultimate aim being to change pharmacist
behavior with respect to advice on using TCS.
This study is unable to place the respondents’ answers within
the context of their relationships with GPs and pharmacists. For
example, a patient who does not have a regular GP may be coun-
seled differently to a patient who has had a long-term relationship
with a trusted GP. Similarly, a patient who has had their inflamma-
tory skin condition managed exclusively by a GP may receive
more extensive counseling on TCS use than a patient who only
sees their GP for dermatologist referrals or TCS repeat
prescriptions.
Another limitation of this study is its inability to consider per-
sonality and other personal factors, which may contribute to
patient and parent behaviors and attitudes (26). While it was
beyond the scope of this study, this is an important consideration
for future exploration. There may be specific personality traits that
are both readily identifiable and have a meaningful impact on
TCS adherence and attitudes, thus warranting clinical intervention.
In interpreting the results of this study, it is important to rec-
ognize the possibility that a “negativity bias” (negative messages
and experiences are more emotive and therefore more memor-
able than neutral or positive ones) has influenced respondents’
recollection of messaging and experiences. This reinforces the
importance of positive messaging when advising patients on the
use of TCS.
Our study is statistically underpowered to draw conclusions
about how adherence and beliefs are influenced by messages
from and experiences with providers. Our research group is con-
sidering the feasibility of additional recruitment for this purpose.
As current practices and educational sources are better under-
stood, we are becoming better-equipped as a dermatological
community to target interventions toward problem areas (e.g.
through continuing professional education, educational campaigns
and modification of teachings at the university level). A collabora-
tive approach to reeducation, involving dermatologists, commu-
nity pharmacists, GPs, university educators, pharmaceutical
companies and patients/parents, will ultimately yield the most
robust results in combating topical corticosteroid phobia and
improving treatment adherence. Dermatologists play a key role in
efforts to reeducate other members of their healthcare team and
in continuing to counsel patients about the conflicting and erro-
neous messages they may receive about TCS use until that reedu-
cation is complete.
Conclusions
Adherence to long-term TCS therapy is poor, while patient and
parent beliefs about the “risks” of TCS are common. Incorrect mes-
sages about the “dangers” of long-term TCS use are being
received by a majority of patients and parents on a consistent
basis from trusted health professionals such as pharmacists and
GPs. Friends, family and the Internet also propagate these inaccur-
acies. Patients and parents report having negative TCS-related
counseling experiences with both pharmacists and GPs, but these
negative experiences occur more frequently with pharmacists.
These findings indicate a need for reeducation of both pharma-
cists and GPs on the safety of TCS use and the potential impact of
their counseling on treatment adherence.
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ABSTRACT
Background: Topical corticosteroids (TCS) are key to managing chronic inflammatory dermatoses (CID).
Parents/patients cite TCS phobia as an impediment to treatment adherence. Family/friends and the
Internet are a source of misinformation on TCS which can negatively impact perceptions of TCS safety.
Purpose: To assess information from family/friends and the Internet, as related to and reported by
patients/parents using long-term TCS.
Methods: A multicenter cross-sectional survey of patients (aged >18 years) and parents of patients
(aged <18 years) with a history of CID requiring long-term (1 month) TCS use assessing messages about
TCS received from family/friends and the Internet.
Results: A total of 123 patients and 78 parents completed the survey (n¼ 201). Parents/patients were more
likely to be informed by the Internet “[having] my [child’s] skin condition means that [I/he/she] will need to
use topical corticosteroids” (p< .001) and that “inflamed skin conditions will improve with the topical corti-
costeroids” (p¼ .007). Family/friends were more likely to recommend parents/patients “try non-prescription
creams/ointments before resorting to the use of prescription topical corticosteroids” (p¼ .014).
Conclusions: High rates of messages about TCS “risk” from family/friends and the Internet may affect
patient/parent understanding about TCS safety. This may contribute to treatment non-adherence.
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Introduction
Chronic inflammatory dermatoses (CID) are commonplace derma-
tological conditions, with atopic dermatitis (AD) alone affecting
more than 20% of children (1) and 7% of adults (2). Topical cor-
ticosteroids (TCS) are a key to managing cutaneous inflammation
with the safety and efficacy of TCS well-supported. In particular,
dermatologists generally agree that with appropriate use, the ben-
efits of TCS therapy continue to outweigh the low incidence of
any putative risks and side effects (3–6). However, unsatisfactory
treatment outcomes and inadequate disease control can result
from poor compliance with medical therapy (7–11). There are sev-
eral factors that can independently or collectively contribute to
poor compliance (12). “Corticosteroid phobia” is anxiety regarding
the use of TCS due to patient or parent concerns about their
safety and efficacy despite the potential for AD and other CID to
be disabling and disruptive for patients and their families
(7,10,11,13,14). This can lead to poor adherence to topical treat-
ment regimens and subsequent poor responses to treatment.
“Corticosteroid phobia” has been identified as a major cause of
noncompliance and treatment failure in CID (15–18). However,
this phenomenon is also seen by pediatricians and respiratory
physicians attempting to manage asthma with inhaled corticoste-
roids (14–17). The amount of misinformation currently available
about TCS means that this concern is widespread. This misinfor-
mation can range from a common belief among parents that
medical treatment for AD with TCS is dangerous through to a
preference for complementary and alternative medicine (CAM),
or that “natural” therapy is safe and therefore preferable (14). The
most common belief that parents offer regarding perceived risk
associated with the use of TCS is that it will thin the skin irrevers-
ibly. However, especially in the pediatric population, many parents
also voice concerns about immune suppression and growth failure
(14). Patients and parents cite a range of sources for their informa-
tion on the safety and efficacy of TCS in AD (14). In particular,
they clearly identify there is a significant role of family/friends and
the Internet as an information resource. However, the information
provided can detrimentally impact a patient’s or parent’s under-
standing of the safety and efficacy of TCS to manage their (or
their child’s) AD. This can lead to abandonment of evidence-based
medical therapy with potentially serious detrimental outcomes,
especially in children (19).
Objectives
To assess advice and information from family/friends and the
Internet, as related to and reported by patients and parents of
patients using TCS on a long-term basis.
Materials and methods
Materials and methods
Survey development
A cross-sectional survey was designed to assess the information
and advice received from family/friends and the Internet in
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relation to and as reported by patients and parents of patients
using TCS on a long-term basis.
The following information was collected:
 Demographics
 Rates of TCS treatment adherence
 Reasons for non-adherence
 Beliefs regarding TCS concerns, necessity, and self-efficacy
 Beliefs regarding consistency and reliability of information
sources
 Frequency of messages received from community pharma-
cists, general practitioners (GPs), family/friends, and the
Internet regarding TCS-related risks and benefits
The survey was piloted with patients and parents prior to the
commencement of data collection. The respondents’ pilot survey
responses and verbal feedback were utilized to optimize survey
design. Piloting and feedback incorporation were iterated until no
further changes were required.
Within questions, statements were ordered randomly so that
related statements were not clustered together and positive and
negative statements were interspersed. Questions were without
jargon or abbreviations. Adult and pediatric versions of the survey
differed in phrasing but not in content, except for one question
pertaining only to the pediatric population (“I worry that TCS may
reduce my child’s growth”).
A psychologist (A.B.) was involved with survey development.
The study protocol was approved by the Human Research
Ethics Committee of the Northern Sydney Local Health District at
Royal North Shore Hospital, and by the North Shore Private
Hospital Ethics Committee.
Study participants and administration
The study participants included dermatological patients (aged
>18 years) and parents of pediatric dermatological patients
(patients aged <18 years) with a history of long-term (1 month)
TCS use for CID. Participants were recruited in the waiting rooms
of three dermatology outpatient clinical sites within Greater
Sydney: public clinics at Royal North Shore Hospital, private pedi-
atric and vulvovaginal clinics at North Shore Private Hospital, and
a private clinic in Gosford. Both adult patients and parents of
pediatric patients were recruited at each site. All qualifying partici-
pants with English language literacy were invited to participate in
the study.
All study participants were informed about the objectives of
the study prior to enrollment, and given an information sheet
about the safety of TCS upon completion of the survey. Survey
responses were anonymous, and participant consent was granted
implicitly. Respondents were allowed to skip questions or mark
them as “not applicable” if the topic was not relevant to their
personal experiences to date. The participants did not receive
compensation for their time.
Statistical analysis
Survey responses were analyzed using descriptive statistics.
Wilcoxon signed-rank tests were used for paired comparisons
between family/friends and the Internet. All statistical analyzes
were performed with SPSS version 23.0 (SPSS Inc., Chicago, IL).
Note: results of the messaging received from GPs and pharmacists
and the impact of these messages has previously been published
(20) and are not included in the results herewith.
Two surveys were excluded from the final results due to
incompleteness.
Results
A total of 201 completed surveys were collected between January
2015 and February 2016, with 61.2% from adult patients (n¼ 123)
and 38.8% from parents of pediatric patients (n¼ 78). Each study
site contributed surveys to this total, with 40.8% (n¼ 82) from
North Shore Private Hospital, 39.3% (n¼ 79) from Royal North
Shore Hospital, and 19.9% (n¼ 40) surveys from the private clinic
in Gosford.
Respondent and patient information (Table 1) has pre-
viously been published in Journal of Dermatological Treatment
(2016) (20).
Risk/benefit messages
Respondents reported that they received all four benefit messages
from family/friends and the Internet (Table 2). Of respondents,
26.8% reported that the Internet often/always had informed them
that “[having] my [child’s] skin condition means that [I/he/she] will
need to use topical corticosteroids” compared with only 15.3%
from family/friends with Wilcoxon signed-rank test demonstrating
Table 1. Respondent and patient characteristics.
Survey type
Adult patients 61.2% n¼ 123
Pediatric patients 38.8% n¼ 78
Mean age
Respondents 47.9 years (range 20–82 years) n¼ 200
Adult patients 53.1 years (range 20–82 years) n¼ 123
Pediatric patients 7.5 years (range 5 months–17 years) n¼ 78
Gender
Respondents 21.1% male, 78.9% female n¼ 199
Adult patients 26.2% male, 73.8% female n¼ 122
Pediatric patients 38.7% male, 61.3% female n¼ 75
Highest level of education attained n¼ 197
Some high school 11.2% n¼ 22
Completed Year 12 8.6% n¼ 17
Diploma/certificate 25.9% n¼ 51
Bachelor degree 35.5% n¼ 70
Master’s degree or doctorate 18.8% n¼ 37
Median duration of TCS use 2.0 years (IQR¼ 0.5–7.0 years) n¼ 201
TCS prescriber(s)a n¼ 201
Dermatologist 70.1% n¼ 141
GP 59.2% n¼ 119
Other 23.4% n¼ 47
aPatients may have been prescribed TCS by more than one type of healthcare provider. IQR: interquartile range.
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a significant difference in the mean/distribution of the responses
(p< .001). Furthermore, 36.4% reported that the Internet often/
always informed them that “inflamed skin conditions will improve
with the topical corticosteroids” as compared to 27.2% with
Wilcoxon signed-rank test demonstrating a significant difference
in mean/distribution of the responses (p¼ .007). For the other two
benefit messages, there was no statistical significant variation on
Wilcoxon signed-rank testing between the frequency of messaging
between family/friends and the Internet: “Using TCS is good for
inflamed skin” (23.2 versus 20.8%); “Topical corticosteroids will
control my [child’s] symptoms, but they will not provide a per-
manent cure. Because of this, [I/my child] need[s] to continue
using topical corticosteroids whenever necessary.” (22.5 versus
23.7%). Benefit messages, overall, were received by approximately
a third of patients from both sources.
Furthermore, respondents reported that they received the six
messages about the risks of TCS from both family/friends and the
Internet (Table 3). In particular, parents/patients stated that they
often/always received the message “Try non-prescription creams/
ointments before resorting to the use of prescription topical corti-
costeroids” more frequently from family/friends than from the
Internet (26.3 versus 19.2%, p¼ .014) with Wilcoxon signed-rank
test demonstrating a significant difference in the mean/distribu-
tion of responses (p¼ .014). For the remaining five risk messages,
there was not a statistically significant difference on Wilcoxon
signed-rank testing between family/friends when compared with
the Internet. However, it does indicate that parent/patients can
consistently (often/always) receive these risk messages from both
of these sources: “Topical corticosteroids may thin the skin” (28.2
versus 27.1%); “Try natural or CAM before resorting to the use of
TCS” (29.0 versus 20.9%); “Apply TCS sparingly or thinly” (24.8 ver-
sus 32.8%); “TCS cannot be used long-term” (31.8 versus 30.1%,
p¼ .708); “TCS may make my [child’s] immune system less
effective” (10.4 versus 10.3%). Overall, approximately one third of
patients received multiple formative risk messages from both
sources.
Discussion
Poor compliance with treatment is common in CID such as AD
and can lead to treatment failure. Treatment failure has significant
impacts on the patient, family and society (9)]. A previous study
has shown that patients commenced on topical therapies for der-
matological conditions frequently failed to comply with
treatment instructions (21). One of the significant contributing fac-
tors affecting treatment adherence in AD and chronic skin condi-
tions requiring long-term treatment is corticosteroid phobia. In
fact, corticosteroid phobia is expressed by between 40 and 73%
of dermatology patients and parents (15,22–24).
Parents often cite that they have been warned of the dangers
of TCS not only by friends, relatives and the media but also by
traditionally trusted sources including their GP and pharmacist
(14). This helps to create a negative cultural environment for
parents of children with AD and for adults with chronic dermato-
ses which they contend with whilst also managing the treatment
demands of their own or their child’s illness.
A recent Australian focus-group study showed that parents
commonly believe that medical treatment for AD with TCS is dan-
gerous and prefer “natural” therapy that they believe is safer (14).
Charman et al. (15) found that 72.5% of people worried about
using TCS on their own or their child’s skin. Although skin thin-
ning remains the most prevalent fear (34.5%), 9.5% of patients
were concerned about systemic absorption resulting in retardation
of growth and development. Hydrocortisone 1% was the mostTa
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commonly used TCS and one-third of the patients using this clas-
sified it as being either strong, very strong, or unsure of its
potency. This highlights the need for evidence-based health liter-
acy education to improve patient education regarding the safety,
potency, and appropriate use of TCS (15). It is important that the
education provided to parents of children suffering pediatric AD
acknowledges the impact of the pediatric AD and pays particular
attention to addressing carers’ treatment beliefs (25).
Previous research from our group has demonstrated a high
level of consistent positive messaging from dermatologists (26). In
contrast, there a significant degree of variability in the knowledge
of GPs (27) and pharmacists (28). Furthermore, it has been shown
that misinformation offered by pharmacists and GPs in Australia
has a major impact on perceptions of parents/patients TCS safety
and efficacy in CID (20). This risk messaging from health professio-
nals can exacerbate risk messages received from family/friends
and Internet sources. This study clearly shows that of parents/
patients who report receiving TCS messaging from friends/family
and the Internet, only about a third receive benefit messages
from these sources. Concurrently, a third of these parents/patients
are also receiving misinformation in the form of exaggerated risk
messages from the same sources. However, parents/patients are
more likely to receive a benefit message about the role of TCS in
AD from the Internet than from family/friends. On the other hand,
they are more likely to receive a risk message from family/friends
than the Internet. Our study did not evaluate which source has
more influence but it is known that risk messages are more
powerful than benefit messages.
Poor compliance with TCS treatment is costly to the commu-
nity and to patients, disruptive to the family unit, frustrating to
treating doctors and not based on evidence. Generation of more
evidence of their safety should be a priority for researchers and
every attempt should be made to disseminate this information to
the community including through the Internet about the safety
and efficacy of TCS in AD. The changing of public attitudes does
take time but in the meantime it is important that all members of
the multidisciplinary treatment team (Dermatologists, GPs and
Pharmacists) provide consistent, evidence-based benefit messag-
ing on safety and efficacy. This in turns helps to arm the parent/
patient to combat the risk messaging from family/friends and
potentially from the Internet.
Conclusion
It is evident that only a minority of patients and parents of
children with chronic inflammatory skin diseases consistently
receive benefit messaging from family/friends and the Internet
whilst concurrently receiving misinformative risk messages from
these influential sources. The varied and mixed nature of this
messaging can help contribute to confusion and poor under-
standing about the safety and efficacy of TCS in CID. This in
turn can lead to treatment non-concordance and poorer treat-
ment outcomes.
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CHAPTER 9 
 
 
 
A comparison between parental perception of disease severity and clinician assessed 
disease severity in childhood atopic dermatitis: perception of disease severity as a 
contributor to treatment adherence. 
 
 
This chapter contains the original research manuscript which compares parent’s perceived 
disease severity with clinician assessed disease severity in dermatology paediatric patients 
suffering atopic dermatitis. 
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Abstract 
COMPARISON BETWEEN PARENT VERSUS CLINICIAN ASSESSMENT OF 
DISEASE SEVERITY IN CHILDHOOD ATOPIC DERMATITIS: A POTENTIAL 
INFLUENCER OF TREATMENT ADHERENCE 
Julia Stone1, Victoria Harris 1,2, Andrew Lee1,2, Shreya Dixit2, Gayle Fischer1,2, 3, Saxon D Smith1,2,4 
1Northern Clinical School, Sydney Medical School, University of Sydney, New South Wales, Australia  
2 Department of Dermatology, Royal North Shore Hospital, St Leonards, New South Wales, Australia  
3 The Centre for Vulvovaginal Health Northern Paediatric Dermatology, St Leonards, New South Wales Australia.  
4 The Dermatology and Skin Cancer Centre, Gosford, New South Wales, Australia  
Background 
Atopic dermatitis (AD) is the most common paediatric dermatological condition [1] with 
90% of cases presenting before five years of age [2].  Children with atopic dermatitis can live 
relatively symptom-free with adequate management. However, despite highly effective 
treatment regimens with minimal side-effect profiles [3] patients can suffer from poorly 
controlled disease due to poor treatment adherence [4]. Possible reasons for this include non-
compliance with treatment due to topical corticosteroid (TCS) phobia. Treatment adherence 
is related to risk perception and perceptions of low disease severity may therefore result in 
compliance that is not optimal. This study examines parents’ perception of disease severity in 
relation to the assessment of the clinician. 
Objectives 
To determine if there is a difference between clinician and caregiver perception of severity of 
childhood AD atopic dermatitis and the impact of any such difference on adherence to 
treatment. Secondary outcomes included the impact on quality of life of patients with 
undertreated AD.  
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Methods 
Consecutive children aged <18 years and their parents, attending a paediatric dermatology 
outpatient clinic with a clinical diagnosis of AD were invited to participate in a prospective 
cohort study. At the first clinic visit patients and parents who participated in the study were 
informed regarding the nature of the study and were counselled on the nature of AD and its 
management including regular and liberal use of emollients, avoidance of potential irritants 
and were prescribed appropriate topical corticosteroids.  Patients with severe atopic 
dermatitis or infected AD were followed up within two weeks, whereas those suffering mild 
to moderate AD were followed up within three months.  
Fifty paediatric patients and their caregivers were recruited. Two independent clinicians 
completed the ratings tool Eczema Area and Severity Index (EASI) and caregivers completed 
the ratings tools Self-Administered EASI and Children’s Dermatology Quality of Life Index 
(CDLQI). Data were analysed using a paired T-test in statistical analysis software SPSS.  
Results 
Of the 50 children affected with AD, 44% were reported by their parents to have moderate to 
severe impact on their quality of life as a result of their disease.  
There was significant difference between clinician assessed EASI score (M= 8.87, SD = 
11.99) and caregiver assessment of the severity of children’s eczema (M= 6.78, SD = 9.86), p 
<0.001. Parents underestimated the severity of their children’s skin disease compared to 
validated clinician assessment.  
On CDLQI testing AD impacted nearly all children with 44% reporting a moderate to very 
large effect. 
Conclusion 
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This study shows that the majority of children and their families are negatively impacted by 
their AD and that their caregivers are significantly underestimating their disease severity. 
Improvement in patient education on the impact of AD and on the safety, efficacy and 
importance of disease control may improve patient outcomes. Ways this may be done include 
visual aids, illustrated treatment ladder information and nurse-led clinics for caregivers of 
children with AD to supplement the patient-doctor encounter.  
 
Introduction 
Atopic dermatitis (AD) is a common inflammatory skin condition that results from a 
dysfunctional epithelial barrier, sometimes due to mutations in the gene encoding filaggrin, 
and Type 2 immune responses [3]. AD can be inherited, as established in familial studies 
[5,6,7] and has associations with allergen sensitisation [8]. TCS play a central role in the 
management of AD [4]. Appropriate use of emollients, wet wraps and appropriate regimens 
to reduce the chance of infection, are recommended for children with atopic dermatitis [9,10]. 
Despite severity and symptomatic disease, paediatric patients are frequently undertreated. 
There are numerous factors contributing to poor treatment adherence including forgetfulness, 
inconvenience and fear of side effects of medications [11,12]. Parental factors are a 
significant aspect in adherence with treatment [11,13]. TCS phobia is prevalent among 
parents, and previous research has established the contribution of doctors, pharmacists and 
other sources, such as internet sites, contribute to the fear and stigma developing around their 
use [12]. Charman et al established that 24% of parents surveyed in regards to use of TCS 
treatment, admitted to having been non-adherent [14]. It has been previously reported that 
measures such as more frequent follow up, clear instructions and disease education are 
effective in improving treatment adherence and thus help to establish disease control [15]. 
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Differences in perception of disease severity between caregiver and clinician of severity of 
disease have been studied in other areas of medicine, such as psychiatry [16] and oncology 
[17]. These studies outlined the impact of such discrepancies on treatment outcomes, patient 
attitude towards disease, assessment of effectiveness of treatment, patient’s expectations of 
treatment effectiveness, underreporting side effects and quality of life impacts not directly 
attributable to disease or treatment side effects [16,17]. Studies of treatment adherence have 
shown that severity perception is directly related to compliance in atopic dermatitis [11] and 
other diseases [18]. 
The key component of management of AD is compliance with regular preventative treatment.  
However, there is a gap in the literature addressing a discrepancy between parent or caregiver 
and clinician perception of disease severity which may impact on treatment adherence and 
ultimately treatment outcomes. An understanding of the differences between parent and 
clinician assessment of disease may improve patient outcomes through improved 
communication and understanding of AD.  
 
Methods 
A prospective study comparing parents’ perception of disease severity with clinician assessed 
disease severity was performed in public outpatient dermatology paediatric clinic within a 
tertiary hospital located in on the North Shore in Sydney, Australia. A total of 50 patients and 
their caregivers were recruited from the paediatric dermatology outpatient department clinic. 
Recruitment for the study commenced January 2015 and ceased when 50 consecutive 
subjects were recruited to the study. Ethics approval for the study was given by Northern 
Sydney Local Health District, Sydney, Australia (HREC: LNR/13/HAWKE/75) 
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All patients were seen by a dermatologist and appropriate treatment was suggested based on 
the severity of their disease. All parents/patients were counselled on preventative measures 
such as regular use of emollients, avoidance of irritants and use of bleach baths where 
appropriate. Parent/patients were given TCS of a potency to match the severity and 
anatomical distribution of their disease such as betamethasone diproprionate 0.05% (a potent 
TCS) to body and methylprednisolone acetonate 0.1% (a moderate TCS) to the face for 
moderate to severe flares, or betamethasone valerate 0.2% (a moderate TCS) to the body and 
hydrocortisone 1% (a mild TCS) to the body for mild flares. 
At the first visit the caregivers were asked to complete ratings on a Self-Administered 
Eczema Area and Severity Index (SA- EASI) tool, Children's Dermatology Life Quality 
Index (DLQI) tool, and a demographics questionnaire. In addition, two independent clinicians 
completed ratings on a separate Eczema Area and Severity Index (EASI) tool to assess the 
severity of the patient’s AD. 
Eczema Area and Severity Index 
EASI is a statistically validated assessment tool for assessing severity of AD. It was 
developed to provide a reliable tool to easily assess the severity of AD across a wide range of 
patients (19). Each body area is assessed for percentage of area affected and the severity of 
disease present (20). 
Self-Administered Eczema Area and Severity Index 
The SA-EASI score allows caregivers to make an assessment of their child's atopic 
dermatitis. Calculation of the final score varies with patient age and chronicity of the disease 
(21). The SA-EASI score has been shown in this study to have a high correlation with the 
EASI score, and therefore enables statistical analysis to be undertaken between scores (21). 
Children's Dermatology Life Quality Index (CDLQI) 
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The CDLQI is a quality of life index tool that can be completed by children, with assistance 
from caregiver if necessary (22,23). Scores range from 0 to 30 with higher scores correlating 
to greater impact on quality of life. The CDLQI can be analysed based on symptoms and 
feelings, and impact on leisure activities, school or holidays, personal relationships, sleep and 
treatment (22). 
To evaluate reliability and consistency of the score between clinicians, the scores were 
compared for significance. A paired sample t-test was used to evaluate significant difference 
between clinician assessment for a given patient. If no significant difference between 
clinicians is established, an average of the EASI scores for each patient was taken in able to 
be utilised when comparisons with the SA-EASI were made. 
EASI vs SA-EASI 
A Spearman’s rank-order correlation was performed to determine the relationship between 
EASI score and SA-EASI score. In order to be analysed for significance, correlation between 
these variables is required to be ascertained. A paired samples t-test was performed to test the 
hypothesis that the EASI and SA-EASI score means were equal. 
Statistical analysis was undertaken by utilising SPSS statistical software.  
 
Results 
The median age of the patients was 5.08 years (range 3 months to 15 years). The median age 
band of parents was 30-39 years old. Nearly all (92%) of the parents had a bachelor degree or 
above higher education qualifications. Of the cohort, 14 had previously seen a dermatologist 
before attending the clinic. 
Comparison of Inter-Clinician Assessment of EASI Score 
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A paired sample t-test was used to evaluate if there was any significant difference between 
clinicians for a given patient. There was no significant difference between clinician 1 (M = 
8.79, SD = 11.96) and clinician 2 (M = 8.95, SD = 12.04), indicating strong inter-rater 
reliability. 
 
 
Figure 1: Analysis of Inter-Clinician Assessment of EASI score 
 Averages of the scores from the two clinicians were taken for statistical analysis of the SA-
EASI. 
EASI vs SA-EASI 
Assessment of correlation between clinician EASI score and caregiver SA-EASI score 
performed using Spearman’s rank-order (Table 1). There was a strong positive correlation 
between EASI score and SA-EASI score, (r = 0.865, p= <0.01). As there is statistically 
significant correlation between variables, a paired t -test were applied.  
The mean EASI (M = 8.87, SD = 11.98) and the mean SA-EASI (M = 6.780, SD = 9.86) 
score means were equal, a paired samples t -test was performed.  
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The mean EASI score was significantly higher than the SA-EASI mean. 
The degree of difference in mean EASI score and mean SA-EASI score is plotted below. This 
shows the overall patients assessed there was discrepancy between EASI and SA-EASI. 
 
Figure 2: Mean difference between EASI score and SA-EASI score 
CDLQI 
The overall result of the CDLQI in the study participants is summarised in Figure 3. Nearly 
all children reported their disease impacted their quality of life (QoL) n = 48/50 (96%). Of 
the cohort surveyed 44% (n =22/50) reported a moderate to extremely large impact on QoL. 
Only 4% (n=50) of the cohort reported no impact on QoL from AD.  
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Figure 3: Children's Dermatology Life Quality Index (CDLQI): Overall effect on quality of 
life 
QoL measures were categorised to determine what aspects of life were affected by the 
disease. These included symptoms, personal relationships, leisure activities, school or holiday 
activities and sleep. The relative contribution of disease on aspects of quality of life is 
summarised in Figure 4, with symptoms of disease having greatest impact, and leisure 
activities most affected (Table 2).  
 
Figure 4: Quality of life areas affected by atopic dermatitis 
Discussion 
The primary aim of this study was to compare parental perception of disease severity with 
clinician assessed disease severity in childhood AD. The secondary aim was to estimate 
quality of life impact in the families studied. Statistical analysis of EASI scores of clinicians 
showed consistency. Therefore, this analysis supports clinician assessment as a reliable 
assessment of disease severity and provides the baseline from which caregiver assessment 
can be compared.  
 Comparison of EASI score to SA-EASI score showed that EASI and SA-EASI scores were 
highly correlated for a given patient. However statistical analysis showed a significant 
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difference between caregiver and clinician assessment of disease severity. Scores given by 
caregivers were consistently lower than those given by clinicians. This cohort of well 
educated parent caregivers significantly underestimated disease severity of their children’s’ 
AD. This has the potential to result in undertreatment. A common statement heard in the 
clinic is “I only use the TCS when things are really bad.” 
Quality of life data was examined and showed that impact is variable. These findings are 
consistent with a meta-analysis conducted by Olsen et al 2016 which showed that most 
children will experience a small impact, but a significant proportion will experience a very 
large impact on quality of life [23]. Furthermore, Holm et al have shown that AD has a 
negative impact on quality of life which is proportional to the severity of the disease [25]. 
Understanding of the parental tendency to underestimate the severity of AD provides 
clinicians with a greater insight into poor treatment adherence commonly observed in clinical 
practice. It highlights a need to provide parents with a greater understanding of their child’s 
disease. Aspects of treatment adherence such as steroid phobia [12] and influence from other 
health care professionals such as general practitioners and pharmacists [26] have previously 
been examined. It is clear that inadequate treatment of the disease impacts quality of life of 
patients and families [27-30]. Understanding this aspect of the problem informs clinicians 
that this is a target for intervention.   
There is a tendency for skin conditions to be trivialised because of the perception that they do 
not pose a significant risk to life however the impact of severe eczema has been shown to be 
similar to other severe debilitating diseases [31]. The relationship between risk perception 
and adherence to treatment is well recognised. If parents are in touch with the risk to their 
child’s quality of and the impact on the family of AD, and if they are given a realistic 
benchmark of severity it may assist them in achieving better treatment outcomes. 
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The limitations of this study include: demographic data showed variation in all aspects of 
areas examined, including caregiver age, education level and household income; however, 
there were inadequate numbers to draw conclusions. The population studied were mainly 
middle class, well educated individuals and the results may not be generalizable to the whole 
population. 
This survey does however, provide useful information regarding trends in patient attendance 
to the clinic and areas in which cultural and socioeconomic identifiers may help assist in 
disease severity and treatment explanation, and possible educational tools that may be 
necessary in the future. Further study in relation to demographic influence on treatment 
adherence is required in this population. 
 
CONCLUSION  
The management of AD in children often requires parents to adjust the potency and 
frequency of topical therapies.  However, this study demonstrates that there is a significant 
gap in parent’s perception of disease severity relative to severity assessed by a clinician.  
When parents under-appreciate the severity of their child’s disease this may lead to decreased 
treatment adherence and poorer treatment outcomes.  Therefore, it is important for clinicians 
to help parents understand the impact of AD on their child and where they are located in 
terms of absolute clinical severity. This may help to educate parents how to assess flare 
severity and guide management. 
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Table 1: Comparison of clinician EASI score and caregiver SA-EASI score 
Patient Average 
Clinician 
Score 
SAEASI 
1 7.3 4 
2 16.5 12.6 
3 0 0.8 
4 2 1.2 
5 4.35 1 
6 29.8 29.2 
7 29.6 20 
8 1.95 1.1 
9 8 4 
10 11.1 3.2 
11 0.6 0.5 
12 12.3 13.3 
13 0.2 0.6 
14 0.75 0 
15 10.8 7 
16 9.8 5.4 
17 19.5 21 
18 10.4 6.3 
19 0.8 0.8 
20 19.25 11.2 
21 1.1 0.4 
22 0.45 1.2 
23 11.55 5.4 
24 15.25 8 
25 3.6 2.4 
26 0 1.2 
27 0.9 0.6 
28 3 1.6 
29 0.9 3.3 
30 2 2.1 
31 16.1 10.5 
32 50.2 37.74 
33 1.2 1.8 
34 27.8 15.2 
35 1.1 0.4 
36 1.5 6.4 
37 0.4 1.4 
38 3.2 1.6 
39 12.4 9.8 
40 1.8 2 
41 1.05 2 
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42 12.9 3.9 
43 55 50.4 
44 2 6.5 
45 1.4 0.28 
46 1.2 1.8 
47 5.6 5.1 
48 1 0.8 
49 6.9 6 
50 7.1 6 
 
 
Table 2: Specific Children's Dermatology Life Quality Index (CDLQI)Impacts 
Grading =  0-1: No effect; 2-6: Small effect; 7-12: Moderate effect; 13-18: Very large effect; 
19-30: Extremely large effect. 
Patient Symptoms 
and 
Feelings 
(/6) 
Leisure 
(/9) 
School 
or 
Holidays 
(/3) 
Personal 
Relationships 
(/6) 
Sleep 
(/3) 
Treatment 
(/3) 
Severity 
Banding 
1 3 1 0 0 2 0 Small 
2 3 0 0 0 2 2 Moderate 
3 0 0 0 0 1 0 No effect 
4 0 0 0 0 0 0 No effect 
5 2 2 0 0 1 0 Small 
6 2 2 0 0 2 3 Moderate 
7 2 2 0 0 2 2 Moderate 
8 1 4 0 2 2 2 Moderate 
9 3 0 1 0 1 0 Small 
10 5 6 3 0 3 2 Extremely 
large  
11 1 1 1 0 0 1 Small 
12 3 4 0 0 2 1 Moderate 
13 3 0 0 1 0 1 Small 
14 3 4 0 0 0 0 Moderate 
15 2 1 0 0 0 1 Small 
16 4 5 2 0 2 1 Very large 
17 6 0 0 0 3 0 Moderate 
18 2 1 0 0 1 1 Small 
19 2 4 0 0 0 0 Small 
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20 3 2 1 0 1 1 Moderate 
21 3 0 1 0 2 0 Small 
22 0 0 0 0 1 2 Small 
23 3 5 2 4 2 1 Very large 
24 6 9 3 6 3 3 Extremely 
large  
25 6 1 3 0 3 3 Very large 
26 1 2 0 0 0 1 Small 
27 6 6 3 5 2 2 Extremely 
large  
28 2 0 0 0 1 1 Small 
29 2 1 0 0 1 2 Small 
30 1 0 0 0 0 1 Small 
31 1 2 1 1 1 0 Small 
32 5 9 0 0 3 2 Extremely 
large  
33 6 6 3 0 3 2 Extremely 
large  
34 3 7 3 0 1 1 Very large 
35 1 1 0 0 1 1 Small 
36 2 2 0 0 0 1 Small 
37 1 1 0 5 1 1 Moderate 
38 1 0 0 0 1 1 Small 
39 3 0 0 0 3 0 Small 
40 1 0 0 0 1 1 Small 
41 1 1 0 0 1 0 Small 
42 4 2 1 1 2 1 Moderate 
43 5 6 3 4 3 2 Extremely 
large  
44 1 3 0 0 1 1 Small 
45 1 1 0 0 2 1 Small 
46 2 0 0 0 1 0 Small 
47 1 1 0 0 2 1 Small 
48 1 1 1 0 1 2 Small 
49 2 4 1 0 0 0 Moderate 
50 3 3 1 2 1 1 Moderate 
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CHAPTER 10 
 
 
Discussion Part 1:  
Impact of healthcare professionals on fears about the safety and efficacy of TCS and 
treatment adherence 
 
 
This chapter contains the original systematic review article, “Childhood atopic dermatitis: 
exploring the safety, efficacy and potential misinformation around topical corticosteroids,” 
published in Australian Journal of Pharmacy 2016;October:83-88. 
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A topic dermatitis (AD) is the most common chronic inflammatory skin condition affecting more 
than 20% of children1 and around 7% 
of adults.2 However, it can be a condition 
that is not well managed. Topical 
corticosteroids (TCS) play a central role 
in the management of the cutaneous 
inflammation in AD. The safety and 
efficacy of TCS are well-supported 
with dermatologists generally agreeing 
that with appropriate use, the benefits 
outweigh the very low incidence of any 
possible risks and side effects.3-6 
On the other hand, poor compliance 
with medical therapy is common and 
often related to an exaggerated fear of 
possible side effects. This can lead to 
poor compliance to topical treatment 
regimens and subsequent poor responses 
to treatment.7-11 There are various factors 
that contribute, directly or collectively, 
to poor compliance with “corticosteroid 
phobia” identified as a key contributor.12 
‘Corticosteroid phobia’ is a misnomer as 
it is not a true phobia. It is the term given 
to parent and patient anxiety regarding 
the use of TCS due to concerns regarding 
safety and efficacy in AD despite AD being 
disabling and disruptive for patients and 
their families.7,10,11,13,14
‘Corticosteroid phobia’ has been 
identified as a major cause of non-
compliance and treatment failure in 
AD.15-18 It is not unique to dermatology 
and is also seen by paediatricians and 
respiratory physicians in the management 
of asthma with inhaled corticosteroids.14-17
Currently, there appears to be a large 
amount of misinformation about the safety 
and efficacy of TCS in AD which means that 
this concern is widespread. It has previously 
been identified that this misinformation 
can range from a common belief among 
parents that medical treatment for AD with 
TCS is dangerous through to a preference 
for complementary and alternative 
medicine (CAM), or that ‘natural’ therapy 
is safe and therefore preferable.14 
However, by far the most common belief 
that parents identify as a perceived risk 
associated with the use of TCS is irreversible 
skin thinning. Many parents also voice 
concerns about immune suppression and 
growth failure.14 Parents cite that there are 
a wide range of sources of information and 
misinformation on the safety and efficacy 
of TCS in AD including family/friends, 
the Internet, pharmacists and general 
practitioners (GPs).14 However, this sea of 
information and sometimes misinformation 
can detrimentally impact a patient’s or 
parent’s understanding of the safety and 
efficacy of TCS to manage their (or their 
child’s) AD. Unfortunately, this can lead to 
abandonment of evidence-based medical 
therapy with potentially serious detrimental 
outcomes, especially in children.19
Childhood atopic dermatitis:  
exploring the safety, efficacy and 
potential misinformation around 
topical corticosteroids
▲  Clinical Associate Professor Saxon D Smith and Associate Professor Gayle Fischer, Department of Dermatology,  
Royal North Shore Hospital, St Leonards; Northern Clinical School, Sydney Medical School, University of Sydney.
Corticosteroid phobia’ has been identified as a  
major cause of non-compliance and treatment  
failure in atopic dermatitis.
AFTER COMPLETING THIS ACTIVITY 
PHARMACISTS SHOULD BE ABLE TO:
•  discuss the contributors to poor adherence to 
topical corticosteroid therapy for childhood 
atopic dermatitis;
•  counsel patients and carers about the 
appropriate use of topical corticosteroids  
for childhood atopic dermatitis.
The 2010 Competency Standards addressed by 
this activity include (but may not be limited to):
4.2, 4.3, 6.3, 7.2
Accreditation Number: A1610AJP2
This activity has been accredited for 1.0 hour of Group 1 
CPD (or 1.0 CPD credits) suitable for inclusion in an individual 
pharmacist’s CPD plan which can be converted to 1.0 
hour of Group 2 CPD (or 2.0 CPD credits) upon successful 
completion of relevant assessment activities.  
Expiry date: 01/10/2018.
Safety and efficacy 
What is the evidence of safety and 
efficacy and where does the concept of 
“thin skin” originate?
Research into the safety of topical 
corticosteroids dates back to the 1960s. 
Epstein et al published an article in 
196320 which was the first to suggest a 
‘skin thinning’ role for TCS. However, 
this was a small case series of five male 
adult patients who were using potent TCS 
unsupervised in an ‘overuse’ fashion.
Later on in 1981, Frosch et al21 
explored corticosteroid atrophy using 
Durhing chambers (occlusive chambers) 
using normal skin in 20 adult volunteers. 
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However, the confidence intervals of the 
telangiectasia (dilated capillaries or tiny 
blood vessels visible in the skin) assessed 
by dermatoscope and atrophy assessed by 
histology for each strength of TCS used 
all crossed 1.0 and had cross over with 
the comparison vehicles. 
This makes it difficult to accept 
their conclusions that TCS may induce 
atrophy. Despite slim evidence, the 
concept of thin skin as a side effect has 
received widespread notoriety. 
Unfortunately, anecdotal reports have 
appeared in the literature of side effects 
of TCS including Cushingoid features. 
The fact that these publications appear 
as single case reports in itself indicates 
the rarity of such events and when 
the evidence is critiqued it invariably 
describes inappropriate use.22,23,24 The 
most recent attack on TCS is the concept 
of “steroid addiction”. 
This is simply the flip side of 
corticosteroid phobia but again if the 
literature is carefully analysed these cases 
are invariably due to inappropriate use.
With no studies in the paediatric 
setting and only decades old adult 
literature, in 2011 Hong et al specifically 
sought to explore whether cutaneous 
atrophy is seen in children using TCS 
appropriately under medical supervision 
for treatment of atopic dermatitis.6 A 
cross-sectional observational study was 
undertaken to assess the potential of TCS 
to cause cutaneous atrophy in children 
with dermatitis requiring long-term 
TCS suppression. All children who were 
able to achieve good disease control, 
as determined by a maximum Eczema 
Area and Severity Index score of 1.0, 
who were using TCS were examined 
for adverse effects. Cutaneous atrophy 
was assessed by examining sites exposed 
to TCS compared with non-exposed 
sites by dermoscopy. For each of the 70 
TCS-exposed children examined, three 
difference sites and a control site were 
assessed and no significant atrophy was 
found. Mild grade 1 telangiectasia of the 
cubital fossa (elbow pit) was observed 
in 3.3% of the test group and a similar 
amount (3.1%) was seen of the control 
group of 22 TCS naıve children.
The authors concluded “that routine, 
appropriate, long-term use of TCS 
in children with dermatitis does not 
cause skin atrophy”. 
Most recently an evidence-based 
consensus statement published from 
paediatric dermatologists from Australia 
and New Zealand explored the broader 
literature on all of the potential side 
effects from the use of TCS in the setting 
of childhood AD.5 They contended that 
the treatment of atopic dermatitis is 
complex and multifaceted but a core 
component of therapy is to manage the 
inflammation with TCS. 
However, it was noted that parents often 
underutilise TCS due fears about their 
potential adverse effects which can lead to 
extended and unnecessary exacerbations 
of eczema for children. Critically the 
consensus group concluded that based on 
both clinical and research evidence that 
“contrary to popular perceptions, (TCS) 
use in paediatric eczema does not cause 
atrophy, hypopigmentation, hypertrichosis 
(abnormal body hair growth), 
osteoporosis, purpura (purple bruise-like 
spots caused by small bleeding vessels near 
the skin surface) or telangiectasia when 
used appropriately as per guidelines”. 
However, they also conceded that “in 
rare cases, prolonged and excessive use 
of potent TCS has contributed to striae 
(stretch marks), short-term hypothalamic-
pituitary-adrenal axis alteration and 
ophthalmological disease”. The consensus 
group stated that “when they are used to 
treat active eczema and stopped once the 
active inflammation has resolved, adverse 
effects are minimal”. 
On the balance of the available 
evidence, parents, pharmacists, and health 
practitioners should be confident about 
the safety of using this treatment.
Negotiating the sea of misinformation
There is a wide range of sources of 
information and misinformation on the 
safety and efficacy of TCS in AD. An 
Australian focus group study14 found 
that all participating parents reported 
they had been told by other people that 
topical corticosteroids were dangerous. 
Friends were the most common group 
of people who had given parents this 
information (88%). They had also been 
advised that topical corticosteroids were 
dangerous by family (50%), pharmacists 
(44%) and general practitioners (25%).
What pharmacists say to patients25
In 2014 a cross sectional survey of 292 
Australian pharmacists attending a 
continuing professional development 
conference demonstrated that they have 
significant knowledge gaps about the use 
and safety of TCS in childhood AD. It was 
concluded that their advice to patients 
might, therefore, potentially contribute to 
poor treatment compliance. 
Application advice
A large portion (67%) of pharmacists 
surveyed advised that the maximum 
duration TCS could be used was two weeks 
or less. When instructing parents of the 
amount of TCS to be applied, 54% reported 
informing the patient that TCS should be 
used sparingly, while 41% reported advising 
patients to use TCS either generously or 
based on fingertip unit guidelines. 
Further analysis of the results 
demonstrated that pharmacists younger 
than 40 years of age and those that had 
been practising less than 10 years were 
more likely to recommend TCS use for a 
short duration. Furthermore, only 14 out 
of 95 that had been practising for less 
than 10 years (15%) recommended that 
TCS be used until the eczema was clear. 
Knowledge 
Nearly half (46%) of pharmacists surveyed 
believed that skin atrophy (skin thinning) 
was the most common side effect of 
There is a wide range of sources of information and 
misinformation on the safety and efficacy of TCS in AD. 
An Australian focus group study found that all 
participating parents reported they had been told by other 
people that topical corticosteroids were dangerous. 
EDUCATION PRACTICE UPDATE
  OCTOBER 201684
96
AJP CPD
continuing 
professional 
development
TCS. Again, pharmacists who had been 
practising for less than 10 years were more 
likely to incorrectly understand this side 
effect of TCS than those who had been 
practising more than 10 years.
Of those surveyed, 64% believed that 
poor TCS compliance was a major reason 
why patients with atopic dermatitis fail 
to get better. The survey did not explore 
the source of this information and it was 
therefore not clear if this was because of 
patients not following pharmacist advice 
or medical advice however it was clear that 
the majority are aware of this problem.
What GPs say to patients26 
In 2015 a cross sectional study of 258 
Australian GPs was performed with 
a surveyed through three separate 
continuing professional development 
(CPD) interactions: a web-based education 
module and two face-to-face CPD lectures 
on management of atopic eczema. 
It demonstrated significant differences 
across GPs on their knowledge of the 
safety and efficacy of TCS in childhood 
atopic dermatitis. Furthermore, it was 
concluded that their advice to patients 
may potentially contribute to poor 
treatment compliance.
Application advice
While 47% of GPs instruct patients to use 
TCS until eczema is clear, 41% instruct 
use for a maximum of two weeks or less. 
Nearly half (49%) recommend to use 
TCS sparingly or the smallest amount 
possible and only 39% recommend 
finger-tip unit measurements. 
Knowledge of safety
Just under a third (30%) believe 
cutaneous atrophy is the most common 
side effect seen in this patient population 
using TCS and reassuringly 58% 
indicated there are no side effects 
when used appropriately. 
Most (66%) strongly agree/agree that 
lack of treatment compliance is a major 
reason for treatment failure but most 
(64%) strongly disagreed/disagreed that 
this is impossible to prevent.
What dermatologists say 
to patients27
A cross-sectional survey of 455 
dermatologists working in Australia 
in 2014 was completed assessing their 
attitudes to safety and efficacy of TCS in 
childhood AD. There were 198 (43.5%) 
completed surveys from the population 
of dermatologists. Unlike GPs and 
pharmacists, there is consensus in the 
knowledge of safety and efficacy of TCS 
amongst Australian dermatologists.
It was concluded that this likely arises 
from the specific training but also the 
general experience of TCS use among 
dermatologists.
Application advice
Only a minority of dermatologists 
(20.9%) indicated that they instructed 
patients to use TCS sparingly. This was 
increasingly likely as the number of years 
practiced increased (p<0.001). 
While most dermatologists (61%) 
answered that they will give patients a 
time limit guidance on how long TCS 
can be used they will temper this by 
further also advising parents to use their 
treatment until their skin had normalised 
regardless of how long it took.
Safety and efficacy of TCS
The majority (69.2%) reported that the 
most common side effect encountered 
from TCS use was not skin thinning but 
peri-orificial dermatitis (red rash with 
red small lumps around the mouth, nose 
and/or eyelids ) with 15.9% reporting 
bruising. Only a small minority (5.6%) 
reported that the most common side 
effect seen was cutaneous atrophy.
Importantly the vast majority of 
dermatologists (92.5%) either agreed 
(16.7%) or strongly agreed (75.8%) that 
TCS if used as directed at an appropriate 
dose and duration in accordance with 
disease severity is unlikely to cause 
cutaneous atrophy. 
Labelling of TCS
Furthermore, most dermatologists 
(77.3%) either agreed (26.8%) or 
strongly agreed (50.5%) that the term 
“sparingly” should not be written on 
the label of prescribed tubes of topical 
corticosteroid. Only a minority (11.6%) 
were ambivalent (11.6%) or disagreed 
(11.2%) with this statement. 
It is evident from these studies that 
there is potential for parents and patients 
to receive differing advice from their 
dermatologists, GP and pharmacist. This 
can lead to confusion or misinformation 
that in turn can affect compliance 
to prescribed therapy.
What Is the impact of the advice 
that pharmacists and GPs 
give patients?28
A multicentre cross-sectional survey 
of patients (aged >18) and parents of 
paediatric patients (aged <18) with a history 
of long-term (≥ 1 month) TCS use explored 
the impact and influence of the benefit and 
risk messages on parents and patients. 
A total of 201 surveys were completed 
consisting of 123 adult patients and 
78 parents. Most respondents (76.6%) 
reported that they consistently (‘Often’ 
or ‘Always’) received one or more 
message(s) regarding TCS ‘risk’ from a 
GP and/or pharmacist. 
Application advice received
Just over half (52.8%) of patients were 
aware of the ‘fingertip unit’ as a measure 
of the amount of TCS to apply. 
Of those that were aware, they 
reported various sources of information 
on the concept, noting that respondents 
could select multiple sources if 
applicable: Dermatologist (54.8%, 
n=57), GP (25.0%, n=26), Pharmacist 
(16.3%, n=17), Other (e.g. another type 
of specialist, the Internet, or written 
materials) (30.8%, n=32).
Knowledge of safety and efficacy
In general, the majority acknowledged 
the necessity for TCS therapy to manage 
their condition. However, the rates 
concerned about the safety of TCS varied, 
depending on the specific concern.
The concern statement with the 
highest ‘Agree’/’Strongly Agree’ rate was 
‘I worry about the long-term effects of 
TCS [on my child]’ (58.1%, n=115).
Only 27.8% of respondents ‘Disagree’ 
or ‘Strongly Disagree’ with the statement 
‘I worry that TCS thin my [child’s] 
skin’ (n=55). 
Interestingly, less than half (44.8%) of 
respondents ‘Agree’ or ‘Strongly Agree’ 
that ‘Pharmacists instruct me to apply the 
TCS exactly as directed by my doctor’.
Messages of risk/benefit patients and 
parents report receiving
Survey respondents reported that they 
had received messages about the benefits 
of TCS significantly more often from 
GPs than from pharmacists (p<0.001). 
On the other hand, they also reported 
they were encouraged to ‘try natural or 
complementary and alternative therapies 
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before resorting to the use of TCS’ 
significantly more often by pharmacists 
than by GPs (p=0.039). 
Messages about the ‘risks’ of TCS were 
equally reported to have been received 
from both GPs or pharmacists without a 
statistical significance between them.
Furthermore, most respondents (76.6%) 
of 192 respondents received at least one of 
the six messages about TCS ‘risk’ from a GP 
and/or pharmacist ‘Often’ or ‘Always’.
The variation in the risk/benefit 
messaging received from GPs and 
pharmacists may contribute to poor 
treatment compliance and ultimately may 
lead to poorer treatment outcomes.
Other factors contributing to 
poor treatment outcomes 
The misinformation and subsequent 
fears about the safety and efficacy of 
TCS in atopic dermatitis are not the only 
contributing factor affecting treatment 
adherence and treatment outcomes. 
It is important for us all, as part of 
the multidiscipline treatment team, 
to recognise when one of these other 
factors may be contributing to issues with 
treatment adherence.
Complexity of treatment regimens
The nature of skin-based treatment 
regimens often are perceived to be 
complex and particularly burdensome due 
to the multiple prescription medications 
used, the frequent dosing schedules and 
the challenge of applying the topical 
preparations.29 This is especially the case 
when long-term treatment is required. 
Evidence shows that even with a twice-daily 
application of topical therapy compliance 
drops by 60% after a few days from the 
commencement of treatment.30 In order 
to simplify treatment regimens and make 
them fit their activities of daily living, 
parents and caregivers admit taking 
shortcuts, such as the reduced frequency 
of topical therapy application.29
Lack of knowledge 
There is commonly a lack of 
understanding of the disease pathogenesis 
and benefits of prescribed treatments in 
AD.10,31 In fact, when questioned, nearly 
half the parents and caregivers cannot 
correctly identify the potency of commonly 
prescribed TCS or the nature of the 
antimicrobial components correctly.31
This lack of knowledge may result 
in the incorrect application of topical 
therapy and confusion about the 
escalation of treatment, leading to poor 
treatment compliance and outcomes.
Impaired quality of life
As AD is a chronic waxing and 
waning condition it requires ongoing 
commitment and resolve from patients 
and parents to be successful. This can 
be a thankless and exhausting task. 
Even when there is no active disease, 
emollients are applied which means 
patients and parents are given little 
respite from their treatment duties. It is 
not surprising that health-related quality 
of life (HRQoL) is significantly impaired 
in children with AD and their caregivers, 
which has direct negative implications 
for treatment compliance.32,33
Patient dissatisfaction
Treatment compliance is significantly 
affected by patient satisfaction.34,35 For 
example, a Japanese cross-sectional survey 
reported that a satisfactory patient/
caregiver–clinician relationship was the 
most important factor driving treatment 
compliance in their population.36
On the other hand, a survey of the UK 
National Eczema Society showed that 
only 19% of initial consultations with a 
dermatologist met patients’ expectations 
and only 40% of patients were satisfied 
with the treatment given.37
There are strategies to improve this 
dissatisfaction with the patient/parent-
clinician relationship. It is important 
to acknowledge the patient/parent’s 
preferences when recommending 
topical therapies. 
This could include taking into 
consideration patient/caregiver vehicle 
preference,38 the type of preparation39 
and the frequency of application.29 
Treatment plans designed without the 
patient/caregiver preferences in mind are 
more likely to lead to treatment failure.10
Frequency of follow up
The frequency of follow-up appointments 
does increase compliance to topical 
therapy in AD as it increases significantly 
around the time of follow-up 
appointments.30 This is called ‘white coat 
compliance’,40 and has also been reported 
in other skin conditions such as psoriasis41 
and hand dermatitis.42 The timing of 
follow-up appointments also seems to be 
important, with earlier follow up resulting 
in higher rates of treatment compliance.43
Use of complementary and 
alternative medicine
CAMs continue to be a popular adjunct 
to treatment despite the lack of evidence 
for their role in the management of AD.44
Common CAM strategies that patient/
parents seek include homeopathy, the 
use of botanical extracts and Chinese 
herbal medicine.44 In fact, more than 
half of AD patients may include a form of 
CAM in their management.45
Patients with a long duration of disease 
or if orthodox treatment has failed 
are more likely to CAM, usually upon 
recommendation by friends or family.45 
However, side-effects, medication 
interactions and even the worsening 
of AD symptoms have been reported 
with the use of some CAM,19,46-48 and 
these confound treatment outcomes.49 
Furthermore, the inappropriate sole 
use of CAM to manage AD can have 
catastrophic consequences.19
What is the risk of non-adherence?
The case of Gloria Sam highlights the 
extreme and catastrophic. 
This tragic case, which occurred in 
Sydney, came before the courts in 200950 
and 2011.51 
A child, presented with her parents 
to GPs for medical treatment on several 
instances over an extended period 
with AD, but her parents did not follow 
through with recommended medical 
advice or with referrals to dermatologists. 
The child’s father, a CAM practitioner, 
administered homeopathic remedies.52 
The child finally presented to hospital 
and died as a result of overwhelming 
sepsis from secondarily infected 
atopic dermatitis. 
This case was judged to constitute 
a case of child abuse. The father’s 
homeopathic treatment of his daughter 
was also assessed and he was found 
culpable under the “reasonable parent” 
test and the “reasonable homeopath” 
test, on the basis that a “reasonable 
homeopath” would have referred non-
improving patients to conventional 
medical assessment for treatment.50
This tragic case represents an extreme 
end of the spectrum of neglect due to 
alternative health belief however lesser 
cases are seen constantly in dermatology 
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practice. Although children who are 
being inadequately treated are not at risk 
of serious harm, they and their parents 
can suffer from disruptive exhaustion and 
sleep deprivation as a result of their child 
being constantly itchy.
The biopsychosocial impacts
Typically, childhood AD can be managed 
and remits with age. However, it still 
places a significant burden on patients 
and their whole family. 
It has been repeatedly shown that 
a child with AD has a significantly 
higher biopsychosocial impact on the 
family unit than a child with diabetes, 
due to problems such as itching, sleep 
loss, problems at school and mood and 
behavioural changes.8,9,11,53
A 1997 Australian study calculated 
conservative estimates of the annual 
personal cost of managing childhood AD 
with mild disease costing $1100 and rising 
to around $6000 for severe disease.53
The cost estimates included doctor 
visits, hospitalisations, medicines, over-
the-counter therapeutic preparations, 
time off work and transport. 
In fact, this study concluded that the 
personal financial cost of managing AD 
was greater than that for asthma.
Furthermore, there are other practical 
difficulties that need to be considered 
when caring for a child with AD including 
skin care, feeding, shopping, washing 
and cleaning, psychological pressure, 
physical exhaustion and restriction of the 
family’s lifestyle.54
Recent changes in Australia
There has been recognition of a need 
to change our approach to the use of 
TCS in Australia. The Pharmaceutical 
Benefits Scheme has recently introduced 
a group of streamline authority numbers 
to allow doctors to prescribed increased 
quantities (to a maximum of 10 tubes and 
5 repeats) of TCS for steroid responsive 
dermatoses. This will enable GPs to move 
past their reluctance to call the Medicare 
Authority Prescription telephone line to 
obtain increased quantities for patients 
requiring them.
Furthermore, some of the pharmacy 
prescription programs have taken 
the step of removing the automatic 
generation of the term ‘sparingly’ on all 
TCS prescriptions. Parents and patients 
are unable to articulate what ‘sparingly’ 
means practically,14 so the removal of this 
confusing term on prescriptions may help 
to improve treatment compliance.
Conclusion
TCS have been successfully used to treat 
AD for more than 50 years. There is no 
convincing evidence that they pose a risk 
if used correctly, that is not in overdose, 
and overwhelming evidence that they 
are effective. 
The current backlash against them 
lacks logic, is driven by incorrect 
information and is at worst dangerous 
and at least disruptive. The exaggerated 
risk messages and advice that limits 
ongoing use in the chronic conditions 
for which they are indicated adversely 
impacts treatment outcomes.
It is costly to the community, with 
patients who could be successfully 
treated in general practice requiring 
referrals to dermatologists simply so that 
they can be reassured that the correct 
treatment is in fact safe.
Corticosteroid phobia is widespread 
among Australian patients and significantly 
reduces compliance to appropriate 
treatment of AD. This belies the fact that 
these products, when used properly and 
under medical supervision are very safe. 
The reasons for corticosteroid phobia 
are many but recent Australian research 
into the benefit and risk messages sent 
to patients by GPs and pharmacists has 
told us that risk messages are outweighing 
benefit messages from both groups. 
With so much misinformation 
circulating in social media it is essential 
that health professionals provide a 
balanced argument and are not seen to 
be complicit in incorrect messaging.
It is time for all primary care providers 
to upskill on the evidence base about TCS 
and deliver messages that are reassuring to 
patients. It is important to also recognise 
that applying topical therapy is not the 
same as taking a pill with a pre-determined 
amount of medication. It can be varied 
enormously by the patient and will be 
minimised unless they have confidence. 
Furthermore, most skin conditions are 
chronic and require ongoing treatment.
Advice that puts a short time limit on 
treatment is likely to result in treatment 
failure and indirectly delivers a message 
about putative risk from the use of TCS. 
It is important for all members of a 
patient’s multidisciplinary treatment 
team to take time to support and educate 
parents whose children have atopic 
dermatitis because it helps to deconstruct 
this complex issue. 
This in turn can dramatically 
increases treatment compliance. This 
‘health educator’ role is critical for 
all clinicians to, but they themselves 
must have confidence in the safety and 
appropriateness of TCS before they 
can recommend these medications to 
patients. Up to date information on the 
safety aspects of TCS and on appropriate 
use is essential for health professionals.
Pharmacists, GPs and dermatologists 
must all be on the same page and it is 
essential that the medical advice provided 
supports patients/parents as they manage 
their chronic skin condition which 
often already affects the rest of their 
life so much. • 
Topical corticosteroids have been successfully used to 
treat AD for more than 50 years. There is no convincing 
evidence that they pose a risk if used correctly… and 
overwhelming evidence that they are effective. 
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1.  Which of the following best describes the advice 
that should be given on the duration of use of 
TCS in active childhood atopic dermatitis?
A  Maximum of three consecutive days
B  5 days of active treatment and 5 days off
C  Two weeks
D  One month
E  Until that area of atopic dermatitis has resolved
2.  Which of the following best describes the advice 
that should be given on the amount of TCS to 
use in active childhood atopic dermatitis?
A Smallest amount possible
B  Sparingly
C  As much as the parent feels necessary
D Based on Finger-Tip-Unit
E Generously
3.  Which of the following is NOT a contributor to 
poor treatment compliance?
A  Complicated combinations of topical therapies
B  Concern about the safety of topical therapies
C  Inability to open container/tube of TCS
D  Patient dissatisfaction with 
therapeutic relationship
E  Infrequent follow up with multi-
disciplinary team
4.  Which of the following is the most common 
potential side effect from the use of TCS in 
children?
A  Cutaneous atrophy
B  Hypertrichosis
C  Easy bruising
D  Peri-orifical dermatitis
E  Hypothalamus-pituitary-adrenal (HPA) axis 
depression
5.  Which of the following are recognised 
potential sources of ‘corticosteroid phobia’?
A  Family 
B  Friends
C  Internet
D Pharmacists
E  General practitioners
F  All of the above
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CHAPTER 11 
 
Discussion Part 2: 
 
Impact of Non-healthcare professional on fears about the safety and efficacy of TCS 
and treatment adherence 
 
This chapter is presented as an unpublished manuscript. 
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Introduction 
Treatment adherence, also known as treatment compliance or treatment concordance, is an 
essential component to successful disease management.  Treatment non-adherence may arise 
from intentional conscious decision making by the patient or by unintentional effects.   
 
Intentional non-adherence to their treatment may arise for a variety of reasons such as health 
beliefs [1, 2] and a desire to pursue complementary and alternative medicine therapies [3].  
Importantly, intentional non-adherence may occur when patients are afraid of the treatment 
due to a perceived risk of treatment adverse effects which may lead patients to make changes 
to their own treatment plan and adherence to treatment independently of the doctor’s original 
guidance [4]. Furthermore, the visual nature of dermatology conditions may contribute to a 
negative effect on adherence because the perceived severity of their condition can be 
‘assessed’ by the patient on a day to day basis [4].  This may lead patients to alter their 
dosage, increase or decrease, or even stop therapy completely without the direct involvement 
of their treating physician. Furthermore, the complex nature of treatment regimens for skin 
conditions leads patients and parents/caregivers to take shortcuts to simplify their treatment, 
such as the reduced frequency of topical therapy application [5]. 
 
On the other hand, patients may also become unintentionally non-adherent to treatment with 
the most common reasons being forgetfulness or lack of knowledge about the disease and its 
treatments [4].  This has been reported in dermatology where there is a level of inconvenience 
at having to apply material to their skin, with forgetfulness being the most common reason 
for non-application of sunscreen [6] and skin conditions [4].  This can be further compounded 
by poor knowledge about the amount and frequency of application, whether by poor 
instructions or conflicting information from members of the healthcare professional team [7]. 
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 Regardless of the whether non-adherence to treatment is intentional or unintentional, 
divergence from physician directed management plans can lead to poorer treatment outcomes 
with the consequences ranging from periodic or complete loss of efficacy through to 
increased risks of adverse events and toxicity [4].  Close to a quarter of patients consistently 
fail to follow their treating doctor’s recommended treatment plan across various medical 
conditions such as asthma [8] and HIV [9].  Adherence rates can vary considerably across 
disease conditions [1] and treatment regimens, and can be quite low, even for treatments that 
are highly effective such as seen in paediatric AD [10].  In fact, in paediatric AD where the 
patient relies on a parent to assist with implementation of treatment, non-adherence occurs in 
24% of cases [10]. Treatment adherence relies on multiple factors which researchers explore 
to improve adherence.  The factors that predict adherence, including the cognitive, 
psychological, social, environmental, contextual, and therapeutic elements of the experience 
of living with illness [1].  
 
Paediatric Atopic Dermatitis 
 
In the setting of paediatric AD intentional and unintentional adherence factors impact on 
treatment adherence. Whilst the available treatments for AD are effective [11,12], the 
treatment regimens are often complex, consisting of regular application of emollients and 
long-term TCS or the use of calcineurin inhibitors as well as adjuvant strategies include 
environmental modification, avoidance of triggers, phototherapy and the management of 
complications such as secondary infections. In severe cases, oral anti-inflammatory 
medications and immunomodulators may be required. However, poor treatment adherence is 
common, and only 32% of patients have been found to be adherent to topical therapy in AD 
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when measured with electronic monitoring [13], leading to poor treatment outcomes. 
Therefore, non-adherence to treatment is an important cause of treatment failure [14]. 
 
Treatment adherence is even more complex in the paediatric AD because the patient is reliant 
on their parent or caregiver to help or administer in entirety the treatments.  This means 
parents and caregivers are a critical factor in treatment outcomes.  However, they are 
influenced by their personal health belief biases, information on disease pathophysiology, and 
the safety and efficacy of treatment from external non-healthcare professionals such as 
family, friends and the Internet. 
 
There are significant implications that arise from poor treatment adherence in AD for patients 
and their families [14]. With respect to the patient, children with AD suffer from sleep 
disturbance, are more irritable, require greater attention [15–17] and are at increased risk of 
mental health problems by the age of ten [18]. This in turn has substantial flow on effects 
with psychosocial implications for their caregivers and families [19]. The ability of parents to 
work, complete household duties and engage in social activities is impaired [14, 20–22] and 
parents also experience significant psychological strain from self-blame, guilt and sadness 
[15]. There can also be significant economic burden to the parents/family [22] as well as to 
society more broadly with significant costs resulting from primary care and emergency 
department presentations, hospital. 
 
Parental Beliefs  
 
There seems to be a commonly held belief in parents in Australia [3] and internationally [23, 
24] that treatment of paediatric AD with TCS carries a risk to their child and that ‘natural’ 
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therapy is safe and therefore preferable. The commonest belief is that use of topical 
corticosteroids will thin the skin irreversibly. However, concerns about immune suppression 
and growth failure are also expressed by many parents [3, 23]. This ‘corticosteroid phobia’ 
has been previously documented as a major cause of non-adherence and treatment failure in 
AD [10, 25-27]. The safety and efficacy of TCS in paediatric AD have been affirmed [28]. 
However, parents have many reasons to be rationally frightened of topical corticosteroids 
because of warnings not only from friends, relatives and the Internet [29], but also from 
traditionally trusted sources including their general practitioner and pharmacist [30]. 
 
Perception of disease severity 
The existence of differences in perception of disease severity between parent/caregiver and 
clinician impacts on treatment outcomes, patient attitude towards disease, assessment of 
effectiveness of treatment, patient’s expectations of treatment effectiveness, underreporting 
side effects and quality of life impacts not directly attributable to disease or treatment side 
effects [31,32]. Furthermore, severity perception is directly related to treatment adherence in 
atopic dermatitis [24] and other disease settings [1].  
Our recent Australian study [33] of the 50 parents of children affected with AD found that 
44% of children were reported by their parents to have moderate to severe impact on their 
quality of life as a result of their disease. However, Parents underestimated the severity of 
their children’s skin disease compared to validated clinician assessment with a significant 
difference between clinician assessed EASI score (M= 8.87, SD = 11.99) and caregiver 
assessment of the severity of children’s eczema (M= 6.78, SD = 9.86), p <0.001.  
The tendency of parents/caregivers to underestimate the severity of AD in their children is 
commonly seen in clinical practice.  This provides an insight into understanding a further 
source of poor treatment adherence because the parent/caregiver perceives the AD to not as 
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severe and therefore undertreat.  This highlights a need for clinicians act as health educators 
to provide parents/caregivers with a greater understanding of their child’s disease. It is 
important to provide education into expectations surrounding treatment, explore potential 
factors leading to non-adherence, and facilitates an approach to the fears and misconceptions 
that caregivers may have. 
 
Family and Friends 
Patients and parents clearly identify there is a significant role of family/friends as an 
information resource about the safety and efficacy of TCS [3].  The information provided can 
detrimentally impact a patient’s or parent’s understanding of the safety and efficacy of TCS 
to manage their (or their child’s) AD, which can lead to poor treatment adherence to 
evidence-based medical therapy [3]. 
 
Our published cross-sectional survey [29] explored that type and frequency of positive and 
negative messaging that dermatological patients (aged 18+) and parents of pediatric 
dermatological patients (patients aged <18) with a history of long-term (≥ 1 month) TCS use 
for chronic inflammatory dermatoses receive from family and friends. Of the 201 participants 
61% were adult patients (n=123) and 39% were parents of pediatric patients (n=78). 
 
The study we performed demonstrated that of parents/patients who report receiving TCS 
messaging from friends/family, only about a third receive benefit messages from these 
sources. Concurrently, a third of these parents/patients are also receiving misinformation in 
the form of exaggerated risk messages from the same source. However, parents/patients are 
more likely to receive a risk message that a benefit message about the role of TCS in atopic 
dermatitis from the family/friends.  The study did not evaluate which source has more 
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influence but it is known that risk messages are more powerful than benefit messages.  
Furthermore, often the messaging received from family and friends is unbidden by the 
patient/parent [3].  This may in turn increase the anxiety of the messaging received. 
 
Charman et al [10] have also reported the high frequency of family and friends as a source of 
information about safety and efficacy of TCS in 26% (14.5% family and 11.5% friends) of 
their study cohort.  This study was performed in 2000 and with the explosion of the advent of 
social media as a source of communication as a way by which to communicate with family 
and friends, it is possible that this percentage would be much higher now.  In fact, in 2006, 
Hon et al [34] indicated that 57% of their research cohort indicated that they receive 
information about safety and efficacy of TCS from family and friends. 
 
It is clear that family and friends are a frequency source of information about the safety and 
efficacy of TCS for patients and parents.  Furthermore, it has been demonstrated that the 
messaging received is potentially a mixture of benefit messages and risk messages.  The 
mixture of these messages can contribute to confusion about the evidence-based safety and 
efficacy of TCS which in turn can impact upon treatment adherence. 
 
The Internet 
Patients and parents also clearly identify there is a significant role of the Internet as an 
information resource about the safety and efficacy of TCS [3].  Patients and parents have 
suggested that the information provided can detrimentally impact their understanding of the 
safety and efficacy of TCS to manage their (or their child’s) AD, which can contribute to 
poor treatment adherence to evidence-based medical therapy [3]. 
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The same published cross-sectional survey [29], referred to above, explored that type and 
frequency of positive and negative messaging that dermatological patients (aged 18+) and 
parents of pediatric dermatological patients (patients aged <18) with a history of long-term (≥ 
1 month) TCS use for chronic inflammatory dermatoses receive from the Internet. Of the 201 
participants 61% were adult patients (n=123) and 39% were parents of pediatric patients 
(n=78). 
 
The study performed also demonstrated that of parents/patients who report receiving TCS 
messaging from the Internet, only about a third receive benefit messages from this source. 
Furthermore, a third of these parents/patients are also receiving misinformation in the form of 
exaggerated risk messages from the same source. However, parents/patients report that they 
are more likely to receive a benefit message than a risk message about the role of TCS in 
atopic dermatitis from the Internet. 
 
In 2006, Hon et al [34] reported that 17% of their patients use the Internet as a source of 
information about TCS.  By 2015, Lee et al [35] reported that the Internet was the most 
common source of information about TCS as reported by 49% of their study cohort.  This 
growth in numbers may reflect the advent of ‘Dr Google’ and the tendency of many patients 
and parents to increasingly rely on the Internet for medical information.   
 
The Lee et al [35]and Hon et al [34] studies also highlighted other media streams as a source 
of information on TCS such as television/broadcast media (Lee et al 45% and Hon et al 52% 
of their cohorts), and newspapers/magazines (Lee et al 34% and Hon et al 62% of their 
cohorts). 
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The Internet is a frequent source of information about the safety and efficacy of TCS for 
patients and parents.  Furthermore, it has been demonstrated that the messaging received can 
contain benefit and risk information.  The mixture of these messages can contribute to 
confusion about the evidence-based safety and efficacy of TCS which in turn can impact 
upon treatment adherence. 
 
 
Conclusion 
There are several non-healthcare professional influences which can contribute to poorer 
treatment adherence with topical corticosteroids in AD.  These factors can compound the 
potential mixed risk and benefit messaging about the safety and efficacy of topical 
corticosteroids that parents and patients may receive from their healthcare professional.  It is 
important to identify these potential treatment adherence factors in order to address them 
through evidence based disease and treatment education.  This will provide patients and 
parents with the tools to negotiate this sea of conflicting information and achieve the best 
control of their AD.   
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Concluding remarks 
 
AD is a readily treatable common dermatological condition.  Poor treatment outcomes are 
often a result of non-adherence with treatment. The fear surrounding the use of 
corticosteroids has been proposed as a cause for failure of compliance [1,2]. “Skin thinning” 
and systemic effects are among the fears expressed by parents, despite evidence that side 
effects are minimal if used appropriately [1]. This is a situation which is seen not only in 
Australia, but also cross-cultural phenomenon seen in many countries around the world [3].  
This highlights an information gap which can lead to a possible disconnect between patient, 
parent and clinician in treatment and safety.  There is a need for better education of 
caregivers. Studies have demonstrated that parental training, multidisciplinary support, 
specialist training nursing support and empowering parents with appropriate education 
improves treatment adherence [4,5,6].  
Identifying factors which contribute to treatment non-adherence in AD 
The systematic review in Chapter 2 helps to identifying the major factors that lead to poor 
treatment adherence of importance in childhood AD.  A common cause of treatment failure in 
AD is poor adherence rather than disease severity or the ineffectiveness of treatment. The 
review indicates that poor adherence is very prevalent for a variety of reasons. A fear about 
side effects arising from the use of TCS, also known as TCS phobia, was a key factor 
identified as to contributing to poor treatment adherence.  This is driven by a poor 
understanding of disease pathophysiology.  Building a strong patient/caregiver–clinician 
relationship, simplifying treatment regimens, implementing comprehensive education 
sessions and increasing the frequency of follow up are important mitigating strategies against 
poor treatment adherence in childhood AD. It was determined that future research was 
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required to define the actual risk from side effects from TCS use as well as identifying the 
sources of misconception about the safety and efficacy of TCS.   
Identifying the likelihood of side effects from TCS use in paediatric AD 
TCS remain the mainstay of the management of active atopic eczema in combination with the 
regular use of emollients, the management of triggers and the treatment of concurrent 
infection. An Australasian consensus statement, outlined in Chapter 3, has been developed to 
explore the actual reported frequency and severity of side effects from TCS in the setting of 
paediatric AD.  The safety profile of TCS remains robust when it is used appropriately. 
Appropriate use is defined as 1–2 generous applications per day to all the inflamed skin until 
the active eczema is controlled as per guidelines. It was found that the advice given by 
dermatologists to parents of children with eczema regarding the use of TCS is unfortunately 
frequently undermined by other health professionals. Therefore, it was important to explore 
the knowledge and attitudes of members of the multidisciplinary healthcare team. 
 
Dermatologist as member of the multidisciplinary healthcare team 
Dermatologists in Australia are the experts in the management of paediatric AD and 
commonly utilise potent or super-potent TCS for its treatment. Research was carried out to 
explore the knowledge and attitudes of Australian dermatologists to the safety and efficacy of 
TCS in this setting. Chapter 4 outlines this research which demonstrated that most 
dermatologists report skin atrophy to be rare and that in general side-effects are uncommon 
when TCS are used appropriately. Dermatologists believe that the effective management of 
pAD is affected by TCS phobia, for which pharmacists are cited as the main contributor. 
Most dermatologists support removing the phrase ‘use sparingly’ from TCS labelling. 
However, despite the known facts on the safety of TCS a substantial number of 
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dermatologists still advise their patients that cutaneous atrophy is a risk of this treatment.  
This may unwittingly contribute to TCS phobia if negative messages about the safety and 
efficacy of TCS are received from other members of the multidisciplinary team. 
 
Pharmacists as a member of the multidisciplinary healthcare team 
Pharmacists are a key member of the multidisciplinary healthcare professional treatment team 
and are typically the last interaction with a healthcare professional when they attend to fill the 
prescription from their doctor.  Therefore, research, which was reported in Chapter 5, was 
performed to explore the knowledge and attitudes of Australian pharmacists about the safety 
and efficacy of TCS in paediatric AD.  This research demonstrated evidence that there are 
wide education gaps in Australian pharmacists’ knowledge of the use and safety of TCS in 
pAD. This ultimately can contribute to the misinformation parents and patients receive about 
the use and safety of TCS.  This, in turn, can directly affect the adherence to evidence based 
treatments used to manage their AD.  Targeted education, especially in pharmacy journals 
and at undergraduate level, preferably delivered by a dermatologist, is needed to Pharmacist 
knowledge of topical steroids to improve pharmacist’s knowledge and eliminate 
misconceptions. Our data indicate that their attitudes may be modified by evidence-based, 
clinically centred re-education. 
 
General practitioners are a member of the multidisciplinary healthcare team. 
General Practitioners are the other key member of the multidisciplinary healthcare 
professional treatment team.  They are the gate keepers to referrals to specialists in Australia 
and often have long established therapeutic relationships developed over years with their 
patients and their families.  Therefore, research, which was reported in Chapter 6, was 
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performed to explore the knowledge and attitudes of Australian general practitioners about 
the safety and efficacy of TCS in paediatric AD.  The research highlighted that there may be 
education gaps in Australian GPs’ knowledge of the use and safety profile of topical 
corticosteroids in pAD. This may contribute to exaggerated risk messaging that reinforces 
misinformation parents/patients currently receive about use and safety of topical 
corticosteroids from other members of the multidisciplinary healthcare professional treatment 
team. Furthermore, this can directly impact upon treatment adherence because 
patients/parents are more likely to avoid/minimise the use of a medication if they do not 
understand it or are fearful of perceived side effects.  
 
Impact of advice from pharmacist and general practitioners 
As the research documented in Chapters 4, 5 and 6 clearly demonstrated the risk of mixed 
benefit and risk messaging from a patient/parent’s multidisciplinary healthcare professional 
treatment team, it was important to try and assess the impact of the messaging received.  
Chapter 7 reported the outcomes of research into the patient/parent reported impact of 
treatment advice around the safety and efficacy of TCS in paediatric AD, as well as exploring 
the actual adherence to treatment by patient/parents.  The results confirmed that in patients 
with chronic inflammatory dermatoses such as AD, adherence to long-term TCS therapy is 
poor.  Furthermore, patient and parent beliefs about the “risks” of TCS are common. The 
negative risk messages about the “dangers” of long-term TCS use are being received by a 
majority of patients and parents on a consistent basis from members of their multidisciplinary 
healthcare professional treatment team, especially pharmacists and GPs. Patients and parents 
report having negative TCS-related counselling experiences with both pharmacists and GPs, 
but these negative experiences occur more frequently with pharmacists. These findings 
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indicate a need for re-education of both pharmacists and GPs on the safety of TCS use and 
the potential impact of their counselling on treatment adherence. Analysis of the data also 
suggested that friends, family and the Internet also propagate the inaccurate messages about 
the safety and efficacy of TCS. 
 
Chapters 4, 5, 6 and 7 documented the potential for members of a patients 
mutidisciplinarymultidisciplinary healthcare professional treatment team to provide differing 
advice on the safety and efficacy of TCS in paediatric AD.  This is likely to be a significant 
contributor to the reported high level of poor treatment adherence with TCS in this and other 
chronic inflammatory dermatoses.  However, this research also helped to highlight the 
possible role of family, friends and the Internet as a non-healthcare professional source of 
misinformation on TCS safety and efficacy in paediatric AD. 
 
Impact of information about TCS from family, friends and the Internet 
Family, friends and the Internet have previously been indicated as a source of information 
about the safety of TCS [7-10].  However, the type of advice and the influence of this advice 
on patient/parent perception of the safety of TCS has not previously been assessed. Chapter 8 
reported the results of research seeking to explore these gaps in the literature.  This research 
demonstrated that only a minority of patients and parents of children with chronic 
inflammatory skin diseases consistently receive benefit messaging from family/friends and 
the Internet.  On the other hand, family/friends and the Internet are a frequent source of 
misinformative risk messages about TCS. The varied and mixed nature of this messaging can 
help contribute to confusion and poor understanding about the safety and efficacy of TCS in 
CID. This in turn can lead to treatment non-adherence and poorer treatment outcomes. 
121
 Parents perception of disease severity 
Atopic dermatitis is a condition characterised by flares and remissions.  Therefore, a key 
factor in the management of paediatric AD is that parents have to often commence and adjust 
the potency and frequency of topical therapies depending on the severity of the active AD.  It 
was documented in the Chapters 3, 4, 5, 6, 7, and 8 of this thesis that negative messaging 
about the safety and efficacy of TCS from a range of sources in paediatric AD contributed 
poor treatment adherence. However, it was important to explore whether parents accurately 
assessed the active disease severity in their child in order to be adherent to the treatment 
advice of their treating clinician.  Chapter 9 reported a study assessing whether was a 
difference in parent perception of disease severity when compared to clinician assessed 
disease severity.  This study demonstrates a significant gap in parent’s perception of disease 
severity relative to severity assessed by a clinician.  When parents under-appreciate the 
severity of their child’s disease this may lead to decreased treatment adherence and poorer 
treatment outcomes.  Therefore, it is important for clinicians to help parents understand the 
impact of AD on their child and where they are located in terms of absolute clinical severity. 
This may help to educate parents how to assess flare severity and guide management. 
 
Conclusion 
The treatment of paediatric AD is impacted up on by mixed benefit and risk messaging about 
the safety and efficacy of TCS.  There are multiple healthcare professional and non-
healthcare professional source for information on TCS.  This means there are multiple 
opportunities for both negative and positive influencers on the perceptions around the long 
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term use of TCS.  This can create a sea of misinformation which is difficult for parents to 
negotiate and in turn contributes to treatment non-adherence and poorer disease outcomes. 
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Clinical and Social Implications 
 
This thesis helps to define the frequency of treatment non-adherence in paediatric AD and 
how fears about the safety and efficacy of treatment mainstay TCS plays a key role.  This 
means that whether at the onset of a new patient-doctor relationship or during well 
established patient-doctor relationship there is potential for targeted education and support as 
an intervention by the members of the multidisciplinary healthcare professional treating team 
to increase treatment adherence with focused counselling.  Therefore, it is important for the 
members of the healthcare team to act as both clinician and health educator for their patients 
and in the wider lay and medical communities. Institutions, particularly the Australasian 
College of Dermatologists, have a role to play in defending and promoting the safety of TCS 
in the treatment of pAD. This thesis has identified the problem. The solutions lie in better 
education for all groups involved. 
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Limitations 
 
A key limitation to the research performed it the difficulty in obtaining research funding to 
perform larger cohort studies.  Dermatology research, outside of melanoma, tends to benefit 
little from classic research funding models.  Instead it relies on the willingness of the 
researcher and the research team to carryout largely unfunded research. 
 
The studies performed in this thesis necessarily focused on the Australian environment.  This 
means that potentially the results are not generalisable to other cultures or countries.  
However, many publications document the existence of the problem in other western 
countries and a recent international meta-analysis highlighted the cross-cultural commonality 
of fears towards the use of TCS in paediatric AD [1]. 
 
A key limitation to the studies presented in this thesis is that the patient populations sampled 
were collected from those attending dermatology clinics.  This is a self-selected group due to 
either having difficult to control disease or more severe disease. Therefore, it may not 
represent the broader Australian community. 
 
A key limitation to the studies presented in this thesis is that the general practitioner and 
pharmacist populations sampled were voluntarily attending continuing professional 
development education sessions.  It is possible that they choose to attend these specific 
sessions because they felt they were not up to date with the latest evidence-based information 
on the safety and efficacy of TCS in paediatric AD.  This might bias the results to indicate a 
larger issue than may actually exist.  On the other hand, as we were unable to sample non-
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attendees to continuing professional development education sessions, it is possible that out 
results under report the extent of the knowledge gap about the safety and efficacy of TCS. 
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Future directions and research 
 
Research to explore the information content of the Internet 
 
The Internet is a key source of health information.  It is common place for patients to 
supplement the information provided to them by the members of their multidisciplinary 
healthcare professional treating team, with information gathered from the Internet.  
Therefore, a future research opportunity would be to explore the content of the Internet to 
assess the level and type of information that patients and parents will obtain from this source. 
 
Research into the knowledge of family and friends about the safety and efficacy of TCS in 
paediatric atopic dermatitis. 
 
This thesis has clearly defined that patients/parents receive mixed benefit and risk messages 
from family and friends.  Therefore, a future research project could be to explore the 
knowledge of the general population towards TCS. 
 
Developed educational materials to target the sources of TCS phobia.  
 
General practitioners and pharmacists could be better equipped with contemporaneous 
evidence-based continuing professional education sessions and revised guidelines focused on 
the safety and efficacy of TCS in the treatment of paediatric AD. These will be best delivered 
to the target audience through the education sessions being provide in their conference and 
continuing professional development events, as well as publishing in their specific 
professional peer-reviewed journals. 
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 There is also an opportunity to develop novel medical education programs such as 
smartphone applications.  This would deliver the target education directly to the hand of the 
healthcare professional holding their electronic device as well as providing flexibility with 
the way in which they interact with the evidence-based educational materials. 
 
The Australasian College of Dermatologists has recently developed an evidence-based 
statement on the safety and efficacy of TCS in paediatric AD.  This will help to counter-
balance other sources of misinformation and hopefully increase awareness of evidence-based 
sources of medical information. 
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Evaluation of the Atrophogenic Potential
of Topical Corticosteroids in Pediatric
Dermatology Patients
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Abstract: We conducted a cross-sectional observational study to
determine the atrophogenic potential of TCS in children with dermatitis
requiring long-term TCS suppression. Children who were able to achieve
good disease control, with a maximum Eczema Area and Severity Index
score of 1.0, using TCS were examined for adverse effects of treatment.
Cutaneous atrophy was assessed using a validated dermoscopic technique.
Cutaneous sites exposed to TCSwere comparedwith nonexposed sites in all
patients. There was no significant atrophy in 70 TCS-exposed and 22 TCS-
naı¨ve children. Mild grade 1 telangiectasia of the cubital fossa was observed
in 3.3% of the test group and 3.1% of the control group (p > 0.99). We
conclude that routine, appropriate, long-term use of TCS in children with
dermatitis does not cause skin atrophy. These data do not support thewidely
held belief that routine use of TCS will ‘‘thin the skin.’’ Parents, pharmacists,
and health practitioners should be confident about the safety of using this
treatment.
Topical corticosteroids (TCS) are the mainstay of
treatment for many inﬂammatory skin conditions and
the criterion standard for treating atopic dermatitis (AD)
(1). Children with corticosteroid-responsive dermatoses
are often undertreated because of parental corticosteroid
phobia (2–5). Parents most often cite ‘‘skin thinning’’ as
the side eﬀect they most fear (6). This fear is entrenched
not only inAustralian parents, but also worldwide (7–9).
Although cutaneous atrophy is a well-documented side
eﬀect ofTCS, particularlywhenpotent products are used
under occlusion, the fear of atrophy in the lay and
medical community has become so exaggerated that
many parents cannot bring themselves to treat their
children appropriately (3,4). TCS phobia is a problem
that is not conﬁned to parents, but also inﬂuences many
nondermatologist health care practitioners. As a result,
children suﬀerwith uncontrolledAD, andmanyhours of
consulting time is wasted convincing parents that the
information on which they base their fears is without
evidence.
We conducted a cross-sectional observational study
to determine the atrophogenic potential of TCS in
pediatric dermatology patients requiring long-term TCS
maintenance treatment.
Our primary aim was to detect and quantify
TCS-related cutaneous atrophy in these children using
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a previously validated dermoscopic methodology
(10–12).
Our secondary aim was to demonstrate that routine
use of TCS in suﬃcient quantities and potency to pro-
duce excellent control of inﬂammatory dermatoses in
children does not result in cutaneous atrophy. We hope
thereby to increase the conﬁdence of parents and health
practitioners in the safe, appropriate use of this essential
medication for children with chronic skin disease.
MATERIALS AND METHODS
TheNorthernSydneyCentralCoastAreaHealthService
Human Research Ethics committee approved the study.
Participants were invited to take part in the study
if they were younger than 18, had atopic dermatitis
(deﬁned byHaniﬁn and Rajka) (13) or eczema–psoriasis
overlap (atopic dermatitis with associated features of
psoriasis, a diagnosis we use in our clinic previously
deﬁned in another study) (14), had used TCS regularly
for at least 3 months, and were assessed as being under
excellent control, with a maximum Eczema Area and
Severity Index (EASI) score of 1.0. Those who had not
been adherent to treatment when assessed on interview
during clinic consultation were excluded until it was
deemed that adequate adherence had been met. Non-
adherence was invariably associated with fear of use of
TCS and evidenced by poor control and underuse of
prescribedmedication.Children in our clinicwho are not
able to be controlled with TCS despite good adherence
are oﬀered systemic therapy. These children are not the
norm and were excluded from the study.
Parents were given a range of TCS to control their
children’s dermatitis, including strong, medium, and
weak preparations. None of our patients were using
calcineurin inhibitors other than on the eyelids. Parents
were instructed to use potent TCS preparations two to
three times a day while skin was ﬂared and then, once
cleared, to reduce treatment to amoderate-strength TCS
twice a day for a further 3 days. Emollients and mois-
turizers were also provided to all patients for application
with TCS and alone as part of routine skin care between
ﬂares. Parents were taught how and when to apply their
medication, including ﬂare management, with the aid of
explanation in the clinic, video demonstration, written
information, and in some cases hospitalization. Parents
were instructed to use enough TCS to create a thin ﬁlm
over areas of active eczema. The amount of TCS used
was assessed according to self-reporting by parents and
the number of prescriptions supplied. Wet dressing
technique was taught, but none were instructed to use
plastic wrap occlusion. Appropriate environmental
modiﬁcation was recommended, and fears of TCS were
addressed using information developed during a previ-
ous study by our group (6).
Evidence of atrophy was assessed using a validated
5-point dermoscopic scale previously demonstrated to
show good correlation with histologic measurement
(10). Histologic investigation was not considered desir-
able or feasible in pediatric patients.
The following data were recorded:
• Demographic (age, gender)
• Diagnosis (skin condition requiring use of TCS)
• Distribution of skin signs or rash
• Type of TCS used
• Areas of body on which TCS was used
• Amount, frequency, and duration of treatment
with TCS (ascertained by directed questioning
during clinical consultationand self-reportingby
parents and number of prescriptions provided)
• Dermoscopy: two independent observers graded
for skin atrophy and telangiectasia using a
5-point scale (Table 1)
Measurements were recorded from three TCS-treated
sites and one untreated self-control site in each patient.
Two observers each scored the four sites for atrophy and
telangiectasia.
Seventy children with well-controlled AD and
eczema–psoriasis overlap were assessed (dermatitis
group). The total number of observations for both
observers was 560 (8 · 70), of which 140 (25%) were
control sites. The total number of sites in the dermatitis
group was 280 (70 · 4). The same assessment was
performed in a control group of 22 age-matched children
who had never used TCS and presented to the same
TABLE 1. Dermal Atrophy and Telangiectasia (Five-Point
Scale Used By Frosch et al (10))
Atrophy
0 No change
1 Slight increase in transparency and dermoglyphic
pattern irregularity
2 Moderate increase in transparency and ﬂattening
of furrows and ridges
3 Severe increase in transparency and dermoglyphic
pattern eﬀacement
4 Very severe thinning with complete loss of
dermoglyphics (‘‘glazed skin’’)
Telangiectasia
0 Normal vascular pattern with ﬁne capillary loops
1 Capillary hyperemia with slight elongation and
dilatation of blood vessels
2 Moderate telangiectasia just visible to the naked eye
3 Severe telangiectasia with marked reduction of
capillary loops
4 Very severe telangiectasia with large blunt vessels
and absence of capillary loops
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pediatric dermatology clinic with unrelated noninﬂam-
matory conditions.
Statistical Analysis
Inter-observer reliability (kappa coeﬃcient) and statisti-
cal diﬀerences (p-values) were calculated using Graph-
pad Software 2010 (Graphpad Software Inc., La Jolla,
CA). All other statistical analyses were performed using
SPSS 17.0 (SPSS Inc., Chicago, IL).
RESULTS
Seventy children in the study groupand22 children in the
control groupwere assessed. The study group (dermatitis
group) consisted of 52 children with AD and 18 children
with eczema–psoriasis overlap. There were no statistical
diﬀerences inbaseline characteristics between the groups;
46% of the study cohort and 41% of the control group
were boys (p = 0.81), the mean age of the study group
was 3.2 years, and the average duration of TCS use was
10.6 months.
The majority (93%) of patients in the study group
were using a combination of potent (betamethasone di-
propionate 0.05% ointment, methylprednisolone acep-
onate 0.1% ointment or mometasone furoate 0.01%
ointment), moderate (betamethasone valerate 0.02%
ointment), and weak (hydrocortisone acetate 1% oint-
ment) TCS as appropriate to severity and site of appli-
cation (Table 2).
All of the children included in the study were under
excellent control, with a maximum EASI score of 1.0.
Neither investigator observed any degree of atrophy
in any of 280 sites from the study group and 88 sites from
the control group.
Onlyminimal telangiectasia (grade 1) was observed in
our patients. All cases of telangiectasia were in cubital
fossa sites. None of the patients showed evidence of
striae, atrophic scars, or purpura.
There was no statistical diﬀerence between the der-
matitis and control groups for rate of telangiectasia
(study group 7 ⁄210 = 3.3%, control group 3 ⁄88 =
3.1%; p > 0.99).
There was 98% agreement between observers (dis-
agreement in ﬁve of 280 sites rated), which corresponded
to an interobserver reliability kappa coeﬃcient of 0.887,
which demonstrated very good strength of agreement
(Graphpad Software).
DISCUSSION
‘‘Corticosteroid phobia’’ is a term that describes an
exaggerated and at times irrational fear of using topical
corticosteroids and that presents a major problem for
doctors using these medications in skin and respiratory
disease (2–4).
Although atrophy is a well-documented side eﬀect of
TCS, previous reports detail inappropriate usage or
safety evaluation usage tests under extreme conditions,
for example theuseof potent topical corticosteroidunder
plastic wrap occlusion (10,15). Although not docu-
mented in the medical literature, overuse of TCS by
parents in an attempt to prevent ﬂares is a potential cause
of atrophy, although it was unusual in our cohort, who
were almost universally corticosteroid phobic (6). These
reports have a great eﬀect on clinicians’ perceptions of
safety but do not address the reality of routine clinical
use.Our experience reﬂects that general practitioners and
even nonpediatric dermatologists are fearful of the use of
appropriate TCS to control AD (6).
Adherence is an important factor in treatment out-
come in dermatitis (3). The widely held fear that TCS
cause ‘‘skin thinning’’ causes many parents and doctors
to hold back on appropriate treatment (3,4). Even with
written action plans (which have been shown to be
eﬀective in increasing adherence) (16), barriers to suc-
cessful treatment can exist if underlying fear of the
treatment itself has not been suﬃciently addressed.
The study was aimed speciﬁcally at adherent families
from our dermatology outpatient clinic who had been
persuaded to adhere to treatment with TCS and thereby
achieve excellent long-term disease control. Patients who
were not able to be adequately treated as outpatients
were admitted to the hospital for treatmentwithTCSwet
dressings. During hospital admission, parents received
further education and support in how to manage their
children’s skin. When these patients achieved adequate
adherence, evidencedbyanEASI scoreof 1.0or less, they
were included in the study. In all cases, we spent sub-
stantial time explaining the relative safety of TCS to
parents, supplementing this with written information
and following up closely. Additionally we ensured that
environmental modiﬁcation, such as use of emollients
and soap substitutes was in place and that appropriate
amounts and potency of TCS were used to produce a
target outcome of normal skin. Mild to moderate TCS
TABLE 2. Strength and Amount of Topical Corticosteroid
(TCS) Used in the Group with Atopic Dermatitis
TCS type
Number of patients
regularly using, %
TCS used per month,
g, mean (range)
Potent 93 79 (15–180)
Moderate 77 128 (50–150)
Weak 70 34 (15–50)
Hong et al: TCS and Atrophy Study 395
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was used for routine maintenance and potent TCS for
ﬂares. Calcineurin inhibitors were used only on the eye-
lids.
Gross, macroscopic signs of cutaneous atrophy such
as striae and translucent skin were not seen in any
patient. We used a simple noninvasive technique to
evaluate microscopic dermal atrophy. This was also not
encountered.
Minimal grade 1 telangiectasia (Fig. 1) was observed
in some cases (seven cubital fossae sites out of 210 TCS-
exposed sites [3.3%]). The same degree of telangiectasia
was found in cubital fossa sites from TCS-naı¨ve control
patients (three out of 88 sites [3.1%]) (p > 0.99), sug-
gesting that some telangiectasia in the cubital fossa may
be a normal variation in the pediatric population.
Our data donot support thewidely held fear thatTCS
treatment produces cutaneous atrophy even in a group
using a substantial amount of medication and achieving
excellent control of chronic dermatitis.
CONCLUSION
This study demonstrates that, in children with mild to
moderately severe dermatitis, it is possible to obtain
excellent control using TCS without also producing
cutaneous atrophy. The ubiquitous fear that all forms of
use of TCS will cause ‘‘thin skin’’ appears to be un-
founded if TCS are used appropriately, even in sub-
stantial quantity and potency.
Patients should be strongly reassured that routine
short- and long-term use of TCS is safe, and pharmacists
and health professionals who may propagate misinfor-
mation regarding their safety require re-education.
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Figure 1. Grade 1 telangiectasia in topical corticosteroid–
naı¨ve cubital fossa. Dermoglyphic patterns are normal, and
there is grade 0 atrophy.
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ABSTRACT
Background/Objectives: Anxieties associated
with corticosteroid treatment and preference for
‘safer natural therapy’ are common in parents of chil-
dren with atopic dermatitis. We used focus groups to
explore the source of these attitudes.
Methods: The study involved 16 parents. Parents
expressed difficulties with living with and treating
atopic dermatitis which were categorized into themes
using qualitative data analysis software.
Results: Themes identified include: emotional
impact of atopic dermatitis; difficulty in accepting
‘control’ verses ‘cure’; topical corticosteroid negative
perceptions; anxiety and confusion with treatment;
preference for ‘natural’ therapy; and attitude-
changing positive experiences.
Conclusions: Our findings illustrate the emotional
impact of atopic dermatitis and the frustration with
the lack of potential cure. ‘Corticosteroid phobia’ was
universal among parents in our cohort and is a fear
generated by doctors, pharmacists, close acquaintan-
ces and information from the internet. Participants
expressed high levels of parental guilt linked to a
desire for an eradicable ‘cause’ for atopic dermatitis,
despite intellectually understanding this is a geneti-
cally determined condition. Parents were willing to
change attitudes with accurate information from
perceived reliable sources, positive hospitalization
experiences and a relationship with a trusted derma-
tologist. Parents’ suggestions to improve confidence
included the provision of readily available informa-
tion and better access to doctor- and nurse-led pae-
diatric dermatology services.
Key words: atopic dermatitis, fear, focus group,
management, paediatric, phobia, topical
corticosteroid.
INTRODUCTION
One of the major reasons for an unsatisfactory treatment
outcome in the treatment of childhood atopic dermatitis
is inadequate compliance.1–3 Previous studies have high-
lighted the fact that even though severe atopic dermatitis is
disabling and disruptive for the patients and their families,
adherence to topical treatment is poor and anxiety regard-
ing the use of treatment is high.1,4–6 A number of studies
have evaluated educational interventions to improve com-
pliance. These include written and video-aided information,
written action plans, nurse-led clinics and educational
group sessions with parents.3,7–9
Topical corticosteroids remain the mainstay of atopic
dermatitis treatment. A major cause of anxiety and barrier
to effective compliance is what has been termed ‘corticos-
teroid phobia’, a phenomenon that causes problems not
only for dermatologists attempting to treat atopic derma-
titis with topical corticosteroids, but also for paediatricians
managing asthma with inhaled corticosteroids.10–12 Fear of
topical corticosteroids appears to be strongly linked to a
preference for what parents of patients frequently term
‘natural therapy’. Alternative and complementary medi-
cines are commonly used by parents of children with
atopic dermatitis.13,14
A focus group is a qualitative research tool in which a
group of up to 12 people are interviewed by a facilitator.
Focus groups allow interviewers to study people in an inter-
active setting. They have high validity and have been widely
used in the social sciences to obtain data and insights,
sometimes unexpected, on topics of interest. Focus group
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theory has been used previously to study the psychological,
physical and social impact of atopic dermatitis.15
The aim of our study was to use focus group theory to
explore parental attitudes to the use of corticosteroids and
the associated desire for natural therapy. Our hypothesis
was that in a group situation, the parents of children with
atopic dermatitis would voice their attitudes to both issues,
and that they would emerge as major barriers to compli-
ance. Our primary aim was to explore these phenomena in
order to generate further hypotheses regarding how to
manage them. Our secondary aim was to derive suggestions
from the parents themselves about how health profession-
als might help them to become more confident in the use of
effective management strategies in atopic dermatitis which
would ensure good long-term control of their children’s
disease.
MATERIALS AND METHODS
A qualitative approach using focus group discussion was
adapted in this study to gain in-depth views of parents about
the use of topical corticosteroids to manage their children’s
atopic dermatitis.
The study protocol was reviewed and approved by the
Health Research Ethics Committee of the Northern Sydney
Central Coast Area Health at Royal North Shore Hospital. All
participants were informed about the objectives of the study
and written consent was obtained. The participants did not
receive compensation for their time.
Study participants
The participants were recruited from parents of children
with atopic dermatitis who required the regular use of
topical corticosteroids and who regularly attended the pae-
diatric dermatology clinic at Royal North Shore Hospital.
The hospital has a catchment area predominately from the
North Shore of Sydney and the Central Coast of New South
Wales. Individuals were considered for participation if they
were parents of children aged of 0–18 years old who suf-
fered from atopic dermatitis, as confirmed by a paediatric
dermatologist, and who required the regular use of topical
corticosteroids to manage their atopic dermatitis. Recruit-
ment was not based on the severity of skin disease.
A total of 16 parents agreed to participate in the study and
consent was obtained before the focus session. Parents who
were unable to speak and read English were excluded.
Focus groups
Focus groups were conducted at the Dermatology Depart-
ment within Royal North Shore Hospital between August
2008 and February 2009. Group discussions were conducted
in English. The participants in the focus group included the
parents and two facilitators: a dermatologist and a clinical
psychologist. There were two observers.
Data saturation was reached after the second focus group
was conducted. An additional focus group discussion was
carried out to ensure that no new data were identified.
Thus, the study comprises three focus group discussions.
Before each group discussion, a brief questionnaire
was administered to the participants to gather informa-
tion regarding their demographic background (age, sex,
relationship to child). Before the first focus group, the ques-
tionnaire was pilot-tested to ensure the wording was under-
standable and that the questions elicited the information
sought. After the pilot test, any wording issues and ambigu-
ities that had been detected were addressed, minor amend-
ments were made, and the final version was consistently
used across all focus groups. The items included in the
pre-focus group questionnaire were scored using a 5-point
scale (where 1 = strongly disagree, 2 = agree, 3 = neither
agree nor disagree, 4 = agree and 5 = strongly agree) and
are listed in Table 1.
The group discussion began with an introductory
welcome before the facilitator-prompted discussion began
with an open-ended question. The facilitator did not partici-
pate in the discussion. The open-ended questions used to
generate discussions are listed in Table 2.
Discussions were conducted for between 1.5 and 2 h.
These discussions were audiotaped and transcribed in a
Word document. Notes were taken by the facilitator and the
Table 1 Pre-focus group questionnaire items
1. I believe that my child is not cooperative with treatment
2. I believe that treatment with creams is too time-consuming
3. I believe that treatment with creams is expensive
4. The word ‘sparingly’ on the label of cortisone creams
worries me
5. I believe that cortisone creams are dangerous
6. I believe that cortisone creams cause thinning of the skin
7. I believe that cortisone creams may reduce my child’s growth
8. I believe that cortisone creams may affect my child’s immune
system
9. I believe that cortisone creams should be reserved for treating
only very severe eczema
10. I believe that cortisone cream is a waste of time because the
eczema just comes back when I stop it
11. I believe that my child’s problem is due to allergy
12. I believe that many treatments cause stinging and itching
13. I think it should be possible to cure eczema
14. I believe that cortisone creams are too dangerous to use on
my child
15. I feel I have been adequately informed by my doctor about
how to manage my child’s eczema
16. I would prefer to use natural therapy to treat my child’s
eczema rather than cortisone cream
17. Information on the internet caused me to be more concerned
about cortisone creams
18. I would be interested to take part in an educational support
group on eczema treatment
19. Information from my friends with children caused me to
become concerned about cortisone creams
20. Written instructions would help me to know what to do to
help my child
21. I would find a video with instructions on applying wet
dressings helpful
22. I found an admission to the hospital a positive experience
23. I was more positive about cortisone creams after admission to
hospital
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research team. These notes were used to supplement the
audiotapes of the discussions. Consistent with grounded
theory methods, focus groups were continued until data
saturation was reached or no new information was
uncovered.
Statistical analysis
QRS NVivo qualitative software (QRS International Pty Ltd,
Doncaster, Victoria, Australia) was used for the data analy-
ses. The transcripts were analysed by two of the investiga-
tors using open-, axial- and selective-coding procedures.
The process of analysis first involved open coding, whereby
data of specific themes and categories were identified.
When specific themes were identified, more specific axial
coding was used to develop axial nodes from the core cat-
egories. Subsequently, selective coding was used to inte-
grate the core categories with other categories. The coding
was carried out by a single independent coder, and the
consistency of coding assessed by an inter-observer. In the
final coding stage, the study’s researchers integrated
the selective codings with the core categories.
Themes identified were used to form a list of suggested
strategies for dermatologists that might enable them to
increase patient confidence in treatment.
RESULTS
Participants
A total of 16 parents attended three focus groups. All were
parents of children with a skin condition requiring the use
of a topical corticosteroid. All but one of the participants
were female and aged between 34 and 49 years. All parents
were from the catchment area of Northern Sydney and Cen-
tral Coast area health service, which is a middle to high
socio-economic-strata area. All participated equally and
enthusiastically to the discussion.
Pre-focus group questionnaire
The demographic data collected are presented in Table 3
and disease-specific questions (such as age of diagnosis, the
use of topical corticosteroids, the cost per month of manag-
ing their child’s atopic dermatitis, and the impact of atopic
dermatitis on their child and family unit) are presented in
Figure 1.
All parents (100%) reported they had been told by other
people that topical corticosteroids were dangerous. Friends
were the most common group of people who had given
parents this information (88%). They had also been advised
that topical corticosteroids were dangerous by family (50%),
pharmacists (44%) and general practitioners (25%).
Most parents believed that topical corticosteroids were
dangerous or were unsure. Skin thinning was the most
prevalent cause for parents’ concern as a perceived risk of
using topical corticosteroids. While most parents did not
believe that topical corticosteroids would interfere with
their child’s growth, they were unsure about its effect on the
immune system. Only one parent disagreed that allergy was
the cause of atopic dermatitis. Given the choice, the major-
ity of parents indicated they would prefer to use ‘natural’
therapies over topical corticosteroids.
Most parents did not believe that treatment was too time-
consuming, which suggests a general acknowledgement of
the amount of parental effort required to treat children with
a chronic skin disease. However, over half of parents
thought that the cost of treatment was expensive. Most
parents indicated a desire for regular scheduled visits with
their doctor for their child’s skin condition.
All but one of the parents had children who were admitted
to hospital for treatment of their skin condition, and the
majority found this to be a positive experience that allevi-
ated their fears about topical corticosteroids. Most parents
agreed that information about the treatment of childhood
atopic dermatitis in the form of written or audiovisual mate-
rial would be useful.
Table 2 Open-ended questions
What is it like to have a child with atopic dermatitis?
How do you feel about control versus cure?
What is your view on allergy?
Tell us about cortisone treatment?
Where did you get your information about eczema?
What about natural therapy?
How do you conceptualise ‘thin skin’?
What were some of the problems you have encountered with
treatment?
What are your concerns about treatment?
How do you feel about petroleum products?
What is a ‘natural product’?
What can we do to help you?
What would give you the most confidence?
Tell us about positive experiences
Tell us about negative experiences
Table 3 Data from questionnaire (n = 16)
Age range of parents 34–49 years
Mean age 40.2 years
Sex of parent 15 female, 1 male
Mean age of child at eczema onset 8.5 months
Cost of treatment per month:
Less than $10 2/16
$11–20 2/16
$21–30 4/16
More than $30 7/16
Unsure 1/16
Respondents were told by the following people that topical
corticosteroids are dangerous (%):
Friends 14/16 (88)
Family 8/16 (50)
Pharmacist 7/16 (44)
General practitioner 4/16 (25)
Dermatologist 0/16 (0)
Frequency of medical follow up desired by parents:
Monthly 2/16
3-monthly 2/16
6-monthly 7/16
12-monthly 1/16
As needed 4/16
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Focus group discussion
All statements made by parents were able to be categorized
into seven broad themes (emotional impact, negative per-
ceptions towards corticosteroids, sources of anxiety and
confusion with treatment, complementary and alternative
medicine, problems with accepting control not cure, sup-
portive or positive experiences that changed attitudes and
key parent-suggested improvements), which were thus con-
sidered to be key issues in atopic dermatitis management.
Table 4 outlines these themes and the corresponding
subthemes relating to examples of the parents’ enunciated
experiences.
DISCUSSION
In September 2009, a couple whose daughter died in
Sydney, Australia as a result of sepsis secondary to severe,
medically untreated atopic dermatitis, was convicted of
criminal negligence in the New South Wales Supreme court
and sentenced to jail. The father, a homoeopath, had treated
the child himself.16 This unusual case illustrates the
extreme end of a phenomenon which is becoming increas-
ingly common behaviour in parents of children with atopic
dermatitis: rejection of treatment that is recognized by der-
matologists to be safe and effective in favour of complemen-
tary medicine13,14 and restricted diets that are based on a
belief in allergy as the cause of atopic dermatitis.17
Treatment of atopic dermatitis with topical corticosteroids
is accepted as the gold standard, with very few side-effects
if correctly used. The belief that medical treatment for
atopic dermatitis with topical corticosteroids is dangerous
and that ‘natural’ therapy is safe and therefore preferable is
common among Australian parents. The majority of parents
of a child with atopic dermatitis seen in our paediatric
dermatology clinic express a fear of the use of topical corti-
costeroids. The commonest belief is that use of topical
corticosteroids will thin the skin irreversibly; however, con-
cerns about immune suppression and growth failure are
also expressed by many parents. Much valuable time is
wasted arguing the case for topical corticosteroid treatment
in an attempt to persuade doubting parents that it is the
safest and most effective treatment for their child. Even
when children are severely affected by atopic dermatitis,
many parents resist advice that involves the use of topical
corticosteroids. Fear of medical treatment includes fear of
the use of ointment-based moisturizers now characterized
by some patients as ‘toxic petrochemicals’.
Previous reports document ‘corticosteroid phobia’ as a
major cause of non-compliance and treatment failure in
atopic dermatitis.10–12,18 In fact, this term may be a misno-
mer. A phobia is an irrational fear. Parents have many
reasons to be rationally frightened of topical corticosteroids
because of warnings not only from friends, relatives and the
internet, but also from traditionally trusted sources includ-
ing their general practitioner and pharmacist.
The aim of our study was to explore the complex aetiology
of the fear of topical corticosteroid treatment for atopic
dermatitis. Our primary aim was to confirm the importance
Figure 1 Mean rating of answers to disease specific questions in pre-focus group questionnaire. Items were scored on a visual analog scale
where 1 = strongly disagree, 2 = disagree, 3 = neutral, 4 = agree, and 5 = strongly agree.
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Table 4 Results of focus group discussion
Analysis of the qualitative data revealed seven key themes:
Theme 1. Emotional impact associated with having a child with significant atopic dermatitis
Parents reported guilt and emotional distress associated with five sub-themes:
1. Physical appearance: a sense of discomfort/distress in response to intrusive comments or reactions by strangers to the physical appearance of the child.
2. Stresses: dealing with interruption to the child and parents’ routine and daily obligations, their child’s distress, and the effects of lack of sleep and
exhaustion from attending to their child’s needs at night.
3. Strain on parent–child relationship: interpersonal strain and frustrations associated with conflicts over the need to coerce their child to comply with
treatment that causes pain/discomfort.
4. Parental guilt and sense of helplessness: feelings of inadequacy and failure in their inability to prevent the eczema, envy of other parents with perceived
normal children, feeling judged by others as inadequate parents, and feeling a failure as a parent. One participant remarked that she felt shame in
response to her belief that others viewed her child as a victim of child abuse.
5. Anxiety related to future prospects: fears and concerns for the child’s future due to their condition, particularly social interactions with peers, self esteem
and dealing with relationships.
Theme 2. Perception of cortisones: negative
A consistent theme of strong negative perceptions, anxiety and lack of clear information over the potential harmful effects and proper application/use of
cortisones emerged:
1. Concern over long-term negative effects: parents expressed the belief that repeated cortisone use would result in skin atrophy (‘Won’t it thin their skin?’),
and possible long-term harm from treatment, for example, leading to suppression of the immune system.
2. Anxiety regarding appropriate use of steroids: concerns that were generated by warning labels that cautioned users to ‘Use sparingly’. This created the
impression that cortisone should only be used when eczema is severe and contributed to the under-utilization of the cream.
3. Belief that cortisone masks but does not treat the underlying cause of the condition: failure to see the point of using a treatment considered simply a
‘band-aid solution’. This belief is reinforced by cautionary comments offered from general practitioner that ‘you should only use this strong cortisone for
3 days’, pharmacist’s cautioning parents to ‘Be careful’ and ‘Do you realize this is cortisone?’, and non-health professional third parties suggesting that
‘everyone has a friend or relative that had terrible side effects from cortisone’. The implicit message is that cortisone does not cure and has side effects,
and therefore parents should limit or avoid prolonged use.
Theme 3. Sources of anxiety and confusion in atopic dermatitis treatment
Qualitative data revealed that parents often had difficulty locating relevant and accurate information about the management of ectopic dermatitis and
cortisone use.
1. Access to accurate information: participants consistently reported a lack of information from expected sources, particularly their general practitioner. As
a consequence, parents felt the need to seek information for themselves from varying unreliable sources such as the Internet, or media discussing
allergies and natural products. Participants indicated that they were not able to evaluate the accuracy of information obtained from these sources.
2. Negative experiences with general practitioner/pharmacist: participants indicated that they obtained insufficient information from general practitioners,
received conflicting opinions from different sources causing confusion, had problems obtaining specialist referrals, and general practitioners tended to
trivialize eczema and were unwilling to refer parents to specialists.
3. Information gleaned from non-medical others: strongly opinionated statements from teachers, family and friends insinuating that medical treatment is
dangerous and unnecessary, and recommending alternative therapies.
Theme 4. Complementary and alternative medicine
Participants expressed several views regarding alternative therapies:
1. Treatment sequence: that medication is scientifically tested is not appreciated by participants is indicated by preferences to begin with ‘natural’
approaches before trying medication. Preferences for ‘natural products’ appear to be related to their beliefs in lower side effects and better safety
profiles, and that moisturizers are ‘toxic petrochemicals’, a view perpetuated by the media.
The promotion of natural therapy in the media and pressure from families and friends effectively influenced most participants to consult naturopaths in
pursuit of natural remedies. Participants’ apparent lack of knowledge as to what constitutes a ‘natural therapy’, combined with naturopathic claims of a
cure, and the promotion of an allergy as the underlying cause are reinforcing factors.
Cost and the realization that complementary ‘natural’ medicines do not work become deterrent factors in their continued use.
Theme 5. Problems accepting concept of control rather than cure
Participants reported experiencing difficulties accepting the notion that management is based on the concept of controlling the severity of the eczema rather
than intervening to cure the condition:
1. Control versus cure: even when participants acknowledged that they understood the genetic basis of the condition, they reported that they found it
difficult to let go of the notion that they may be able to find a ‘cause’ that can be eliminated: ‘I will never stop searching’. As a consequence, recognizing
the need for long-term management was described as a major factor wearing down participants. Participants indicated that there was a need to fully
understand the rationale for cortisone before they considered they could accept this as standard treatment
Theme 6. Supportive or positive experiences that produced attitude change
Participants reported a number of significant positive factors that reduced their uncertainties and anxieties, and led to greater understanding and acceptance
of cortisone treatment. These included:
1. Positive experience and outcomes of hospital treatment:
a. Evidence of rapid improvement in their child’s condition.
b. Demonstration of the liberal application of cortisone and emollient by nurses.
c. Demonstration of the use of wet dressings.
d. Supportive experience with nursing staff.
These observations and experiences resulted in participants reporting that they benefitted from gaining insights and guidelines into the appropriate use of
cortisone, resulting in an increased sense of control. Applying their newly learnt techniques and knowledge resulted in positive results and improved their
confidence in using cortisone and their quality of life through improved sleep, concentration, and self-esteem, and the child’s improved performance at
school.
In addition, participants reported that the involvement of other specialists such as immunologists was seen as a positive step, with trust in their
dermatologist a key factor improving compliance.
Theme 7. Key parent-suggested improvements
Participants were asked to express their views on possible changes to current practices and sources of information that they considered would enhance their
knowledge and reduce anxieties related to their child’s atopic dermatitis and use of cortisone. Emerging themes suggested improvements in doctor–patient
communication, sources of information, and importantly, observation of nursing staff applying wet dressings:
1. Doctor–patient communication: participants suggested that doctors should be more cognizant of the challenges confronting anxious parents absorbing
information during a consultation and stresses linked to:
a. Consultation time limits.
b. Children’s attention spans.
2. Information source: participants indicated greater confidence in the quality information from perceived reliable source, such as a university or hospital
department, presented through various forms of media: websites, information sheets and information/demonstration DVD.
3. Access to services: participants reported that improved and earlier access to paediatric dermatology services would increase their knowledge and reduce
their anxieties. In particular, observing a dermatology nurse apply regular wet dressings in clinics was identified as a significant factor alleviating
anxieties and improving the management of their child’s atopic eczema.
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of fear of topical corticosteroids in treatment failure, with the
corollary of this being that the only viable alternative left to
parents was ‘complementary medicine and/or allergen
avoidance’, the latter often being advocated by natural thera-
pists. We expected that if parents were allowed to discuss
their experiences in a group session, this would emerge as a
major concern. We also expected that group discussion
would generate possible solutions for the problem.
The emotional impact of atopic dermatitis is well reported
to be substantial.2,5,6,15,19 In addition to this, parents of children
with atopic dermatitis do not have access to the level of
support and public understanding experienced by parents of
children with other chronic conditions such as diabetes.19
This theme emerged strongly, relating to the appearance of
the child, sleep deprivation, social isolation and the stress of
administering treatment, as well as conflict between parent
and child over treatment. Our results are similar to those
documented in a previous focus group study.15
There is a high degree of guilt experienced by parents,
who voiced feelings of failure, inadequacy and sense that
they could have somehow prevented the disease. We
hypothesize that this is linked to the desire to find an exter-
nal cause for their child’s condition, resulting on a focus on
allergy by many parents. It may also explain how relentless
some parents can be in the search for such a cause, despite
an intellectual appreciation that the disease is genetically
determined.
Fear of topical corticosteroids did emerge as a major
deterrent to effective treatment. All parents expressed an
initial fear of topical corticosteroids before seeking treat-
ment. Concern that topical corticosteroids use would ‘thin
the skin’ was the major concrete fear; however, a vaguer
concern about unknown long-term effects was also voiced.
The term ‘use sparingly’ on labels dispensed by pharmacists
emerged as a major deterrent to correct use. This has pre-
viously been documented in a UK study.20
Sources of fear of topical corticosteroids included not only
the Internet and similarly worried friends and relatives, but
also general practitioners and pharmacists.
With regard to complementary therapy, parents related
that the media and the Internet placed a great emphasis on
natural products and focussed on allergy as having a central
role in the aetiology of atopic dermatitis. Their preference in
treatment order was to commence therapy with something
‘natural’ and move on to topical corticosteroids only when
the atopic dermatitis was ‘very severe’. Parents also felt
under pressure from family, friends and even school teach-
ers to avoid ‘dangerous and unnecessary’ medical treatment.
When prompted to discuss their understanding of what a
‘natural product’ was, parents were unable to give a clear
answer. However, their belief was that it was safer and would
have fewer side-effects than topical corticosteroids. Parents
did not have an understanding of regulatory testing, includ-
ing safety testing. Thus, despite the excellent therapeutic
results available using conventional medicine, parents still
sought unproven complementary treatments. The simplistic
theories on which these preferences are based are easily
understood by lay people, but have been noted in the past to
result in the withholding of effective treatment.21
Despite the well-documented impact on quality of life,
an unexpected finding was that parents related how diffi-
cult it had been to convince their general practitioner to
refer them to a dermatologist for what was allegedly seen
by the general practitioner as a trivial condition, and one
for which the dermatologist would offer nothing over and
above the general practitioner. This was a great source of
frustration.
A theme that emerged which was relevant to beliefs about
medical treatment was the parents’ inability to accept the
concept of ‘Control rather than cure’ that is central to effec-
tive atopic dermatitis management. Recurrence of disease
during treatment or when treatment was suspended was a
source of disappointment and discouragement relating to a
poor acceptance of the need to control a chronic condition.
This underpinned rejection of topical corticosteroids, which
parents saw as simply masking the underlying condition.
Their hope was not for treatment but for cure and this was
another reason for the search for an allergen that, if
avoided, would resolve the atopic dermatitis. This also
explained the preference for naturopathy, which itself
focuses on allergy and promises cure.
All of the parents in the group had initially been scared of
topical corticosteroids but had been persuaded to use them
effectively to control their children’s disease. They related
that the influences that changed their attitude were the
rapid improvement witnessed during inpatient treatment,
interaction with nursing staff who confidently showed use
of topical corticosteroids, improved quality of life of the
child and family once the atopic dermatitis was under
control, and gaining an understanding of safety issues from
a trusted source. Parents voiced the view that ‘knowledge is
power’ but that knowledge must be from what is perceived
to be a reliable source. When asked for examples, they
nominated an Australian university or teaching hospital as
being most reliable.
An interesting point that emerged was how important it
was to the parents to have a trusting relationship with a
dermatologist and how early referral to a dermatologist
would have saved them a great deal of uncertainly and
suffering. This has been reported previously.22
Parents also saw the involvement of other specialists, par-
ticularly allergists, as positive, even when the outcome of
investigation was to rule out allergy in their children. This is
not surprising when one understands the significance that
parents place on allergy and suggests that dermatologists
will validate their patients’ concerns and thus improve com-
pliance by carrying out allergen testing, even if they expect
the outcome to have minimal impact on management.
The key suggestions for dermatologists which emerged
from the study are shown in Tables 5 and 6. Dermatologists
should understand the sources of parental concern and
realize that corticosteroid ‘phobia’ is in fact a rational fear
generated by misinformation, which can be modified by
correct information. They should not underestimate the
power of the trust that a patient will place in them if they
provide adequate support, which involves alleviating guilt,
providing facts and encouraging an understanding of the
chronic nature of atopic dermatitis. Despite the fact that
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allergy is of limited importance in many patients, a willing-
ness to validate parental hopes by investigating is seen as
part of this support.
Parents require empowerment to withstand the many
negative influences they encounter on a day-to-day basis.
When providing facts, ensuring that parents see them as
coming from a reliable source and including information on
the parent’s areas of concern is important. The use of video
recordings was also seen as very helpful. Utilization of a
hospital stay emerged as a powerful tool and one which
dermatologists should not hesitate to use.
Finally, re-education of other healthcare providers, par-
ticularly pharmacists and general practitioners, emerged as
a potential solution which could help to improve confidence
in medical treatment.
CONCLUSIONS
Atopic dermatitis has a substantial effect on the quality of
life of the subject child and the entire family. Children and
parents suffer needlessly because of inadequate disease
control as a result of poor compliance. Fear of treatment,
particularly with topical corticosteroids, is a realistic reac-
tion to misinformation, much of which comes from sources
which patients trust: their general practitioners and phar-
macists. An understanding of parents’ difficulties and fears
provides a framework from which dermatologists can
develop strategies to increase confidence in treatment and
improve quality of life.
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Table 5 Suggestions for dermatologists
• Understand, respect and validate parental concerns
• Do not dismiss the desire to investigate allergy
• Alleviate guilt
• Emphasize the positives: outcome, safety, prognosis
• Encourage acceptance of ‘no cure’
• Use your hospital
• Re-educate pharmacists
• Realize parental trust in you is a major factor
• Empower parents to withstand negative forces
• Provide written and videotaped information that addresses
parents fears
• Encourage general practitioners to refer children with atopic
dermatitis
Table 6 Suggested information to increase parental confidence
• Safety data on topical corticosteroids
• Safety data on moisturizers
• Information on relative potencies of prescribed topical
corticosteroids
• Demonstration of use of topical corticosteroids
• Understanding of the concept of scientific testing
• True role of allergy in atopic dermatitis
• Explanation of how topical corticosteroids work in atopic
dermatitis
• Possible outcomes of failure to treat
• Importance of improving the child’s quality of life
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